

DNAX RESEARCH INSTITUTE

901 California Avenue
Palo Alto, CA 94304-1104
(650) 852-9196

ASSISTANT COMMISSIONER FOR PATENTS
Box: Patent Application
Washington, D. C. 20231

Honorable Sir:

Transmitted herewith for filing under 37 CFR 1.53(b) is the:
☒ patent application, ☐ continuation patent
application, ☐ divisional patent application
☐ continuation-in-part (CIP) patent application of:

**MAMMALIAN GENES; RELATED
REAGENTS AND METHODS**

Inventors: **Constance H. Zlot, Gosse Jan Adema, Carl Figdor and Joseph H. Phillips**

Sir:

1. ☒ This application claims priority from each of the following Application Nos./filing dates:
Provisional Patent Application No. 60/165,438, filed November 15, 1999.
2. ☐ Please amend the specification by replacing the first paragraph with the following:
3. Enclosed are:

- ☒ RETURN RECEIPT POSTCARD
- ☒ PATENT APPLICATION TRANSMITTAL **EL 367 647 917 US**: 1 Page (in duplicate)
- ☒ DECLARATION BY INVENTORS/POWER OF ATTORNEY: 3 Pages: ☐ Signed ☒ Unsigned
- ☒ PATENT APPLICATION TITLE PAGE: 1 Page (unnumbered)
- ☒ SPECIFICATION: 83 Pages: 1 through 83
- ☒ CLAIMS (20 claims): 4 Pages: 84 through 87
- ☒ SEQUENCE LISTING: 12 Page(s): 88-99
- ☒ ABSTRACT: 1 Page: page 100
- ☒ Sequence Transmittal (2 pages), diskette and paper print-out (13 pages)

**In view of the Unsigned Declaration as filed with this application,
Applicant requests deferral of the filing fee until submission of
the response to Missing Parts of Application.**

Please charge DNAX Deposit Account No. 04-1239 as follows:

- ☒ Any additional fees associated with this paper or during the
pendency of this application

-two- copies of this sheet are enclosed.

Telephone:
(650) 852-9196

PATENT

"Express Mail" Label No.: **EL 367 647 545 US**

Date of Deposit: **November 14, 2000**

Atty. Docket No.: **DX01051Q**

I hereby certify that this is being deposited with the United States
Postal Service "Express Mail Post Office to Addressee" service
under 37 CFR 1.10 on the date indicated above and is addressed
to the Commissioner of Patents and Trademarks, Box: Patent
Application, Washington, D. C. 20231.

By *Lois E. Miller* *Nov. 14, 2000*
Lois E. Miller November 14, 2000

Respectfully submitted,
DNAX RESEARCH INSTITUTE

Edwin P. Ching *November 14, 2000*
Edwin P. Ching November 14, 2000
Reg. No. 34,090

PATENT APPLICATION

5

MAMMALIAN GENES; RELATED REAGENTS AND METHODS

INVENTORS:

10 Constance H. Zlot, a citizen of the United States,
residing at 949 Filbert Street, Apt. 6, San
Francisco, California 94133;

15 Gosse Jan Adema, a citizen of the Netherlands,
residing at Haydnstraat 53, 6561 ED Groesbeek,
The Netherlands;

20 Carl Figdor, a citizen of the Netherlands, residing at
Westwal 54, 5211 DD Den Bosch, The Netherlands;
and

25 Joseph H. Phillips, a citizen of the United States,
residing at 1511 Walnut Drive, Palo Alto,
California 94303.

EL367647917US

30 "Express Mailing" mailing label number EL 367 647 917 US
Date of Deposit November 14, 2000
I hereby certify that this paper is being deposited with the
United States Postal Service "Express Mail Post to
Addressee" service under 37 C.F.R. § 1.10 on the date
indicated above and is addressed to: Box PATENT
35 APPLICATION; Assistant Commissioner for Patents; Washington
D.C. 20231.


Lois E. Miller

Nov. 14, 2000
date

40

DNAX Research Institute
901 California Avenue
45 Palo Alto, California 94304-1104
Tel: (650)852-9196
Fax: (650)496-1200

MAMMALIAN GENES; RELATED REAGENTS AND METHODS

This filing is a U.S. utility Patent Application
claiming priority to USSN 60/165,438, filed November 15,
5 1999, which is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention pertains to compositions related
to proteins which function in controlling biology and
10 physiology of mammalian cells, e.g., cells of a mammalian
immune system. In particular, it provides purified genes,
proteins, antibodies, and related reagents useful, e.g., to
regulate activation, development, differentiation, and
function of various cell types, including hematopoietic
15 cells.

BACKGROUND OF THE INVENTION

Recombinant DNA technology refers generally to the
technique of integrating genetic information from a donor
20 source into vectors for subsequent processing, such as
through introduction into a host, whereby the transferred
genetic information is copied and/or expressed in the new
environment. Commonly, the genetic information exists in
the form of complementary DNA (cDNA) derived from messenger
25 RNA (mRNA) coding for a desired protein product. The
carrier is frequently a plasmid having the capacity to
incorporate cDNA for later replication in a host and, in
some cases, actually to control expression of the cDNA and
thereby direct synthesis of the encoded product in the host.

30 Cell lineages especially important to the immune
response include two classes of lymphocytes: B-cells, which
can produce and secrete immunoglobulins (proteins with the
capability of recognizing and binding to foreign matter to
effect its removal), and T-cells of various subsets that
35 secrete lymphokines and induce or suppress the B-cells and
various other cells (including other T-cells) making up the

immune network. These lymphocytes interact with many other cell types.

Dendritic cells (DC) are the professional antigen presenting cells (APC) of the immune system. They have the unique capability to activate naive T lymphocytes and as such play an important role in the induction of immune responses. Multiple studies have indicated that DC are superior in priming naive T cells when compared to other APC such as B cells and macrophages. Steinman (1991) Ann. Rev. Immunol. 9:271-296; Hart (1997) Blood 90:3245-3287; and Levin, et al. (1993) J. Immunol. 151:6742-6750. Recent experiments suggest that distinct DC subsets can be recognized that have strikingly different influences on the type of immune response generated in vivo. See, e.g., Rissoan, et al. (1999) Science 283, 1183-1186; Pulendran, et al. (1999) Proc. Natl. Acad. Sci. USA 96:1036-1041; Maldonado-Lopez, et al. (1999) J. Exp. Med. 189:587-592; and Smith and Fazekas de St. Groth (1999) J. Exp. Med. 189:593-598.

DC are bone marrow-derived cells, that in their immature stage are scattered throughout the body and are particularly efficient in antigen uptake through a variety of cell surface receptors specialized in capturing antigens. See Sallusto, et al. (1995) J. Exp. Med. 182:389-400. Upon inflammation, DC migrate via lymph or blood to the secondary lymphoid organs. This migration process seems to be regulated by a coordinated up- and downregulation of chemokine receptors. See Sallusto, et al. (1998) Eur. J. Immunol. 28:2760-2769; and Sozzani, et al. (1998) J. Immunol. 161:1083-1086.

Upon arrival in the T cells areas, DC are mature and fully stimulatory, well-equipped to attract and interact with naive T cells. These DC express high levels of MHC class I, MHC class II, adhesion molecules and co-stimulatory molecules, that supports the induction of primary T cell responses. Subsequently, CD40 ligation on the DC after interaction with CD4+ T helper cells leads to maximal

activation of the mature DC, further increasing their capacity to stimulate naive cytotoxic T lymphocytes. See Caux, et al. (1994) J. Exp. Med. 180:1263-1272; Cella, et al. (1996) J. Exp. Med. 184:747-752; Schoenberger, et al. (1998) Nature 393:480-483; Ridge, et al. (1998) Nature 393:474-478; and Bennett, et al. (1998) Nature 393:478-480.

Besides T cells, NK cells, and macrophages, another important cell lineage is the mast cell (which has not been positively identified in all mammalian species), which is a granule-containing connective tissue cell located proximal to capillaries throughout the body. These cells are found in especially high concentrations in the lungs, skin, and gastrointestinal and genitourinary tracts. Mast cells play a central role in allergy-related disorders, particularly anaphylaxis as follows: when selected antigens crosslink one class of immunoglobulins bound to receptors on the mast cell surface, the mast cell degranulates and releases mediators, e.g., histamine, serotonin, heparin, and prostaglandins, which cause allergic reactions, e.g., anaphylaxis.

Although the role of DC in a wide variety of immunological processes has been demonstrated, the molecular mechanisms that regulate DC differentiation, migration and maturation are still poorly understood. Research to better understand and treat various immune disorders has been hampered by the general inability to maintain cells of the immune system in vitro. Immunologists have discovered that culturing these cells can be accomplished through the use of T-cell and other cell supernatants, which contain various growth factors, including many of the lymphokines.

From the foregoing, it is evident that the discovery and development of new surface antigens could contribute to new therapies for a wide range of degenerative or abnormal conditions which directly or indirectly involve the immune system and/or hematopoietic cells. In particular, the discovery and development of lymphokines which enhance or

potentiate the beneficial activities of known lymphokines would be highly advantageous. The present invention provides new compositions and related compounds, and methods for their use.

SUMMARY OF THE INVENTION

The present invention is directed to mammalian, e.g., rodent, canine, feline, primate, proteins designated Dendritic Cell Specific Transmembrane Protein (DC-STAMP) and DNAX Surface Protein (DSP-1) and their biological activities. It includes nucleic acids coding for polypeptides themselves and methods for their production and use. The nucleic acids of the invention are characterized, in part, by their homology to complementary DNA (cDNA) sequences disclosed herein, and/or by functional assays applied to the polypeptides, which are typically encoded by these nucleic acids. Methods for modulating or intervening in the control of surface protein dependent physiology or an immune response are provided.

The present invention is based, in part, upon the discovery of novel surface proteins from dendritic cells or mast cells. In particular, it provides primate, e.g., human, sequences. Functional equivalents exhibiting significant sequence homology will be available from other mammalian, e.g., cow, horse, rat, mouse, and non-mammalian species, e.g., warm blooded animals, including birds.

In various protein embodiments, the invention provides: a substantially pure or recombinant DC-STAMP or DSP-1 polypeptide exhibiting identity over a length of at least about 12 amino acids to SEQ ID NO: 2 or 5 or 7; a natural sequence DC-STAMP of SEQ ID NO: 2; a natural sequence DSP-1 of SEQ ID NO: 5 or 7; and a fusion protein comprising DC-STAMP or DSP-1 sequence. In certain embodiments, the segment of identity is at least about 14, 17, or 19 amino acids. In other embodiments, the DC-STAMP or DSP-1: comprises a mature sequence comprising the sequence from Tables 1 or 2; or exhibits a post-translational modification pattern distinct from natural DC-STAMP or DSP-1; or the polypeptide: is from a warm blooded animal selected from a mammal, including a primate; comprises at least one polypeptide segment of SEQ ID NO: 2 or 5 or 7; exhibits a plurality of fragments; is a natural

allelic variant of DC-STAMP or DSP-1; has a length at least about 30 amino acids; exhibits at least two non-overlapping epitopes which are specific for a primate DC-STAMP or DSP-1; exhibits sequence identity over a length of at least about 20 amino acids to primate DC-STAMP or DSP-1; is glycosylated; has a molecular weight of at least 30 kD with natural glycosylation; is a synthetic polypeptide; is attached to a solid substrate; is conjugated to another chemical moiety; is a 5-fold or less substitution from natural sequence; or is a deletion or insertion variant from a natural sequence. Preferred embodiments include a composition comprising: a sterile DC-STAMP or DSP-1 polypeptide; or the DC-STAMP or DSP-1 polypeptide and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration. In fusion protein embodiments, the protein can have: mature polypeptide sequence from Tables 1 or 2; a detection or purification tag, including a FLAG, His6, or Ig sequence; and/or sequence of another cytokine or chemokine, including Flt3 ligand.

Kit embodiments include those with a DC-STAMP or DSP-1 polypeptide, and: a compartment comprising the polypeptide; and/or instructions for use or disposal of reagents in the kit.

In binding compound embodiments, the compound may have an antigen binding site from an antibody, which specifically binds to a natural DC-STAMP or DSP-1 polypeptide, wherein: the DC-STAMP or DSP-1 is a primate protein; the binding compound is an Fv, Fab, or Fab2 fragment; the binding compound is conjugated to another chemical moiety; or the antibody: is raised against a peptide sequence of a mature polypeptide portion from Tables 1 or 2; is raised against a mature DC-STAMP or DSP-1; is raised to a purified primate DC-STAMP or DSP-1; is immunoselected; is a polyclonal antibody; binds to a denatured DC-STAMP or DSP-1; exhibits a Kd of at least 30 μ M; is attached to a solid substrate,

including a bead or plastic membrane; is in a sterile composition; or is detectably labeled, including a radioactive or fluorescent label. Kits containing binding compounds include those with: a compartment comprising the binding compound; and/or instructions for use or disposal of reagents in the kit. Often the kit is capable of making a qualitative or quantitative analysis. Preferred compositions will comprise: a sterile binding compound; or the binding compound and a carrier, wherein the carrier is: an aqueous compound, including water, saline, and/or buffer; and/or formulated for oral, rectal, nasal, topical, or parenteral administration.

Nucleic acid embodiments include an isolated or recombinant nucleic acid encoding a DC-STAMP or DSP-1 polypeptide or fusion protein, wherein: the DC-STAMP or DSP-1 is from a primate; and/or the nucleic acid: encodes an antigenic peptide sequence of Tables 1 or 2; encodes a plurality of antigenic peptide sequences of Tables 1 or 2; exhibits identity to a natural cDNA encoding the segment; is an expression vector; further comprises an origin of replication; is from a natural source; comprises a detectable label; comprises synthetic nucleotide sequence; is less than 6 kb, preferably less than 3 kb; is from a primate, including a human; comprises a natural full length coding sequence; is a hybridization probe for a gene encoding the DC-STAMP or DSP-1; or is a PCR primer, PCR product, or mutagenesis primer. The invention also provides a cell, tissue, or organ comprising such a recombinant nucleic acid, and preferably the cell will be: a prokaryotic cell; a eukaryotic cell; a bacterial cell; a yeast cell; an insect cell; a mammalian cell; a mouse cell; a primate cell; or a human cell.

Kit embodiments include those with such nucleic acids, and: a compartment comprising the nucleic acid; a compartment further comprising the DC-STAMP or DSP-1 protein or polypeptide; and/or instructions for use or disposal of

reagents in the kit. Typically, the kit is capable of making a qualitative or quantitative analysis.

In certain embodiments, the nucleic acid: hybridizes
under wash conditions of 30° C and less than 2M salt, or of
5 45° C and/or 500 mM salt, or 55° C and/or 150 mM salt, to
SEQ ID NO: 1 or 4 or 6; or exhibits identity over a stretch
of at least about 30, 55, or 75 nucleotides, to a primate
DC-STAMP or DSP-1.

The invention embraces a method of modulating
10 physiology or development of a cell or tissue culture cells
comprising contacting the cell with an agonist or antagonist
of a primate DC-STAMP or DSP-1. The method may be where:
the contacting is in combination with an agonist or
antagonist of Flt3 ligand; or the contacting is with an
15 antagonist, including a binding composition comprising an
antibody binding site which specifically binds a DC-STAMP or
DSP-1.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

All references cited herein are incorporated herein by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.

OUTLINE

- I. General
- 10 II. Purified DC-STAMP or DSP-1
 - A. physical properties
 - B. biological properties
- III. Physical Variants
 - 15 A. sequence variants, fragments
 - B. post-translational variants
 - 1. glycosylation
 - 2. others
- IV. Functional Variants
 - 20 A. analogs, fragments
 - 1. agonists
 - 2. antagonists
 - B. mimetics
 - 1. protein
 - 2. chemicals
 - 25 C. species variants
- V. Antibodies
 - A. polyclonal
 - B. monoclonal
 - C. fragments, binding compositions
- 30 VI. Nucleic Acids
 - A. natural isolates; methods
 - B. synthetic genes
 - C. methods to isolate
- VII. Making DC-STAMP or DSP-1, mimetics
 - 35 A. recombinant methods
 - B. synthetic methods
 - C. natural purification
- VIII. Uses
 - 40 A. diagnostic
 - B. therapeutic
- IX. Kits
 - A. nucleic acid reagents
 - B. protein reagents
 - C. antibody reagents
- 45 X. Isolating receptors for DC-STAMP or DSP-1

I. General

The present invention provides amino acid sequences and DNA sequences encoding various mammalian proteins which are membrane proteins, e.g., which are surface molecules
5 which may mediate a signal between immune or other cells. See, e.g., Paul (1997) Fundamental Immunology (3d ed.) Raven Press, N.Y. The proteins, and fragments, or antagonists will be useful in physiological modulation of cells expressing a receptor or binding partner. It is likely that
10 DC-STAMP or DSP-1 has either stimulatory or inhibitory effects on hematopoietic cells, including, e.g., lymphoid cells, such as T-cells, B-cells, natural killer (NK) cells, macrophages, dendritic cells, hematopoietic progenitors, mast cells, etc. The proteins will also be useful as
15 antigens, e.g., immunogens, for raising antibodies to various epitopes on the protein, both linear and conformational epitopes.

Various cDNAs encoding DC-STAMP or DSP-1 were identified. The DC-STAMP was identified from cDNA libraries
20 prepared from human monocyte-derived dendritic cells. The DSP-1 was identified from a cDNA library derived from a human HEL cell line.

Along with B lymphocytes and mononuclear phagocytes, dendritic cells (DC) are the professional antigen presenting
25 cells (APC). DC are unique in their ability to present antigen to naive T cells, and play therefore a central role in the initiation of immune responses. Characterization of DC specific genes may help to unravel the mechanism underlying their potent antigen presenting capacity. Here
30 is described the identification of a novel transcript, isolated by random sequencing of clones from a cDNA library prepared from monocyte-derived DC. A 2.3 kb messenger RNA is specifically expressed by DC, and not in a panel of other leukocytes or non-hematopoietic cells. In addition, no
35 expression was detected in tissue of several human organs. The transcript encodes an approximately 470 amino acid protein, which is comprised of 7 putative transmembrane

domains. This novel protein has been designated Dendritic Cell Specific Transmembrane Protein (DC-STAMP). Expression of a DC-STAMP-GFP fusion protein in 293 cells indicates that DC-STAMP is expressed at the cell surface. No sequence
5 homology was found with another protein or multimembrane spanning receptor. DC-STAMP appears to be a novel DC-specific multimembrane spanning protein, representing a new group of transmembrane proteins.

To characterize DC at the molecular level, cDNA
10 libraries were prepared from human monocyte-derived dendritic cells (DC) and over 250 cDNA clones were characterized by nucleotide sequence analysis. See Marland, et al. (1997) in Ricciardi-Castagnoli (ed.) Dendritic Cells in Fundamental and Clinical Immunology, Vol 3, Plenum Publ.
15 Corp. One of these cDNA clones was analyzed in further detail as it contained a unique sequence not present in the GenBank databases and its partial open reading frame (ORF) appeared to encode a putative transmembrane (TM) region. To determine the expression pattern of this novel messenger
20 RNA, Northern blot analysis was performed using RNA from non-stimulated DC as well as RNA from a panel of freshly isolated leukocyte populations and several T, B, and monocytic cell lines. A message of 2.3 kb was specifically detected in DC but not in any of the other cell populations
25 tested. Therefore, this novel protein was designated DC-STAMP (DC-Specific Transmembrane Protein). The finding that this RNA is enriched in the poly A⁺ RNA fraction from DC indicates that the mRNA encoding DC-STAMP is polyadenylated.

The human DC-STAMP gene will encode a membrane
30 protein, of about 470 amino acids. See Table 1 and SEQ. ID. NO: 1 and 2. DC-STAMP exhibits structural motifs characteristic of a member of multiple membrane spanning proteins, e.g., 7 transmembrane receptors. Other notable motifs or features include asn168-thr170, asn187-ser188, and
35 asn357-ser359 (three predicted N-linked glycosylation sites); and thr286-lys288 (potential site for

phosphorylation by PKC); and lys426-ser429 and arg438-ser441 (potential sites for cAMP-dependent protein kinases).

The human DSP-1 appears to exist in two forms. One form, designated the long form, encodes a membrane protein of about 313 amino acids, and the other, designated the short form, encodes a membrane protein of about 200 amino acids. The short form seems to result from deletion of nucleotides 94-433 of the long form, and the corresponding amino acids of the protein. Both forms seem to encode type I membrane proteins, with the transmembrane segment corresponding to long form residues about leu172-gly188. Other notable motifs or features include three ITIM motifs, corresponding to long form residues leu222-leu227, val244-val251, and leu258-val263. See, e.g., Thomas (1995) J. Exp. Med. 181:1953-xx; and Lanier (1997) Immunity 6:371. Classically, the Immunoreceptor Tyrosine-based Inhibitory Motifs (ITIM) recruit intracellular tyrosine phosphatases, and the receptors provide an inhibitory signal to the cell. This suggests that the DSP-1 antigen is involved in a negative regulatory signaling pathway in the expressing cells, e.g., monocytes, T, NK, and/or mast cells. Thus, the binding partner, probably a surface receptor or soluble ligand, might inhibit monocyte, T, NK, and/or mast cell degranulation, chemotaxis, or signaling.

Table 1: Primate, e.g., human, DC-STAMP (SEQ ID NO: 1 and 2):

	ggggggtggc atttctgcat tcgaagaaga atctgagaga aacctgacgc agggagc	57
5	atg ggt atc tgg acc tca ggc act gat atc ttc cta agt ctt tgg gag Met Gly Ile Trp Thr Ser Gly Thr Asp Ile Phe Leu Ser Leu Trp Glu 1 5 10 15	105
10	att tac gtg tct cca aga agc ccc gga tgg atg gac ttt atc cag cat Ile Tyr Val Ser Pro Arg Ser Pro Gly Trp Met Asp Phe Ile Gln His 20 25 30	153
15	ttg gga gtt tgc tgt ttg gtt gct ctt att tca gtg ggc ctc ctg tct Leu Gly Val Cys Cys Leu Val Ala Leu Ile Ser Val Gly Leu Leu Ser 35 40 45	201
20	gtg gcc gcc tgc tgg ttt ctg cca tca atc ata gcg gcc gct gcc tcc Val Ala Ala Cys Trp Phe Leu Pro Ser Ile Ile Ala Ala Ala Ser 50 55 60	249
25	ttg att atc acg tgt gtt ctg ctg tgt tgc tcc aag cat gca cga tgt Trp Ile Ile Thr Cys Val Leu Leu Cys Cys Ser Lys His Ala Arg Cys 65 70 75 80	297
30	ttt att ctt ctt gtc ttt ctc tct tgt ggc ctg cgt gaa ggc agg aat Phe Ile Leu Leu Val Phe Leu Ser Cys Gly Leu Arg Glu Gly Arg Asn 85 90 95	345
35	gct ttg att gca gct ggc aca ggg atc gtc atc ttg gga cac gta gaa Ala Leu Ile Ala Ala Gly Thr Gly Ile Val Ile Leu Gly His Val Glu 100 105 110	393
40	aat att ttt cac aac ttt aaa ggt ctc cta gat ggt atg act tgc aac Asn Ile Phe His Asn Phe Lys Gly Leu Leu Asp Gly Met Thr Cys Asn 115 120 125	441
45	cta agg gca aag agc ttt tcc ata cat ttt cca ctt ttg aaa aaa tat Leu Arg Ala Lys Ser Phe Ser Ile His Phe Pro Leu Leu Lys Lys Tyr 130 135 140	489
50	att gag gca att cag tgg att tat ggc ctt gcc act cca cta agt gta Ile Glu Ala Ile Gln Trp Ile Tyr Gly Leu Ala Thr Pro Leu Ser Val 145 150 155 160	537
55	ttt gat gac ctt gtt tct tgg aac cag acc ctg gca gtc tct ctt ttc Phe Asp Asp Leu Val Ser Trp Asn Gln Thr Leu Ala Val Ser Leu Phe 165 170 175	585
60	agt ccc agc cat gtc ctg gag gca cag cta aat gac agc aaa ggg gaa Ser Pro Ser His Val Leu Glu Ala Gln Leu Asn Asp Ser Lys Gly Glu 180 185 190	633
65	gtc ctg agc gtc ttg tac cag atg gca aca acc aca gag gtg ttg tcc Val Leu Ser Val Leu Tyr Gln Met Ala Thr Thr Thr Glu Val Leu Ser 195 200 205	681
70	tcc ctg ggt cag aag cta ctt gcc ttt gca ggg ctt tcg ctc gtc ctg Ser Leu Gly Gln Lys Leu Leu Ala Phe Ala Gly Leu Ser Leu Val Leu 210 215 220	729

	ctt ggc act ggc ctc ttc atg aag cga ttt ttg ggc cct tgt ggt tgg	777
	Leu Gly Thr Gly Leu Phe Met Lys Arg Phe Leu Gly Pro Cys Gly Trp	
	225 230 235 240	
5	aag tat gaa aac atc tac atc acc aga caa ttt gtt cag ttt gat gaa	825
	Lys Tyr Glu Asn Ile Tyr Ile Thr Arg Gln Phe Val Gln Phe Asp Glu	
	245 250 255	
10	agg gag aga cat caa cag agg ccc tgt gtg ctc ccg ctg aat aag gag	873
	Arg Glu Arg His Gln Gln Arg Pro Cys Val Leu Pro Leu Asn Lys Glu	
	260 265 270	
15	gaa agg agg aag tat gtc atc atc ccg act ttc tgg ccg act cct aaa	921
	Glu Arg Arg Lys Tyr Val Ile Ile Pro Thr Phe Trp Pro Thr Pro Lys	
	275 280 285	
20	gaa agg aaa aac ctg ggg ctg ttt ttc ctc ccc ata ctt atc cat ctc	969
	Glu Arg Lys Asn Leu Gly Leu Phe Phe Leu Pro Ile Leu Ile His Leu	
	290 295 300	
25	tgc atc tgg gtg ctg ttt gca gct gta gat tat ctg ctg tat cgg ctc	1017
	Cys Ile Trp Val Leu Phe Ala Ala Val Asp Tyr Leu Leu Tyr Arg Leu	
	305 310 315 320	
30	att ttc tca gtg agc aag cag ttt caa agc ttg cca ggg ttt gag gtt	1065
	Ile Phe Ser Val Ser Lys Gln Phe Gln Ser Leu Pro Gly Phe Glu Val	
	325 330 335	
35	cac ttg aaa ctg cac gga gag aaa caa gga act caa gat att atc cat	1113
	His Leu Lys Leu His Gly Glu Lys Gln Gly Thr Gln Asp Ile Ile His	
	340 345 350	
40	gat tct tcc ttt aat ata tct gtg ttt gaa ccc aac tgt atc cca aaa	1161
	Asp Ser Ser Phe Asn Ile Ser Val Phe Glu Pro Asn Cys Ile Pro Lys	
	355 360 365	
45	cca aaa ttc ctt cta tct gag acc tgg gtt cct ctc agt gtt att ctt	1209
	Pro Lys Phe Leu Leu Ser Glu Thr Trp Val Pro Leu Ser Val Ile Leu	
	370 375 380	
50	ttg ata tta gtg atg ctg gga ctg ttg tcc tct atc ctt atg caa ctt	1257
	Leu Ile Leu Val Met Leu Gly Leu Leu Ser Ser Ile Leu Met Gln Leu	
	385 390 395 400	
55	aaa atc ctg gtg tca gca tct ttc tac ccc agc gtg gag agg aag cgc	1305
	Lys Ile Leu Val Ser Ala Ser Phe Tyr Pro Ser Val Glu Arg Lys Arg	
	405 410 415	
60	atc caa tat ctg cat gca aag ctg ctt aaa aaa aga tca aag cag ccg	1353
	Ile Gln Tyr Leu His Ala Lys Leu Leu Lys Lys Arg Ser Lys Gln Pro	
	420 425 430	
65	ctg gga gaa gtc aaa aga cgg ctg agt ctc tat ctt aca aag att cat	1401
	Leu Gly Glu Val Lys Arg Arg Leu Ser Leu Tyr Leu Thr Lys Ile His	
	435 440 445	
70	ttc tgg ctt cca gtc ctg aaa atg att agg aag aag caa atg gac atg	1449
	Phe Trp Leu Pro Val Leu Lys Met Ile Arg Lys Lys Gln Met Asp Met	
	450 455 460	

gca agt gca gac aag tca tgagagaccc cgactactcc tcagccacat 1497
Ala Ser Ala Asp Lys Ser
465 470

5 cgcaccaaca attctcttca ggtctaggat ggcagtcact attcatgccg gataatagag 1557
aactatgtga cgcagtcctc tcaggagtct gagtttacag agccaacttg cagcacctgg 1617
ttatgcctcc tttcatctca aagccaaaga gctgccaggt aaatgggtat gtgggtctatg 1677
10 ttccaaacaa accacatgat cttgcctgtg tcacaatgta acaagactct agctgggtcc 1737
cctgggtgatg agtttcagca tagaataatg ttcaaggaaa agaaaacgaa aacagtttaa 1797
15 atctctacca cagcctcaca agcaaagtct aaggggaaca tacatgtaaa aagccagcaa 1857
actatcttca aactcttccg tccttaatgt cttccatggc tattgcccc acaatgggtct 1917
ctttctctcc tgctccctta ttaaagaact ctttctgaaa ccc 1960

20 MGIWTSGETDIFLSLWEIYVSPRSPGWMDFIQHLGVCCLVALLISVGLLSVAACWFLPSIIAAAASWIITC
VLLCCSKHARCFILLVFLSCGLREGRNALIAAGTGIVILGHVENIFHNFKGLLDGMTCNLRKSFISIHF
PLLKKYIEAIQWIYGLATPLSVFDDLVSWNQTLAVSLFSPSHVLEAQLNDSKGEVLSVLYQMATTTEVL
25 SSLGQKLLAFAGLSLVLLGTGLFMKRFLGPCGWKYENIYITRQFVQFDERERHQORPCVLPNKEERRK
YVIPTFWPTPKERKNLGLFFLPILHLICWVLF AAVDYLLYRLIFSVSKQFQSLPGFEVHLKLHGEKQ
GTQDIIHDSFNIISVFEPNCIPKPKFLLSETWVPLSVILLILVMLGLLSSILMQLKILVSASFYPSVER
KRIQYLHAKLLKRSKQPLGEVKRRLSLYLTKIHFVLPVLKMIRKKQMDMASADKS

30 Reverse translation, e.g., nucleic acids encoding
polypeptides (N can be A, C, G, or T; SEQ ID NO: 3):

ATGGGNATHHTGGACNWSNGGNACNGAYATHHTTYTNTWSNYTNTGGGARATHHTAYGTNWSNCCNMGNWSN
CCNGGNTGGATGGAYTTYATHCARCAYTNGGNGTNTGYTGYYTNGTNGCNYTNATHWSNGTNGGNYTN
35 YTNWSNGTNGCNGCNTGYTGTTYTNTCCNWSNATHATHGCGCNGCNGCNGCNSNTGGATHATHACNTGY
GTNYTNTYNTGYTGYSNAARCAAYGCNMGNTGYTTYATHYTNNTNGTNTTYTNTWSNTGYGGNYTNMGN
GARGGNMGNAAYGCNYTNATHGCGCNGGACNNGNATHGTNATHYTNNGNCAYGTNGARAAYATHHTTY
CAYAAYTTYAARGGNYTNNGAYGGNATGACNTGYAAYTNMGNCGNARWSNTTYWSNATHCAYTTY
CCNYTNTYNAARAARTAYATHGARGCNATHCARTGGATHAYGGNYTNGCNCACNCCNYTNWSNGTNTTY
40 GAYGAYTNGTNSNTGGAAACARACNYTNGCNGTNSNYTNTTYWSNCCNWSNCAAYGTNYTNGARGCN
CARYTNAAYGAYWSNAARGGNGARGTNYTNWSNGTNYTNTAYCARATGGCNACNACNACNGARGTNYTN
WSNWSNYTNGGNCARAARYTNYTNGCNTTYGCNGGNYTNWSNYTNGTNYTNYTNGGNCNGGNYTNTTY
ATGAARMGNTTYTNGGNCNTGYGGNTGGAARTAYGARAAYATHHTAYATHACNMGNCARTTYGTNCAR
TTYGAYGARMGNGARMGNCAAYCARCARMGNCNTGYGTNYTNCCNYTNAAYAARGARGARMGNMGNAAR
45 TAYGTNATHATHCCNACNTTYGGCCNACCCNAARGARMGNAARAAYTNGGNYTNTTYTNTCCN
ATHYTNATHCAYTNTGYATHHTGGGTNTNTTYGCNGCNGTNGAYTAYTNTNTAYMGNYTNATHHTTY
WSNGTNSNAARCARTTYCARWSNYTNCCNGGNTTYGARGTNCAAYTNAARYTNCAYGNGARAARCAR
GGNACNCARGAYATHATHCAYGAYWSNWSNTTYAAYATHWSNGTNTTYGARCCNAAATGYATHCCNAAR
CCNAARTTYTNTYTNWSNGARACNTGGGTNCCNYTNWSNGTNATHYTNNTYTNATHYTNGTNATGYTNGG
50 YTNNTYTNWSNWSNATHYTNATGCARYTNAARATHYTNGTNWSNGCNSNTTYTAYCCNWSNGTNGARMGN
AARMGNATHCARTAYTNCAYGCNAAARYTNTYTNARAARMGNWSNAARCARCCNYTNGGNGARGTNAAR
MGNMGNYTNWSNYTNTAYTNCANAAATHCAYTTYTGGYTNCNGTNYTNAARATGATHMGNAARAAR
CARATGGAYATGGCNWSNGCNGAYARWSN

Table 2: Primate, e.g., human, DSP-1 forms, both long and short forms:

DSP-1L (SEQ ID NO: 4 and 5):

5	atg gcc tta cca gtg acc gcc ttg ctc ctg ccg cta gcc ttg ctg ctc	48
	Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu	
	-20 -15 -10	
10	cac gcc gcc agg ccg gat tac aag gac gat gac gac aag atc gat ctg	96
	His Ala Ala Arg Pro Asp Tyr Lys Asp Asp Asp Asp Lys Ile Asp Leu	
	-5 -1 1 5 10	
15	agc aaa tgc agg acc gtg gcg ggc ccc gtg ggg gga tcc ctg agt gtg	144
	Ser Lys Cys Arg Thr Val Ala Gly Pro Val Gly Gly Ser Leu Ser Val	
	15 20 25	
20	cag tgt ccc tat gag aag gaa cac agg acc ctc aac aaa tac tgg tgc	192
	Gln Cys Pro Tyr Glu Lys Glu His Arg Thr Leu Asn Lys Tyr Trp Cys	
	30 35 40	
25	aga cca cca cag att ttc cta tgt gac aag att gtg gag acc aaa ggg	240
	Arg Pro Pro Gln Ile Phe Leu Cys Asp Lys Ile Val Glu Thr Lys Gly	
	45 50 55	
30	tca gca gga aaa agg aac ggc cga gtg tcc atc agg gac agt cct gca	288
	Ser Ala Gly Lys Arg Asn Gly Arg Val Ser Ile Arg Asp Ser Pro Ala	
	60 65 70 75	
35	aac ctc agc ttc aca gtg acc ctg gag aat ctc aca gag gag gat gca	336
	Asn Leu Ser Phe Thr Val Thr Leu Glu Asn Leu Thr Glu Glu Asp Ala	
	80 85 90	
40	ggc acc tac tgg tgt ggg gtg gat aca ccg tgg ctc cga gac ttt cat	384
	Gly Thr Tyr Trp Cys Gly Val Asp Thr Pro Trp Leu Arg Asp Phe His	
	95 100 105	
45	gat ccc gtt gtc gag gtt gag gtg tcc gtg ttc ccg gca tca acg tca	432
	Asp Pro Val Val Glu Val Glu Val Ser Val Phe Pro Ala Ser Thr Ser	
	110 115 120	
50	atg aca cct gca agt atc act gcg gcc aag acc tca aca atc aca act	480
	Met Thr Pro Ala Ser Ile Thr Ala Ala Lys Thr Ser Thr Ile Thr Thr	
	125 130 135	
55	gca ttt cca cct gta tca tcc act acc ctg ttt gca gtg ggt gcc acc	528
	Ala Phe Pro Pro Val Ser Thr Thr Leu Phe Ala Val Gly Ala Thr	
	140 145 150 155	
60	cac agt gcc agc atc cag gag gaa act gag gag gtg gtg aac tca cag	576
	His Ser Ala Ser Ile Gln Glu Glu Thr Glu Glu Val Val Asn Ser Gln	
	160 165 170	
65	ctc ccg ctg ctc ctc tcc ctg ctg gca ttg ttg ctg ctt ctg ttg gtg	624
	Leu Pro Leu Leu Leu Ser Leu Leu Ala Leu Leu Leu Leu Leu Leu Val	
	175 180 185	
70	ggg gcc tcc ctg cta gcc tgg agg atg ttt cag aaa tgg atc aaa gct	672
	Gly Ala Ser Leu Leu Ala Trp Arg Met Phe Gln Lys Trp Ile Lys Ala	
	190 195 200	

	ggt gac cat tca gag ctg tcc cag aac ccc aag cag gct gcc acg cag	720									
	Gly Asp His Ser Glu Leu Ser Gln Asn Pro Lys Gln Ala Ala Thr Gln										
	205 210 215										
5	agt gag ctg cac tac gca aat ctg gag ctg ctg atg tgg cct ctg cag	768									
	Ser Glu Leu His Tyr Ala Asn Leu Glu Leu Leu Met Trp Pro Leu Gln										
	220 225 230 235										
10	gaa aag cca gca cca cca agg gag gtg gag gtg gaa tac agc act gtg	816									
	Glu Lys Pro Ala Pro Pro Arg Glu Val Glu Val Glu Tyr Ser Thr Val										
	240 245 250										
15	gcc tcc ccc agg gaa gaa ctt cac tat gcc tcg gtg gtg ttt gat tct	864									
	Ala Ser Pro Arg Glu Glu Leu His Tyr Ala Ser Val Val Phe Asp Ser										
	255 260 265										
20	aac acc aac agg ata gct gct cag agg cct cgg gag gag gaa cca gat	912									
	Asn Thr Asn Arg Ile Ala Ala Gln Arg Pro Arg Glu Glu Glu Pro Asp										
	270 275 280										
	tca gat tac agt gtg ata agg aag aca tag	942									
	Ser Asp Tyr Ser Val Ile Arg Lys Thr										
	285 290										
25											
30	MALPVTALLLPLALLLHAARPDYKDDDDKIDLSKRTVAGPVGGSLSVQCPYEKEHRTLNKYWCRRPQI FLCDKIVETKGSAGKRNGRVSIRDSPANLSFTVTLENLTEEDAGTYWCGVDTPLWRDFHDPVVEVEVSV FPASTSMTPASITAAKTSTITTAFFPVSSSTTLFAVGATHSASIQEETEEVNSQLPLLLSLLALLLLLL VGASLLAWRMFQKWIKAGDHSSELSQNPQAATQSELHYANLELLMWPLQEKAPPREVEVEYSTVASPR EELHYASVVFDSENTNRIAAQRPREEEPDSYSVIRKT										
35	DSP-1S form (SEQ ID NO: 6 and 7):										
	atg gcc tta cca gtg acc gcc ttg ctc ctg ccg cta gcc ttg ctg ctc	48									
	Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu										
	-20 -15 -10										
40	cac gcc gcc agg ccg gat tac aag gac gat gac gac aag atc gat atg	96									
	His Ala Ala Arg Pro Asp Tyr Lys Asp Asp Asp Lys Ile Asp Met										
	-5 -1 1 5 10										
45	aca cct gca agt atc act gcg gcc aag acc tca aca atc aca act gca	144									
	Thr Pro Ala Ser Ile Thr Ala Ala Lys Thr Ser Thr Ile Thr Thr Ala										
	15 20 25										
50	ttt cca cct gta tca tcc act acc ctg ttt gca gtg ggt gcc acc cac	192									
	Phe Pro Pro Val Ser Ser Thr Thr Leu Phe Ala Val Gly Ala Thr His										
	30 35 40										
55	agt gcc agc atc cag gag gaa act gag gag gtg gtg aac tca cag ctc	240									
	Ser Ala Ser Ile Gln Glu Glu Thr Glu Glu Val Val Asn Ser Gln Leu										
	45 50 55										
	ccg ctg ctc ctc tcc ctg ctg gca ttg ttg ctg ctt ctg ttg gtg ggg	288									
	Pro Leu Leu Leu Ser Leu Leu Ala Leu Leu Leu Leu Leu Leu Val Gly										
	60 65 70 75										

gcc tcc ctg cta gcc tgg agg atg ttt cag aaa tgg atc aaa gct ggt 336
 Ala Ser Leu Leu Ala Trp Arg Met Phe Gln Lys Trp Ile Lys Ala Gly
 80 85 90

5 gac cat tca gag ctg tcc cag aac ccc aag cag gct gcc acg cag agt 384
 Asp His Ser Glu Leu Ser Gln Asn Pro Lys Gln Ala Ala Thr Gln Ser
 95 100 105

10 gag ctg cac tac gca aat ctg gag ctg ctg atg tgg cct ctg cag gaa 432
 Glu Leu His Tyr Ala Asn Leu Glu Leu Leu Met Trp Pro Leu Gln Glu
 110 115 120

15 aag cca gca cca cca agg gag gtg gag gtg gaa tac agc act gtg gcc 480
 Lys Pro Ala Pro Pro Arg Glu Val Glu Val Glu Tyr Ser Thr Val Ala
 125 130 135

20 tcc ccc agg gaa gaa ctt cac tat gcc tcg gtg gtg ttt gat tct aac 528
 Ser Pro Arg Glu Glu Leu His Tyr Ala Ser Val Val Phe Asp Ser Asn
 140 145 150 155

20 acc aac agg ata gct gct cag agg cct cgg gag gag gaa cca gat tca 576
 Thr Asn Arg Ile Ala Ala Gln Arg Pro Arg Glu Glu Glu Pro Asp Ser
 160 165 170

25 gat tac agt gtg ata agg aag aca tag 603
 Asp Tyr Ser Val Ile Arg Lys Thr
 175

30 MALPVTALLLPLALLLHAARPDYKDDDDKIDMTPASITAAKTSTITTAFPPVSSTTLFAVGATHSASIQ
 EETEEVNSQLPLLLSLALLLLLLLVGASLLAWRMFQKWIKAGDHSELSQNPQAATQSELHYANLELL
 MWPLQEKPPAPPREVEVEYSTVASPREELHYASVVFDSNTNRIAAQRPREEEPDSDSYVIRKT

Alignment of long and short forms:

5 DSP-1L 1 MALPVTALLLPLALLLHAARPDYKDDDDKIDLSKCR TVAGPVGGSLSVQC 50
 DSP-1S 1 MALPVTALLLPLALLLHAARPDYKDDDDKID----- 31

DSP-1L 51 PYEKEHRTL NKYWC RPPQIFLCDKIVETKGSAGKRNGRVSI RDS PANLSF 100
 DSP-1S 32 ----- 31

10 DSP-1L 101 TVTLENLTEEDAGTYWCGV DTPWLRDFHDPVVEVEVSVFPASTSMT PASI 150
 DSP-1S 32 -----MTPASI 37

15 DSP-1L 151 TAAKTSTITTAFFPVSS TTLFAVGATHSASIQEETEEVVNSQLPLLLSLL 200
 DSP-1S 38 TAAKTSTITTAFFPVSS TTLFAVGATHSASIQEETEEVVNSQLPLLLSLL 87

20 DSP-1L 201 ALLLLLLLVGASLLAWRMFQK WIKAGDHSELSONPKQAATQSELHYANLEL 250
 DSP-1S 88 ALLLLLLLVGASLLAWRMFQK WIKAGDHSELSONPKQAATQSELHYANLEL 137

DSP-1L 251 LMWPLQEK PAPPREVEVEYSTVASPREELHYASVVFDSNTNR IAAQRPRE 300
 DSP-1S 138 LMWPLQEK PAPPREVEVEYSTVASPREELHYASVVFDSNTNR IAAQRPRE 187

25 DSP-1L 301 EEPDSDYSVIRKT 313
 DSP-1S 188 EEPDSDYSVIRKT 200

30

Reverse translation, e.g., nucleic acids encoding polypeptides (N can be A, C, G, or T):

35 long (SEQ ID NO: 8); N may be A, C, G, or T:
 ATGGCNYTNCCNGTNACNGCNYTNYTNYTNCCNYTNGCNYTNYTNCAYGCNGCNMGNCCNGAYTAY
 AARGAYGAYGAYGAYAA RATHGAYYT NWSNAARTGYMG NACNGTNGCNGGNCNGTNGGNGGNWSNYTN
 WSGTNCARTGYCCNTAYGARAARGARCA YMG NACNYTNAAYAARTAYTGGTGYMG NCCNCCNCARATH
 TTYTNTGTGYGAYAA RATHGTNGARACNAARGGNWSNGCNGGNAARMGNAAYGGMNGNTNWSNATHMGN
 40 GAYWSNCCNGCNAAYYTNWSNTTYACNGTNACNYTNGARAAYTNACNGARGARGAYGCNGGNACNTAY
 TGGTGYGGNGTNGAYACNCCNTGGYT NMNGAYTTYCAYGAYCCNGTNGTNGARGTNGARGTNWSGTN
 TTYCCNGCNWSNACNWSNATGACNCCNGCNWSNATHACNGCNGCNAAACNWSNACNATHACNACNGCN
 TTYCCNCCNGT NWSNWSNACNACNYTNTTYGCNGTNGGNGCNACNCAYWSNGCNWSNATHCARGARGAR
 ACNGARGARGTNGTNAAYWSNCARYTNCCNYTNYTNYTNWSNYTNYTNGCNYTNYTNYTNYTNYTN
 45 GTNGGNGCNWSNYTNYTNGCNTGGMG NATGTTYCARAARTGGATHAARGCNGGNGAYCAYWSNGARYTN
 WSNCARAAYCCNAARCARGCNGCNACNCARWSNGARYTNCA YTAGCNAAYYTNGARYTNYTNATGTGG
 CCNYTNCARGARAARCCNGCNCNCCNMGNGARGTNGARGTNGARTAYWSNACNGTNGCNWSNCCNMGN
 GARGARYTNCA YTAGCNWSNGTNGTNTTYGAYWSNAAYACNAAYMG NATHGCNGCNCARMGNCCNMGN
 GARGARGARCCNGAYWSNGAYTAYWSNGTNATHMGNAAACN

50 short (SEQ ID NO: 9); N may be A, C, G, or T:
 ATGGCNYTNCCNGTNACNGCNYTNYTNYTNCCNYTNGCNYTNYTNYTNCAYGCNGCNMGNCCNGAYTAY
 AARGAYGAYGAYGAYAA RATHGAYATGACNCCNGCNWSNATHACNGCNGCNAAACNWSNACNATHACN
 ACNGCNTTYCCNCCNGT NWSNWSNACNACNYTNTTYGCNGTNGGNGCNACNCAYWSNGCNWSNATHCAR
 55 GARGARACNGARGARGTNGTNAAYWSNCARYTNCCNYTNYTNYTNWSNYTNYTNGCNYTNYTNYTNYTN
 YTNYTNGTNGGNGCNWSNYTNYTNGCNTGGMG NATGTTYCARAARTGGATHAARGCNGGNGAYCAYWSN
 GARYTNWSNCARAAYCCNAARCARGCNGCNACNCARWSNGARYTNCA YTAGCNAAYYTNGARYTNYTN
 ATGTGGCCNYTNCARGARAARCCNGCNCNCCNMGNGARGTNGARGTNGARTAYWSNACNGTNGCNWSN
 CCNMGNARGARYTNCA YTAGCNWSNGTNGTNTTYGAYWSNAAYACNAAYMG NATHGCNGCNCARMGN
 60 CCNMGNARGARGARCCNGAYWSNGAYTAYWSNGTNATHMGNAAACN

The currently available methods to generate large amounts of DC in vitro allow detailed molecular analysis of DC. See Romani, et al. (1994) J. Exp. Med. 180:83-93. cDNA libraries derived from monocyte-derived DC were analyzed leading to the identification of several interesting gene products, including a novel DC-specific chemokine, DC-CK1. See Zhou and Tedder (1996) Proc. Natl. Acad. Sci. USA 93:2588-2592.

Pairwise protein sequence alignments performed between DC-STAMP and members of several 7 TM subclasses (ClustalW) showed identities below 20%, suggesting that the DC-STAMP protein represents a novel protein family. However, the structural homology of DC-STAMP to members of the superfamily of G-protein coupled (or linked) receptors (GPCR, or GPLR) suggests related function of this molecule. As a class, these receptors are integral membrane proteins characterized by amino acid sequences which contain seven hydrophobic domains. See, e.g., Ruffolo and Hollinger (eds. 1995) G-Protein Coupled Transmembrane Signaling Mechanisms CRC Press, Boca Raton, FL; Watson and Arkinstall (1994) The G-Protein Linked Receptor FactsBook Academic Press, San Diego, CA; Peroutka (ed. 1994) G Protein-Coupled Receptors CRC Press, Boca Raton, FL; Houslay and Milligan (1990) G-Proteins as Mediators of Cellular Signaling Processes Wiley and Sons, New York, NY; and Dohlman, et al. (1991) Ann. Rev. Biochem. 60:653-688. These hydrophobic domains are predicted to represent transmembrane spanning regions of the proteins. These GPCRs are found in a wide range of organisms and are typically involved in the transmission of signals to the interior of the cell, e.g., through interaction, e.g., with heterotrimeric G-proteins. They respond to a wide and diverse range of agents including lipid analogs, amino acid derivatives, small peptides, and other molecules.

A predicted model of the structure of the DC-STAMP protein has an extracellular N-terminus, a cytoplasmic C-terminus, 3 cytoplasmic loops, and 3 extracellular loops,

containing 2 consensus sequences for N-linked glycosylation on the second and one on the third extracellular loop.

The serine residues in the C-terminus of DC-STAMP are putative targets for phosphorylation. For several 7 TM proteins, it has been shown that phosphorylation of serine and threonine residues in the C-tail of the receptor by G protein coupled receptor kinases results in uncoupling of the activated receptor from its G proteins, thereby desensitizing the receptor. See Böhm, et al. (1997) J. Biol. Chem. 332:1-18. Further experiments can be performed to determine whether the DC-STAMP protein can be phosphorylated at these serine residues.

Other characteristics of 7 TM proteins include a signature of cysteine residues in the first two extracellular loops, which might form disulphide bridges and stabilize the protein structure. See Savarese and Fraser (1992) J. Biol. Chem. 283:1-19. Also, cysteine residues in the carboxyl tails are potential sites for palmitoylation and may serve to form a fourth intracellular loop. See O'Dowd et al. (1989) J. Biol. Chem. 264:7564-7569; and Strader, et al. (1994) Ann. Rev. Biochem. 63:101-132. The DC-STAMP protein contains an alternative signature of cysteines in TM1 and TM2, and has no cysteine residues in its C-terminus. Combined with the absence of any sequence homology to 7 TM receptors, the described characteristics of the DC-STAMP protein suggest that this novel protein does not belong to any of the existing 7 TM subclasses. DC-STAMP could either form a novel 7 TM protein subclass or be the first member of a new family of multi-membrane spanning proteins.

Characteristic of the DC-STAMP terminus is its very basic amino acid composition. There is some indication that juxtamembrane clusters of positively charged residues in cytoplasmic receptor tails can associate with proteins of the ERM (ezrin, radixin, moesin) family. See Bretscher (1999) Curr. Op. Cell Biol. 11:109-116. Since these ERM proteins have been implicated as membrane cytoskeletal

linkers, this might suggest association of DC-STAMP with the cytoskeleton. Ligation of DC-STAMP might affect adhesive or migratory capacities, essential for proper DC function. These can be tested.

5 Structural predictions for the type III membrane protein suggest hydrophobic transmembrane segments from about val35-ala51 (TM1); ser57-ser75 (TM2); asn96-ile114 (TM3); tyr144-aspl62 (TM4); leu214-phe230 (TM5); leu295-val313 (TM6); and pro379-met398 (TM7). The use of several
10 TM prediction programs for the hydropathy analysis of DC-STAMP resulted in different models, regarding the position and number of transmembrane domains. The data suggest a model in which the DC-STAMP protein contains 7 transmembrane domains. First, the position of potential glycosylation
15 sites, putative phosphorylation recognition sites and the intracellular C-terminus favor this model. Second, based on the presence of charged amino acids, which generally flank transmembrane regions, the model supports a type IIIb integral membrane protein, with the N-terminus of DC-STAMP
20 outside and the C-terminus on the luminal side of the membrane. Finally, the DC-STAMP protein contains a proline residue between TM1 and TM2. Prolines are known to disrupt helices and the proline residue at position 56 in DC-STAMP could help to establish a loop and redirect the protein into
25 the membrane. This could possibly compensate for the rather short hydrophobic stretches of TM1 (transmembrane region 1) and TM2, 17 and 18 amino acids in length, respectively. Also, both TM1 and TM2 contain a pair of cysteine residues, which could further stabilize this intramembrane loop by a
30 disulphide bridge near the outer membrane side.

 However, since TM2, TM3, and TM4 are rather weak TM regions, alternative models cannot be excluded comprising 5 or 4 TM regions, in which TM1 and TM2 form a single transmembrane domain and either TM3 or TM4 or both are not
35 present. Only two 5 TM spanning proteins have been described so far, the 865 amino acid AC133 orphan receptor, expressed by hematopoietic stem cells (Miraglia, et al.

(1997) Blood 90:5013-5021), and the CD47 molecule (Lindberg, et al. (1993) J. Cell. Biol. 123:485-496). The TM4 superfamily consists of nearly 20 genes, encoding proteins which are thought to be involved in the grouping and
5 stabilization of cell-surface proteins. The DC-STAMP protein however, does not show significant homology to either these TM4 or TM5 proteins, indicating that DC-STAMP represents a novel protein family.

Transmembrane segments are typically 20-25 amino acids
10 in length. Based upon models and data on bacteriorhodopsin, these regions are predicted to be α -helices and be oriented to form a ligand binding pocket. See, e.g., Findley, et al. (1990) Trends Pharmacol. Sci. 11:492-499. Other data suggest that the amino termini of the proteins are
15 extracellular, and the carboxy termini are intracellular. See, e.g., Lodish, et al. (1995) Molecular Cell Biology 3d ed., Scientific American, New York; and Watson and Arkinstall (1994) The G-Protein Linked Receptor FactsBook Academic Press, San Diego, CA. Phosphorylation cascades
20 have been implicated in the signal transduction pathway of these receptors.

7 TM receptors comprise a family of very heterogeneous proteins that signal through heterotrimeric G proteins (Strader, et al. (1994) Ann. Rev. Biochem. 63:101-132),
25 including chemokine, hormone and photoreceptors. The vast majority of 7 TM proteins are G-protein coupled. The presence of an aspartate in the second transmembrane region and a so-called "DRY or ERY motif", closely following the third transmembrane region, are both thought to be involved
30 in the signal transduction via G-proteins. See Savarese and Fraser (1992) J. Biol. Chem. 267:1-19; and Bourne (1997) Curr. Op. Cell Biol. 9:134-142. DC-STAMP contains neither of these sequences, but such motifs may possibly not be recognized as such. Similarly, other 7 TM proteins, such as
35 the Duffy antigen receptor (DARC) on erythrocytes and the EGF-7TM receptors, also lack consensus sequences for G protein coupling and no signal transduction via these

receptors has been proven as yet. See Horuk, et al. (1996) J. Leukoc. Biol. 59:29-38; and McKnight and Gordon (1996) Immunol. Today 17:283-287.

Although the full spectrum of biological activities mediated by these 7 transmembrane receptors has not been fully determined, chemoattractant effects are recognized. Chemokine receptors are notable members of the GPCR family. See, e.g., Samson, et al. (1996) Biochemistry 35:3362-3367; and Rapport, et al. (1996) J. Leukocyte Biology 59:18-23.

The best known biological functions of chemokine molecules relate to chemoattraction of leukocytes. However, new chemokines and receptors are being discovered, and their biological effects on the various cells responsible for immunological responses are topics of continued study.

DC-STAMP agonists, or antagonists, may also act as functional or receptor antagonists, e.g., which block DC interactions or physiology, or mediating the opposite actions. DC are implicated in T cell mediated immunity, which is important in various diseases. T cell immunity is deficient in various contexts, e.g., in tumor immunotherapy and allergic responses. Conversely, it is overactive in autoimmune diseases and transplantation rejection contexts. Thus, DC-STAMP, or its antagonists, may be useful in the treatment of abnormal medical conditions, including immune disorders, e.g., immune deficiencies, chronic inflammation, or tissue rejection, or other physiological conditions. The implication of antigen presentation in initiation of an immune response is a likely condition to be affected by the use of a DC-STAMP related reagent. Compositions combining the DC-STAMP and other DC affecting reagents will often be used. See below.

The DSP-1 forms are highly expressed in mast cells, which are implicated in allergic responses, particularly in release of histamine. See, e.g., Kaliner and Metcalfe (eds. 1992) The Mast Cell in Health and Disease. Reagents related to activation or deactivation of DSP-1 signaling may be important in medical conditions mediated by cells expressing

the antigen. Both the long (L) and short (s) forms are type I membrane proteins, and possess cytoplasmic domains with multiple ITIM motifs, suggesting an inhibitory receptor signaling role. See, e.g., Kung, et al. (1999) J. Immunol. 162:5876-87; Carlyle, et al. (1999) J. Immunol. 162:5917-5923; Nakamura, et al. (1997) J. Exp. Med. 185:673-684; Olcese, et al. (1996) J. Immunol. 156:4531-4534; and Daëron, et al. (1995) Immunity 3:635-646. The transmembrane segments correspond approximately to residues 172-188 (166-198) for the L form, and 59-75 (53-85) of the S form. However the actual boundaries of transmembrane segments may vary or depend upon kinetic and other factors.

These natural antigens will be capable of mediating various biochemical responses which lead to biological or physiological responses in target cells. The preferred embodiments characterized herein are from primate, e.g., human, but other species counterparts will exist in nature. Additional sequences for proteins in other mammalian species, e.g., primates, canines, felines, and rodents, should also be available, particularly the domestic animal species. See below. The descriptions below are directed, for exemplary purposes, to a human DC-STAMP or DSP-1, but are likewise applicable to related embodiments from other species.

25

II. Purified DC-STAMP or DSP-1

Primate, e.g., human, DC-STAMP or DSP-1 amino acid sequences, are shown in Tables 1 or 2. Other naturally occurring nucleic acids which encode the proteins can be isolated by standard procedures using the provided sequences, e.g., PCR techniques, or by hybridization. Primer extension or RACE methods can extend to adjacent sequence, either on message or genomic. These amino acid sequences, provided amino to carboxy, are important in providing sequence information for the proteins allowing for distinguishing the protein antigen from other proteins and exemplifying numerous variants. Moreover, the peptide

sequences allow preparation of peptides to generate antibodies to recognize such segments, and nucleotide sequences allow preparation of oligonucleotide probes, both of which are strategies for detection or isolation, e.g., cloning, of genes encoding such sequences.

As used herein, the term "human DC-STAMP" shall encompass, when used in a protein context, a protein having amino acid sequence corresponding to a polypeptide shown in SEQ ID NO: 2, or significant fragments thereof. Preferred embodiments comprise a plurality of distinct, e.g., nonoverlapping, segments of the specified length. Typically, the plurality will be at least two, more usually at least three, and preferably 5, 7, or even more. While the length minima are provided, longer lengths, of various sizes, may be appropriate, e.g., one of length 7, and two of length 12. Similarly with the term DSP-1 and SEQ ID NO: 4 and 6.

Binding components, e.g., antibodies, typically bind to an antigen with high affinity, e.g., at least about 100 nM, usually better than about 30 nM, preferably better than about 10 nM, and more preferably at better than about 3 nM. Counterpart proteins will be found in mammalian species other than human, e.g., other primates, ungulates, or rodents. Non-mammalian species should also possess structurally or functionally related genes and proteins, e.g., birds or fish.

The term "polypeptide" as used herein includes a significant fragment or segment, and encompasses a stretch of amino acid residues of at least about 8 amino acids, generally at least about 12 amino acids, typically at least about 16 amino acids, preferably at least about 20 amino acids, and, in particularly preferred embodiments, at least about 30 or more amino acids, e.g., 35, 40, 45, 50, etc. Such fragments may have ends which begin and/or end at virtually all positions, e.g., beginning at residues 1, 2, 3, etc., and ending at, e.g., 150, 149, 148, etc., in all practical combinations. Particularly interesting peptides

have ends corresponding to structural domain boundaries, e.g., transmembrane segments or identified motifs. See Tables 1 and 2.

The term "binding composition" refers to molecules
5 that bind with specificity to DC-STAMP or DSP-1, e.g., in an antibody-antigen interaction. The specificity may be more or less inclusive, e.g., specific to a particular embodiment, or to groups of related embodiments, e.g., primate, rodent, etc. It also includes compounds, e.g.,
10 proteins, which specifically associate with DC-STAMP, including in a natural physiologically relevant protein-protein interaction, either covalent or non-covalent. The molecule may be a polymer, or chemical reagent. A functional analog may be a protein with structural
15 modifications, or it may be a molecule which has a molecular shape which interacts with the appropriate binding determinants. The compounds may serve as agonists or antagonists of a receptor binding interaction, see, e.g., Goodman, et al. (eds.) Goodman & Gilman's: The
20 Pharmacological Bases of Therapeutics (current ed.) Pergamon Press.

Substantially pure, e.g., in a protein context, typically means that the protein is free from other contaminating proteins, nucleic acids, or other biologicals
25 derived from the original source organism. Purity may be assayed by standard methods, typically by weight, and will ordinarily be at least about 40% pure, generally at least about 50% pure, often at least about 60% pure, typically at least about 80% pure, preferably at least about 90% pure,
30 and in most preferred embodiments, at least about 95% pure. Carriers or excipients will often be added.

Solubility of a polypeptide or fragment depends upon the environment and the polypeptide. Many parameters affect polypeptide solubility, including temperature, electrolyte
35 environment, size and molecular characteristics of the polypeptide, and nature of the solvent. Typically, the temperature at which the polypeptide is used ranges from

about 4° C to about 65° C. Usually the temperature at use is greater than about 18° C. For diagnostic purposes, the temperature will usually be about room temperature or warmer, but less than the denaturation temperature of components in the assay. For therapeutic purposes, the temperature will usually be body temperature, typically about 37° C for humans and mice, though under certain situations the temperature may be raised or lowered in situ or in vitro.

10 The size and structure of the polypeptide should generally be in a substantially stable state, and usually not in a denatured state. The polypeptide may be associated with other polypeptides in a quaternary structure, e.g., to confer solubility, or associated with lipids or detergents.

15 The solvent and electrolytes will usually be a biologically compatible buffer, of a type used for preservation of biological activities, and will usually approximate a physiological aqueous solvent. Usually the solvent will have a neutral pH, typically between about 5 and 10, and preferably about 7.5. On some occasions, one or more detergents will be added, typically a mild non-denaturing one, e.g., CHS (cholesteryl hemisuccinate) or CHAPS (3-[3-cholamidopropyl]dimethylammonio]-1-propane sulfonate), or a low enough concentration as to avoid significant disruption of structural or physiological properties of the protein. In other instances, a harsh detergent may be used to effect significant denaturation.

III. Physical Variants

30 This invention also encompasses proteins or peptides having substantial amino acid sequence identity with the amino acid sequences of the DC-STAMP or DSP-1 antigens. The variants include species, polymorphic, or allelic variants.

Amino acid sequence homology, or sequence identity, is determined by optimizing residue matches, if necessary, by introducing gaps as required. See also Needleham, et al. (1970) J. Mol. Biol. 48:443-453; Sankoff, et al. (1983)

Chapter One in Time Warps, String Edits, and Macromolecules:
The Theory and Practice of Sequence Comparison, Addison-

Wesley, Reading, MA; and software packages from

IntelliGenetics, Mountain View, CA; and the University of

- 5 Wisconsin Genetics Computer Group, Madison, WI. Sequence identity changes when considering conservative substitutions as matches. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid; asparagine, glutamine; serine, threonine; 10 lysine, arginine; and phenylalanine, tyrosine. The conservation may apply to biological features, functional features, or structural features. Homologous amino acid sequences are typically intended to include natural polymorphic or allelic and interspecies variations of a protein sequence. Typical homologous proteins or peptides will have from 25-100% identity (if gaps can be introduced), to 50-100% identity (if conservative substitutions are included) with the amino acid sequences of the antigens. 15 Identity measures will be at least about 35%, generally at least about 40%, often at least about 50%, typically at least about 60%, usually at least about 70%, preferably at least about 80%, and more preferably at least about 90%. 20

- The isolated DC-STAMP or DSP-1 DNA can be readily modified by nucleotide substitutions, nucleotide deletions, nucleotide insertions, and inversions of short nucleotide stretches. These modifications may result in novel DNA sequences which encode these antigens, their derivatives, or proteins having similar physiological, immunogenic, or antigenic, or other functional activity. These modified sequences can be used to produce mutant antigens or to enhance expression. Enhanced expression may involve gene amplification, increased transcription, increased translation, and other mechanisms. "Mutant DC-STAMP" 25 encompasses a polypeptide otherwise falling within the sequence identity definition of the DC-STAMP as set forth above, but having an amino acid sequence which differs from 30 35

that of the antigen as normally found in nature, whether by way of deletion, substitution, or insertion. This generally includes proteins having significant identity with a protein having sequence of SEQ ID NO: 2, and as sharing various biological activities, e.g., antigenic or immunogenic, with those sequences, and in preferred embodiments contain most of the natural full length disclosed sequences. Full length sequences will typically be preferred, though truncated versions will also be useful, likewise, genes or proteins found from natural sources are typically most desired. Similar concepts apply to different DC-STAMP proteins, particularly those found in various warm blooded animals, e.g., mammals and birds. These descriptions are generally meant to encompass many DC-STAMP proteins, not limited to the particular primate embodiments specifically discussed.

DC-STAMP or DSP-1 mutagenesis can also be conducted by making amino acid insertions or deletions. Substitutions, deletions, insertions, or any combinations may be generated to arrive at a final construct. Insertions include amino- or carboxy- terminal fusions. Random mutagenesis can be conducted at a target codon and the expressed mutants can then be screened for the desired activity. Methods for making substitution mutations at predetermined sites in DNA having a known sequence are well known in the art, e.g., by M13 primer mutagenesis or polymerase chain reaction (PCR) techniques. See, e.g., Sambrook, et al. (1989); Ausubel, et al. (1987 and Supplements); and Kunkel, et al. (1987) Methods in Enzymol. 154:367-382. Preferred embodiments include, e.g., 1-fold, 2-fold, 3-fold, 5-fold, 7-fold, etc., preferably conservative substitutions at the nucleotide or amino acid levels. Preferably the substitutions will be away from the conserved cysteines, and often will be in the regions away from the extramembrane domains. Such variants may be useful to produce specific antibodies, and often will share many or all biological properties.

The present invention also provides recombinant proteins, e.g., heterologous fusion proteins using segments

from these proteins. A heterologous fusion protein is a fusion of proteins or segments which are naturally not normally fused in the same manner. A similar concept applies to heterologous nucleic acid sequences.

5 In addition, new constructs may be made from combining similar functional domains from other proteins. For example, target-binding or other segments may be "swapped" between different new fusion polypeptides or fragments. See, e.g., Cunningham, et al. (1989) Science 243:1330-1336; 10 and O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992.

The phosphoramidite method described by Beaucage and Carruthers (1981) Tetra. Letts. 22:1859-1862, will produce useful synthetic DNA fragments. A double stranded fragment will often be obtained either by synthesizing the 15 complementary strand and annealing the strand together under appropriate conditions or by adding the complementary strand using DNA polymerase with an appropriate primer sequence, e.g., PCR techniques.

Structural analysis can be applied to this gene, in 20 comparison to members of related gene families, e.g., GPCRs. In particular, β -sheet and α -helix residues can be determined using, e.g., RASMOL program, see Bazan, et al. (1996) Nature 379:591; Lodi, et al. (1994) Science 263:1762-1766; Sayle and Milner-White (1995) TIBS 20:374-376; and 25 Gronenberg, et al. (1991) Protein Engineering 4:263-269. Preferred residues for substitutions include the surface exposed extramembrane residues which would be predicted to interact with a counterstructure or ligand. Other residues which should conserve function will be conservative 30 substitutions, particularly at a position far from the surface exposed residues, e.g., an intramembrane residue.

IV. Functional Variants

The blocking of physiological response to DC-STAMP or 35 DSP-1 may result from the competitive inhibition of binding of a ligand or counterstructure to the antigen.

In vitro assays of the present invention will often use isolated protein, soluble fragments comprising receptor binding segments of these proteins, or fragments attached to solid phase substrates. These assays will also allow for
5 the diagnostic determination of the effects of either binding segment mutations and modifications, or ligand mutations and modifications.

This invention also contemplates the use of competitive drug screening assays, e.g., where neutralizing
10 antibodies to the antigen, or receptor binding fragments compete with a test compound.

"Derivatives" of DC-STAMP or DSP-1 antigens include amino acid sequence mutants from naturally occurring forms, glycosylation variants, and covalent or aggregate conjugates
15 with other chemical moieties. Covalent derivatives can be prepared by linkage of functionalities to groups which are found in amino acid side chains or at the N- or C- termini, e.g., by standard means. See, e.g., Lundblad and Noyes (1988) Chemical Reagents for Protein Modification, vols. 1-
20 2, CRC Press, Inc., Boca Raton, FL; Hugli (ed. 1989) Techniques in Protein Chemistry, Academic Press, San Diego, CA; and Wong (1991) Chemistry of Protein Conjugation and Cross Linking, CRC Press, Boca Raton, FL.

In particular, glycosylation alterations are included,
25 e.g., made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing, or in further processing steps. See, e.g., Elbein (1987) Ann. Rev. Biochem. 56:497-534. Also embraced are versions of the peptides with the same primary amino acid sequence which
30 have other minor modifications, including phosphorylated amino acid residues, e.g., phosphotyrosine, phosphoserine, or phosphothreonine.

Fusion polypeptides between DC-STAMP or DSP-1 and other homologous or heterologous proteins are also provided.
35 Many 7TM receptors or other surface proteins are multimeric, e.g., homodimeric entities, and a repeat construct may have various advantages, including lessened susceptibility to

proteolytic cleavage. Typical examples are fusions of a reporter polypeptide, e.g., luciferase, with a segment or domain of a protein, e.g., a receptor-binding segment, so that the presence or location of the fused ligand may be easily determined. See, e.g., Dull, et al., U.S. Patent No. 4,859,609. Other gene fusion partners include bacterial β -galactosidase, trpE, Protein A, β -lactamase, alpha amylase, alcohol dehydrogenase, yeast alpha mating factor, and detection or purification tags such as a FLAG sequence of His6 sequence. See, e.g., Godowski, et al. (1988) Science 241:812-816.

Fusion peptides will typically be made by either recombinant nucleic acid methods or by synthetic polypeptide methods. Techniques for nucleic acid manipulation and expression are described generally, e.g., in Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.), vols. 1-3, Cold Spring Harbor Laboratory; and Ausubel, et al. (eds. 1993) Current Protocols in Molecular Biology, Greene and Wiley, NY. Techniques for synthesis of polypeptides are described, e.g., in Merrifield (1963) J. Amer. Chem. Soc. 85:2149-2156; Merrifield (1986) Science 232: 341-347; Atherton, et al. (1989) Solid Phase Peptide Synthesis: A Practical Approach, IRL Press, Oxford; and Grant (1992) Synthetic Peptides: A User's Guide, W.H. Freeman, NY. Refolding methods, e.g., with membranes, may be applicable to synthetic proteins.

This invention also contemplates the use of derivatives of DC-STAMP or DSP-1 proteins other than variations in amino acid sequence or glycosylation. Such derivatives may involve covalent or aggregative association with chemical moieties or protein carriers. Covalent or aggregative derivatives will be useful as immunogens, as reagents in immunoassays, or in purification methods such as for affinity purification of binding partners, e.g., other antigens. A DC-STAMP or DSP-1 can be immobilized by covalent bonding to a solid support such as cyanogen bromide-activated SEPHAROSE, by methods which are well known

in the art, or adsorbed onto polyolefin surfaces, with or without glutaraldehyde cross-linking, for use in the assay or purification of antibodies or an alternative binding composition. These proteins can also be labeled with a detectable group, e.g., for use in diagnostic assays. Purification of antigen may be effected by an immobilized antibody or complementary binding partner, e.g., binding portion of a receptor.

A solubilized fragment of this invention can be used as an immunogen for the production of antisera or antibodies specific for binding. Purified antigen can be used to screen monoclonal antibodies or antigen-binding fragments, encompassing antigen binding fragments of natural antibodies, e.g., Fab, Fab', F(ab)₂, etc. Purified DC-STAMP or DSP-1 antigens can also be used as a reagent to detect antibodies generated in response to the presence of elevated levels of the antigen, which may be diagnostic of an abnormal or specific physiological or disease condition. This invention contemplates antibodies raised against amino acid sequences encoded by nucleotide sequence shown in SEQ ID NO: 1 or 4 or 6, or fragments of proteins containing it. In particular, this invention contemplates antibodies having binding affinity to or being raised against specific domains, e.g., extracellular segments.

The present invention contemplates the isolation of additional closely related species variants. Southern and Northern blot analysis will establish that similar genetic entities exist in other mammals. It is likely that antigens are widespread in species variants, e.g., rodents, lagomorphs, carnivores, artiodactyla, perissodactyla, and primates.

The invention also provides means to isolate a group of related antigens displaying both distinctness and similarities in structure, expression, and function. Elucidation of many of the physiological effects of the molecules will be greatly accelerated by the isolation and characterization of additional distinct species or

polymorphic variants of them. In particular, the present invention provides useful probes for identifying additional homologous genetic entities in different species.

5 The isolated genes will allow transformation of cells lacking expression of DC-STAMP or DSP-1, e.g., either species types or cells which lack corresponding proteins and exhibit negative background activity. This should allow analysis of the function of antigen in comparison to untransformed control cells.

10 Dissection of critical structural elements which effect the various physiological functions mediated through these antigens is possible using standard techniques of modern molecular biology, particularly in comparing members of the related class. See, e.g., the homolog-scanning
15 mutagenesis technique described in Cunningham, et al. (1989) Science 243:1339-1336; and approaches used in O'Dowd, et al. (1988) J. Biol. Chem. 263:15985-15992; and Lechleiter, et al. (1990) EMBO J. 9:4381-4390.

Intracellular functions would probably involve
20 receptor signaling. However, protein internalization may occur under certain circumstances, and interaction between intracellular components and ligand or receptor may occur. Specific segments of interaction of membrane antigen with interacting components may be identified by mutagenesis or
25 direct biochemical means, e.g., cross-linking or affinity methods. Structural analysis by crystallographic or other physical methods will also be applicable. Further investigation of the mechanism of signal transduction will include study of associated components which may be
30 isolatable by affinity methods or by genetic means, e.g., complementation analysis of mutants.

Further study of the expression and control of DC-STAMP or DSP-1 will be pursued. The controlling elements associated with the antigens should exhibit differential
35 physiological, developmental, tissue specific, or other expression patterns. Upstream or downstream genetic regions, e.g., control elements, are of interest.

Structural studies of the membrane antigens will lead to design of new antigens, particularly analogs exhibiting agonist or antagonist properties on the molecule. This can be combined with previously described screening methods to isolate antigens exhibiting desired spectra of activities.

V. Antibodies

Antibodies can be raised to various epitopes of the membrane proteins, including species, polymorphic, or allelic variants, and fragments thereof, both in their naturally occurring forms and in their recombinant forms. Additionally, antibodies can be raised to the proteins in either their active forms or in their inactive forms, including native or denatured versions. Anti-idiotypic antibodies are also contemplated.

Antibodies, including binding fragments and single chain versions, against predetermined fragments of the antigens can be raised by immunization of animals with conjugates of the fragments with immunogenic proteins. Monoclonal antibodies are prepared from cells secreting the desired antibody. These antibodies can be screened for binding to normal or defective proteins, or screened for agonistic or antagonistic activity, e.g., mediated through a receptor. Antibodies may be agonistic or antagonistic, e.g., by sterically blocking binding to a receptor. These monoclonal antibodies will usually bind with at least a K_D of about 1 mM, more usually at least about 300 μ M, typically at least about 100 μ M, more typically at least about 30 μ M, preferably at least about 10 μ M, and more preferably at least about 3 μ M or better.

A DC-STAMP or DSP-1 protein that specifically binds to or that is specifically immunoreactive with an antibody generated against a defined immunogen, such as an immunogen consisting of the amino acid sequence of SEQ ID NO: 2, is typically determined in an immunoassay. The immunoassay typically uses a polyclonal antiserum which was raised, e.g., to a protein of SEQ ID NO: 2. This antiserum is

selected to have low crossreactivity against other related proteins, e.g., human or rodent DC-STAMP, preferably from the same species, and any such crossreactivity is removed by immunoabsorption prior to use in the immunoassay.

5 In order to produce antisera for use in an immunoassay, the protein of SEQ ID NO: 2, or a combination thereof, is isolated as described herein. For example, recombinant protein may be produced in a mammalian cell line. An appropriate host, e.g., an inbred strain of mice
10 such as Balb/c, is immunized with the selected protein, typically using a standard adjuvant, such as Freund's adjuvant, and a standard mouse immunization protocol (see Harlow and Lane, supra). Alternatively, a synthetic peptide derived from the sequences disclosed herein and conjugated
15 to a carrier protein can be used as an immunogen. Polyclonal sera are collected and titered against the immunogen protein in an immunoassay, e.g., a solid phase immunoassay with the immunogen immobilized on a solid support. Polyclonal antisera with a titer of 10^4 or greater are selected and
20 tested for their cross reactivity against other related family members, e.g., rodent DC-STAMP, using a competitive binding immunoassay such as the one described in Harlow and Lane, supra, at pages 570-573. Preferably at least one other related family member is used in this determination in
25 conjunction with, e.g., the primate embodiment. The desired target family members can be produced as recombinant proteins and isolated using standard molecular biology and protein chemistry techniques as described herein.

Immunoassays in the competitive binding format can be
30 used for the crossreactivity determinations. For example, the protein of SEQ ID NO: 2 can be immobilized to a solid support. Proteins added to the assay compete with the binding of the antisera to the immobilized antigen. The ability of the above proteins to compete with the binding of
35 the antisera to the immobilized protein is compared to the protein of SEQ ID NO: 2. The percent crossreactivity for the above proteins is calculated, using standard

calculations. Those antisera with less than 10% crossreactivity with each of the proteins listed above are selected and pooled. The cross-reacting antibodies are then removed from the pooled antisera by immunoabsorption with the above-listed proteins.

The immunoabsorbed and pooled antisera are then used in a competitive binding immunoassay as described above to compare a second protein to the immunogen protein (e.g., the protein of SEQ ID NO: 2). In order to make this comparison, the two proteins are each assayed at a wide range of concentrations and the amount of each protein required to inhibit 50% of the binding of the antisera to the immobilized protein is determined. If the amount of the second protein required is less than twice the amount of the protein of the selected protein or proteins that is required, then the second protein is said to specifically bind to an antibody generated to the immunogen.

The antibodies of this invention can also be useful in diagnostic applications. As capture or non-neutralizing antibodies, they can be screened for ability to bind to the antigens without inhibiting binding to a receptor. As neutralizing antibodies, they can be useful in competitive binding assays. They will also be useful in detecting or quantifying DC-STAMP or DSP-1 protein or their receptors. See, e.g., Chan (ed. 1987) Immunology: A Practical Guide, Academic Press, Orlando, FL; Price and Newman (eds. 1991) Principles and Practice of Immunoassay, Stockton Press, N.Y.; and Ngo (ed. 1988) Nonisotopic Immunoassay, Plenum Press, N.Y. Cross absorptions, depletions, or other means will provide preparations of defined selectivity, e.g., unique or shared species specificities. These may be the basis for tests which will identify various groups of antigens.

Further, the antibodies, including antigen binding fragments, of this invention can be potent antagonists that bind to the antigen and inhibit functional binding, e.g., to a receptor which may elicit a biological response. They

also can be useful as non-neutralizing antibodies and can be coupled to toxins or radionuclides so that when the antibody binds to antigen, a cell expressing it, e.g., on its surface, is killed. Further, these antibodies can be
5 conjugated to drugs or other therapeutic agents, either directly or indirectly by means of a linker, and may effect drug targeting.

Antigen fragments may be joined to other materials, particularly polypeptides, as fused or covalently joined
10 polypeptides to be used as immunogens. An antigen and its fragments may be fused or covalently linked to a variety of immunogens, such as keyhole limpet hemocyanin, bovine serum albumin, tetanus toxoid, etc. See Microbiology, Hoeber
15 Medical Division, Harper and Row, 1969; Landsteiner (1962) Specificity of Serological Reactions, Dover Publications, New York; Williams, et al. (1967) Methods in Immunology and Immunochemistry, vol. 1, Academic Press, New York; and
Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press, NY, for descriptions of methods of preparing
20 polyclonal antisera.

In some instances, it is desirable to prepare monoclonal antibodies from various mammalian hosts, such as mice, rodents, primates, humans, etc. Description of techniques for preparing such monoclonal antibodies may be
25 found in, e.g., Stites, et al. (eds.) Basic and Clinical Immunology (4th ed.), Lange Medical Publications, Los Altos, CA, and references cited therein; Harlow and Lane (1988) Antibodies: A Laboratory Manual, CSH Press; Goding (1986) Monoclonal Antibodies: Principles and Practice (2d ed.),
30 Academic Press, New York; and particularly in Kohler and Milstein (1975) in Nature 256:495-497, which discusses one method of generating monoclonal antibodies.

Other suitable techniques involve in vitro exposure of lymphocytes to the antigenic polypeptides or alternatively
35 to selection of libraries of antibodies in phage or similar vectors. See, Huse, et al. (1989) "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in

Phage Lambda," Science 246:1275-1281; and Ward, et al. (1989) Nature 341:544-546. The polypeptides and antibodies of the present invention may be used with or without modification, including chimeric or humanized antibodies.

5 Frequently, the polypeptides and antibodies will be labeled by joining, either covalently or non-covalently, a substance which provides for a detectable signal. A wide variety of labels and conjugation techniques are known and are reported extensively in both the scientific and patent literature.

10 Suitable labels include radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent moieties, chemiluminescent moieties, magnetic particles, and the like. Patents, teaching the use of such labels include U.S. Patent Nos. 3,817,837; 3,850,752; 3,939,350; 3,996,345; 4,277,437;

15 4,275,149; and 4,366,241. Also, recombinant immunoglobulins may be produced, see Cabilly, U.S. Patent No. 4,816,567; Moore, et al., U.S. Patent No. 4,642,334; and Queen, et al. (1989) Proc. Nat'l Acad. Sci. USA 86:10029-10033.

The antibodies of this invention can also be used for

20 affinity chromatography in isolating the protein. Columns can be prepared where the antibodies are linked to a solid support. See, e.g., Wilchek et al. (1984) Meth. Enzymol. 104:3-55. The converse may be used to purify antibodies.

Antibodies raised against DC-STAMP or DSP-1 will also

25 be useful to raise anti-idiotypic antibodies. These will be useful in detecting or diagnosing various immunological conditions related to expression of the respective antigens.

VI. Nucleic Acids

30 The described peptide sequences and the related reagents are useful in detecting, isolating, or identifying a DNA clone encoding DC-STAMP or DSP-1, e.g., from a natural source. Typically, it will be useful in isolating a gene from mammal, and similar procedures will be applied to

35 isolate genes from other species, e.g., warm blooded animals, such as birds and mammals. Cross hybridization will allow isolation of DC-STAMP from the same, e.g.,

polymorphic variants, or other species. A number of different approaches will be available to successfully isolate a suitable nucleic acid clone.

The purified protein or defined peptides are useful
5 for generating antibodies by standard methods, as described above. Synthetic peptides or purified protein can be presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane
10 (1989) Antibodies: A Laboratory Manual, Cold Spring Harbor Press.

For example, the specific binding composition could be used for screening of an expression library made from a cell line which expresses a DC-STAMP. Screening of intracellular
15 expression can be performed by various staining or immunofluorescence procedures. Binding compositions could be used to affinity purify or sort out cells expressing a surface fusion protein.

The peptide segments can also be used to predict
20 appropriate oligonucleotides to screen a library. The genetic code can be used to select appropriate oligonucleotides useful as probes for screening. See, e.g., SEQ ID NO: 1 or 4 or 6. In combination with polymerase chain reaction (PCR) techniques, synthetic oligonucleotides
25 will be useful in selecting correct clones from a library. Complementary sequences will also be used as probes, primers, or antisense strands. Various fragments should be particularly useful, e.g., coupled with anchored vector or poly-A complementary PCR techniques or with complementary
30 DNA of other peptides.

This invention contemplates use of isolated DNA or fragments to encode an antigenic or biologically active corresponding polypeptide, particularly lacking the portion coding an untranslated 5' portion of the described sequence.
35 In addition, this invention covers isolated or recombinant DNA which encodes a biologically active protein or polypeptide and which is capable of hybridizing under

appropriate conditions with the DNA sequences described herein. Said biologically active protein or polypeptide can be an intact antigen, or fragment, and have an amino acid sequence disclosed in, e.g., SEQ ID NO: 2 or 5 or 7,

5 particularly a mature, secreted polypeptide. Further, this invention covers the use of isolated or recombinant DNA, or fragments thereof, which encode proteins which exhibit high identity to membrane DC-STAMP or DSP-1. The isolated DNA can have the respective regulatory sequences in the 5' and
10 3' flanks, e.g., promoters, enhancers, poly-A addition signals, and others. Alternatively, expression may be effected by operably linking a coding segment to a heterologous promoter, e.g., by inserting a promoter upstream from an endogenous gene.

15 An "isolated" nucleic acid is a nucleic acid, e.g., an RNA, DNA, or a mixed polymer, which is substantially separated from other components which naturally accompany a native sequence, e.g., ribosomes, polymerases, and/or flanking genomic sequences from the originating species.
20 The term embraces a nucleic acid sequence which has been removed from its naturally occurring environment, and includes recombinant or cloned DNA isolates and chemically synthesized analogs or analogs biologically synthesized by heterologous systems. A substantially pure molecule
25 includes isolated forms of the molecule. Generally, the nucleic acid will be in a vector or fragment less than about 50 kb, usually less than about 30 kb, typically less than about 10 kb, and preferably less than about 6 kb.

An isolated nucleic acid will generally be a
30 homogeneous composition of molecules, but will, in some embodiments, contain minor heterogeneity. This heterogeneity is typically found at the polymer ends or portions not critical to a desired biological function or activity.

35 A "recombinant" nucleic acid is defined either by its method of production or its structure. In reference to its method of production, e.g., a product made by a process, the

process is use of recombinant nucleic acid techniques, e.g., involving human intervention in the nucleotide sequence, typically selection or production. Alternatively, it can be a nucleic acid made by generating a sequence comprising
5 fusion of two fragments which are not naturally contiguous to each other, but is meant to exclude products of nature, e.g., naturally occurring mutants. Thus, e.g., products made by transforming cells with a nonnaturally occurring vector is encompassed, as are nucleic acids comprising
10 sequence derived using any synthetic oligonucleotide process. Such is often done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or removing a sequence recognition site.

15 Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a single genetic entity comprising a desired combination of functions not found in the commonly available natural forms. Restriction enzyme recognition sites are often the target of
20 such artificial manipulations, but other site specific targets, e.g., promoters, DNA replication sites, regulation sequences, control sequences, or other useful features may be incorporated by design. A similar concept is intended for a recombinant, e.g., fusion, polypeptide. Specifically
25 included are synthetic nucleic acids which, by genetic code redundancy, encode polypeptides similar to fragments of these antigens, and fusions of sequences from various different species or polymorphic variants.

A significant "fragment" in a nucleic acid context is
30 a contiguous segment of at least about 17 nucleotides, generally at least about 22 nucleotides, ordinarily at least about 29 nucleotides, more often at least about 35 nucleotides, typically at least about 41 nucleotides, usually at least about 47 nucleotides, preferably at least
35 about 55 nucleotides, and in particularly preferred embodiments will be at least about 60 or more nucleotides, e.g., 67, 73, 81, 89, 95, etc.

A DNA which codes for a DC-STAMP or DSP-1 protein will be particularly useful to identify genes, mRNA, and cDNA species which code for related or similar proteins, as well as DNAs which code for homologous proteins from different species. There will be homologs in other species, including primates, rodents, canines, felines, birds, and fish. Various DC-STAMP or DSP-1 proteins should be homologous and are encompassed herein. However, even proteins that have a more distant evolutionary relationship to the antigen can readily be isolated under appropriate conditions using these sequences if they are sufficiently homologous. Primate membrane proteins are of particular interest.

Recombinant clones derived from the genomic sequences, e.g., containing introns, will be useful for transgenic studies, including, e.g., transgenic cells and organisms, and for gene therapy. See, e.g., Goodnow (1992) "Transgenic Animals" in Roitt (ed.) Encyclopedia of Immunology, Academic Press, San Diego, pp. 1502-1504; Travis (1992) Science 256:1392-1394; Kuhn, et al. (1991) Science 254:707-710; Capecchi (1989) Science 244:1288; Robertson (ed. 1987) Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, IRL Press, Oxford; Rosenberg (1992) J. Clinical Oncology 10:180-199; and Cournoyer and Caskey (1993) Ann. Rev. Immunol. 11:297-329. Alternatively, expression may be effected by operably linking a coding segment to a heterologous promoter, e.g., by inserting a promoter upstream from an endogenous gene. See, e.g., Treco, et al. W096/29411 or USSN 08/406,030.

Substantial homology, e.g., identity, in the nucleic acid sequence comparison context means either that the segments, or their complementary strands, when compared, are identical when optimally aligned, with appropriate nucleotide insertions or deletions, in at least about 50% of the nucleotides, generally at least about 58%, ordinarily at least about 65%, often at least about 71%, typically at least about 77%, usually at least about 85%, preferably at least about 95 to 98% or more, and in particular

embodiments, as high as about 99% or more of the nucleotides. Alternatively, substantial homology exists when the segments will hybridize under selective hybridization conditions, to a strand, or its complement, typically using a sequence of DC-STAMP or DSP-1, e.g., in SEQ ID NO: 1 or 4 or 6. Typically, selective hybridization will occur when there is at least about 55% identity over a stretch of at least about 30 nucleotides, preferably at least about 75% over a stretch of about 25 nucleotides, and most preferably at least about 90% over about 20 nucleotides. See, Kanehisa (1984) Nuc. Acids Res. 12:203-213. The length of identity comparison, as described, may be over longer stretches, and in certain embodiments will be over a stretch of at least about 17 nucleotides, usually at least about 28 nucleotides, typically at least about 40 nucleotides, and preferably at least about 75 to 100 or more nucleotides.

Stringent conditions, in referring to homology in the hybridization context, will be stringent combined conditions of salt, temperature, organic solvents, and other parameters, typically those controlled in hybridization reactions. Stringent temperature conditions will usually include temperatures in excess of about 30° C, usually in excess of about 37° C, typically in excess of about 55° C, 60° C, or 65° C, and preferably in excess of about 70° C. Stringent salt conditions will ordinarily be less than about 1000 mM, usually less than about 400 mM, typically less than about 250 mM, preferably less than about 150 mM, including about 100, 50, or even 20 mM. However, the combination of parameters is much more important than the measure of any single parameter. See, e.g., Wetmur and Davidson (1968) J. Mol. Biol. 31:349-370. Hybridization under stringent conditions should give a background of at least 2-fold over background, preferably at least 3-5 or more.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test

and reference sequences are input into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. The sequence comparison algorithm then calculates the percent
5 sequence identity for the test sequence(s) relative to the reference sequence, based on the designated program parameters.

Optical alignment of sequences for comparison can be conducted, e.g., by the local homology algorithm of Smith
10 and Waterman (1981) Adv. Appl. Math. 2:482, by the homology alignment algorithm of Needleman and Wunsch (1970) J. Mol. Biol. 48:443, by the search for similarity method of Pearson and Lipman (1988) Proc. Nat'l Acad. Sci. USA 85:2444, by computerized implementations of these algorithms (GAP,
15 BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by visual inspection (see generally Ausubel et al., supra).

One example of a useful algorithm is PILEUP. PILEUP
20 creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments to show relationship and percent sequence identity. It also plots a tree or dendrogram showing the clustering relationships used to create the alignment. PILEUP uses a
25 simplification of the progressive alignment method of Feng and Doolittle (1987) J. Mol. Evol. 35:351-360. The method used is similar to the method described by Higgins and Sharp (1989) CABIOS 5:151-153. The program can align up to 300 sequences, each of a maximum length of 5,000 nucleotides or
30 amino acids. The multiple alignment procedure begins with the pairwise alignment of the two most similar sequences, producing a cluster of two aligned sequences. This cluster is then aligned to the next most related sequence or cluster of aligned sequences. Two clusters of sequences are aligned
35 by a simple extension of the pairwise alignment of two individual sequences. The final alignment is achieved by a series of progressive, pairwise alignments. The program is

run by designating specific sequences and their amino acid or nucleotide coordinates for regions of sequence comparison and by designating the program parameters. For example, a reference sequence can be compared to other test sequences
5 to determine the percent sequence identity relationship using the following parameters: default gap weight (3.00), default gap length weight (0.10), and weighted end gaps.

Another example of algorithm that is suitable for determining percent sequence identity and sequence
10 similarity is the BLAST algorithm, which is described Altschul, et al. (1990) J. Mol. Biol. 215:403-410. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first
15 identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with a word of the same length in a database sequence. T is referred to as the neighborhood
20 word score threshold (Altschul, et al., supra). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are then extended in both directions along each sequence for as far as the cumulative alignment score can be increased.
25 Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of
30 either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLAST program uses as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff and Henikoff (1989) Proc. Nat'l Acad. Sci. USA 89:10915)
35 alignments (B) of 50, expectation (E) of 10, M=5, N=4, and a comparison of both strands.

In addition to calculating percent sequence identity, the BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, e.g., Karlin and Altschul (1993) Proc. Nat'l Acad. Sci. USA 90:5873-5787).

5 One measure of similarity provided by the BLAST algorithm is the smallest sum probability ($P(N)$), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a
10 reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.1, more preferably less than about 0.01, and most preferably less than about 0.001.

A further indication that two nucleic acid sequences
15 of polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second
20 polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules hybridize to each other under stringent conditions, as described below.

25 DC-STAMP or DSP-1 from other mammalian species can be cloned and isolated by cross-species hybridization of closely related species. Homology may be relatively low between distantly related species, and thus hybridization of relatively closely related species is advisable.
30 Alternatively, preparation of an antibody preparation which exhibits less species specificity may be useful in expression cloning approaches.

VII. Making DC-STAMP or DSP-1; Mimetics

35 DNA which encodes the DC-STAMP or DSP-1 or fragments thereof can be obtained by chemical synthesis, screening cDNA libraries, or screening genomic libraries prepared from

a wide variety of cell lines or tissue samples. See, e.g., Okayama and Berg (1982) Mol. Cell. Biol. 2:161-170; Gubler and Hoffman (1983) Gene 25:263-269; and Glover (ed. 1984) DNA Cloning: A Practical Approach, IRL Press, Oxford.

- 5 Alternatively, the sequences provided herein provide useful PCR primers or allow synthetic or other preparation of suitable genes encoding a DC-STAMP or DSP-1; including naturally occurring embodiments.

10 This DNA can be expressed in a wide variety of host cells for the synthesis of a full-length DC-STAMP or DSP-1 or fragments which can in turn, e.g., be used to generate polyclonal or monoclonal antibodies; for binding studies; for construction and expression of modified molecules; and for structure/function studies.

- 15 Vectors, as used herein, comprise plasmids, viruses, bacteriophage, integratable DNA fragments, and other vehicles which enable the integration of DNA fragments into the genome of the host. See, e.g., Pouwels, et al. (1985 and Supplements) Cloning Vectors: A Laboratory Manual, Elsevier, N.Y.; and Rodriguez, et al. (eds. 1988) Vectors: A Survey of Molecular Cloning Vectors and Their Uses, Buttersworth, Boston, MA.
- 20

For purposes of this invention, DNA sequences are operably linked when they are functionally related to each other. For example, DNA for a presequence or secretory leader is operably linked to a polypeptide if it is expressed as a preprotein or participates in directing the polypeptide to the cell membrane or in secretion of the polypeptide. A promoter is operably linked to a coding sequence if it controls the transcription of the polypeptide; a ribosome binding site is operably linked to a coding sequence if it is positioned to permit translation. Usually, operably linked means contiguous and in reading frame, however, certain genetic elements such as repressor genes are not contiguously linked but still bind to operator sequences that in turn control expression. See, e.g., Rodriguez, et al., Chapter 10, pp. 205-236; Balbas and

25

30

35

Bolivar (1990) Methods in Enzymology 185:14-37; and Ausubel, et al. (1993) Current Protocols in Molecular Biology, Greene and Wiley, NY.

Representative examples of suitable expression vectors
5 include pCDNA1; pCD, see Okayama, et al. (1985) Mol. Cell Biol. 5:1136-1142; pMC1neo Poly-A, see Thomas, et al. (1987) Cell 51:503-512; and a baculovirus vector such as pAC 373 or pAC 610. See, e.g., Miller (1988) Ann. Rev. Microbiol. 42:177-199.

10 It will often be desired to express a DC-STAMP or DSP-1 polypeptide in a system which provides a specific or defined glycosylation pattern. See, e.g., Luckow and Summers (1988) Bio/Technology 6:47-55; and Kaufman (1990) Meth. Enzymol. 185:487-511.

15 The DC-STAMP or DSP-1, or a fragment thereof, may be engineered to be phosphatidyl inositol (PI) linked to a cell membrane, but can be removed from membranes by treatment with a phosphatidyl inositol cleaving enzyme, e.g., phosphatidyl inositol phospholipase-C. This releases the
20 antigen in a biologically active form, and allows purification by standard procedures of protein chemistry. See, e.g., Low (1989) Biochim. Biophys. Acta 988:427-454; Tse, et al. (1985) Science 230:1003-1008; and Brunner, et al. (1991) J. Cell Biol. 114:1275-1283.

25 Now that the DC-STAMP or DSP-1 has been characterized, fragments or derivatives thereof can be prepared by conventional processes for synthesizing peptides. These include processes such as are described in Stewart and Young (1984) Solid Phase Peptide Synthesis, Pierce Chemical Co.,
30 Rockford, IL; Bodanszky and Bodanszky (1984) The Practice of Peptide Synthesis, Springer-Verlag, New York; Bodanszky (1984) The Principles of Peptide Synthesis, Springer-Verlag, New York; and Villafranca (ed. 1991) Techniques in Protein Chemistry II, Academic Press, San Diego, Ca.

VIII. Uses

The present invention provides reagents which will find use in diagnostic applications as described elsewhere herein, e.g., in DC, T, NK, monocyte, or mast cell mediated conditions, or below in the description of kits for diagnosis. The gene may be useful in forensic sciences, e.g., to distinguish rodent from human, or as a marker to distinguish between different cells exhibiting differential expression or modification patterns.

This invention also provides reagents with significant commercial and/or therapeutic potential. The DC-STAMP or DSP-1 (naturally occurring or recombinant), fragments thereof, and antibodies thereto, along with compounds identified as having binding affinity to DC-STAMP or DSP-1, should be useful as reagents for teaching techniques of molecular biology, immunology, or physiology. Appropriate kits may be prepared with the reagents, e.g., in practical laboratory exercises in production or use of proteins, antibodies, cloning methods, histology, etc.

The reagents will also be useful in the treatment of conditions associated with abnormal physiology or development, including immunological conditions. They may be useful in vitro tests for presence or absence of interacting components, which may correlate with success of particular treatment strategies. In particular, modulation of physiology of various, e.g., hematopoietic or lymphoid, cells will be achieved by appropriate methods for treatment using the compositions provided herein. See, e.g., Thomson (ed. 1998) The Cytokine Handbook (3d ed.) Academic Press, San Diego; Metcalf and Nicola (1995) The Hematopoietic Colony Stimulating Factors Cambridge University Press; and Aggarwal and Gutterman (1991) Human Cytokines Blackwell Pub.

For example, a disease or disorder associated with abnormal expression or abnormal signaling by a DC-STAMP should be a likely target for an agonist or antagonist. The new membrane proteins should play a role in regulation or development of hematopoietic cells, e.g., lymphoid cells,

which affect immunological responses, e.g., inflammation and/or autoimmune disorders. Alternatively, it may affect vascular physiology or development, or neuronal effects.

In particular, the DC-STAMP is likely to be important
5 in mediating DC function. DC are the professional antigen presenting cells to T and B cells, and should be important in T cell mediated immune responses. Increases in T cell immunity should be important in, e.g., tumor immunotherapy, allergic conditions, and vaccine adjuvants. Important
10 tumors include, e.g., carcinomas, including lung, colon, prostate, and breast, and melanomas. See, e.g., Bertino, et al. (eds. 1996) Encyclopedia of Cancer Academic Press; Devita, et al. (eds. 1997) Cancer: Principles & Practice of Oncology Lippincott, Williams and Wilkins; Devita (1997)
15 Principles and Practice of Oncology Lippincott Williams and Wilkins; Cavalli, et al. (1996) Textbook of Medical Oncology Dunitz Martin Ltd; Horwich (ed. 1995) Oncology: A Multidisciplinary Textbook Lippincott-Raven; Peckham, et al. (eds. 1995) Oxford Textbook of Oncology Oxford Univ. Press;
20 Mendelsohn, et al. (1995) The Molecular Basis of Cancer Saunders, Philadelphia; and McArdle (1990) Surgical Oncology: Current Concepts and Practice Butterworth-Heinemann. Among the allergic conditions, e.g., where a shift from Th2 humoral responses to Th1 cellular responses
25 may be indicated, include asthma, pollen rhinitis, medicament allergies, food allergies, house dust mite allergies, etc. See, e.g., See, e.g., Lockey and Bukantz (eds. 1998) Allergen Immunotherapy; and Patterson (ed. 1997) Allergic Diseases: Diagnosis and Management. Conversely,
30 decreases in T cell immunity should be important in, e.g., autoimmune conditions or transplantation rejection circumstances. Autoimmune diseases include, e.g., diabetes melitis, psoriasis, and multiple sclerosis. See, e.g., Morrow (ed. 1999) Autoimmune Rheumatic Disease, Weetman (ed.
35 1998) Endocrine Autoimmunity and Associated Conditions; Rose and Mackay (eds. 1998) The Autoimmune Diseases (3d ed.) Academic Press, San Diego; Kay (ed. 1997) Allergy and

Allergic Diseases Blackwell Science, Malden MA; Samter, et al. (eds.) Immunological Diseases vols. 1 and 2, Little, Brown and Co.; and Coutinho and Kazatchkine (eds. 1993)

Autoimmunity: Physiology and Disease. Transplant rejection and treatment are an established branch of medicine as described, e.g., in Racusen (ed. 1998) Kidney Transplant Rejection; Kelso and Clouston (1996) Cytokines in Transplantation; and Solez, et al. (eds. 1996) Solid Organ Transplant Rejection. Combination treatments might be used, combining a therapeutic related to the DC-STAMP or DSP-1 signaling with another therapeutic used to treat symptoms of the conditions, e.g., with Flt3 ligand, G, CSF, radiation or chemotherapy, antihistamines, IL-10, Treg1 cells, cyclosporin, or interferons.

Likewise, the DSP-1 therapeutic reagents may be useful to modulate function of monocyte, T, NK, or mast cell mediated conditions. It should be useful as a mast cell marker, being present on those cells, and likely modulates signaling with or by those cells.

Various abnormal conditions are known in different cell types which will produce DC-STAMP, e.g., as evaluated by mRNA expression by Northern blot analysis. See Berkow (ed.) The Merck Manual of Diagnosis and Therapy, Merck & Co., Rahway, N.J.; Thorn, et al. Harrison's Principles of Internal Medicine, McGraw-Hill, N.Y.; and Weatherall, et al. (eds.) Oxford Textbook of Medicine, Oxford University Press, Oxford. Many other medical conditions and diseases involve activation by T cells, and many of these will be responsive to treatment by an agonist or antagonist provided herein. See, e.g., Stites and Terr (eds.; 1991) Basic and Clinical Immunology Appleton and Lange, Norwalk, Connecticut; and Samter, et al. (eds.) Immunological Diseases Little, Brown and Co. These problems should be susceptible to prevention or treatment using compositions provided herein.

DC-STAMP or DSP-1, antagonists, antibodies, etc., can be purified and then administered to a patient, veterinary or human. These reagents can be combined for therapeutic

use with additional active or inert ingredients, e.g., in conventional pharmaceutically acceptable carriers or diluents, e.g., immunogenic adjuvants, along with physiologically innocuous stabilizers, excipients, or preservatives. These combinations can be sterile filtered and placed into dosage forms as by lyophilization in dosage vials or storage in stabilized aqueous preparations. This invention also contemplates use of antibodies or binding fragments thereof, including forms which are not complement binding.

Drug screening using DC-STAMP or DSP-1 or fragments thereof can be performed to identify compounds having binding affinity to or other relevant biological effects on DC-STAMP or DSP-1 functions, including isolation of associated components. Subsequent biological assays can then be utilized to determine if the compound has intrinsic stimulating activity and is therefore a blocker or antagonist in that it blocks the activity of DC-STAMP or DSP-1 signaling. Likewise, a compound having intrinsic stimulating activity can activate the signal pathway and is thus an agonist in that it simulates the activity of DC-STAMP or DSP-1 signaling. Antibodies may be used to mediate, e.g., antigen dependent cell-mediated cytotoxicity, complement fixation, to localize enzymes or other means of activating inert pro-toxins, as diagnostic labels, or conjugated to compounds which will absorb energy to eliminate cells in proximity to where the antibody binds.

This invention further contemplates the therapeutic use of blocking antibodies to these antigens as antagonists and of stimulatory antibodies as agonists. This approach should be particularly useful with other DC-STAMP or DSP-1 species variants.

The quantities of reagents necessary for effective therapy will depend upon many different factors, including means of administration, target site, physiological state of the patient, and other medicants administered. Thus, treatment dosages should be titrated to optimize safety and

efficacy. Typically, dosages used in vitro may provide useful guidance in the amounts useful for in situ administration of these reagents. Animal testing of effective doses for treatment of particular disorders will provide further predictive indication of human dosage. Various considerations are described, e.g., in Gilman, et al. (eds.) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, latest Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, latest ed., Mack Publishing Co., Easton, Penn. Methods for administration are discussed therein and below, e.g., for oral, intravenous, intraperitoneal, or intramuscular administration, transdermal diffusion, and others. Pharmaceutically acceptable carriers will include water, saline, buffers, and other compounds described, e.g., in the Merck Index, Merck & Co., Rahway, New Jersey. Dosage ranges would ordinarily be expected to be in amounts lower than 1 mM concentrations, typically less than about 10 μ M concentrations, usually less than about 100 nM, preferably less than about 10 pM (picomolar), and most preferably less than about 1 fM (femtomolar), with an appropriate carrier. Slow release formulations, or a slow release apparatus will often be utilized for continuous or long term administration. See, e.g., Langer (1990) Science 249:1527-1533.

DC-STAMP or DSP-1, fragments thereof, and antibodies to it or its fragments, antagonists, and agonists, may be administered directly to the host to be treated or, depending on the size of the compounds, it may be desirable to conjugate them to carrier proteins such as ovalbumin or serum albumin prior to their administration. Therapeutic formulations may be administered in many conventional dosage formulations. While it is possible for the active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation. Formulations typically comprise at least one active ingredient, as defined above, together with one or more acceptable carriers thereof. Each carrier should be both pharmaceutically and

physiologically acceptable in the sense of being compatible with the other ingredients and not injurious to the patient. Formulations include those suitable for oral, rectal, nasal, topical, or parenteral (including subcutaneous, intramuscular, intravenous and intradermal) administration. The formulations may conveniently be presented in unit dosage form and may be prepared by any methods well known in the art of pharmacy. See, e.g., Gilman, et al. (eds. 1990) Goodman and Gilman's: The Pharmacological Bases of Therapeutics, 8th Ed., Pergamon Press; and Remington's Pharmaceutical Sciences, 17th ed. (1990), Mack Publishing Co., Easton, Penn.; Avis, et al. (eds. 1993) Pharmaceutical Dosage Forms: Parenteral Medications, Dekker, New York; Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Tablets, Dekker, New York; and Lieberman, et al. (eds. 1990) Pharmaceutical Dosage Forms: Disperse Systems, Dekker, New York. The therapy of this invention may be combined with or used in association with other agents, e.g., other therapeutics for treatment of symptoms of the indications described.

Both naturally occurring and recombinant forms of the DC-STAMPs or DSP-1s of this invention are particularly useful in kits and assay methods which are capable of screening compounds for binding activity to the proteins. Several methods of automating assays have been developed in recent years so as to permit screening of tens of thousands of compounds in a short period. See, e.g., Fodor, et al. (1991) Science 251:767-773, which describes means for testing of binding affinity by a plurality of defined polymers synthesized on a solid substrate. The development of suitable assays can be greatly facilitated by the availability of large amounts of purified, soluble antigens as provided by this invention.

Other methods can be used to determine the critical residues in DC-STAMP or DSP-1 counterreceptor or ligand interactions. Mutational analysis can be performed, e.g., see Somoza, et al. (1993) J. Exptl. Med. 178:549-558, to

determine specific residues critical in the interaction and/or signaling. PHD (Rost and Sander (1994) Proteins 19:55-72) and DSC (King and Sternberg (1996) Protein Sci. 5:2298-2310) can provide secondary structure predictions of
5 α -helix (H), β -strand (E), or coil (L). Surface exposed residues would affect ligand or receptor binding, while embedded residues would affect general structure.

For example, antagonists can normally be found once the antigen has been structurally defined, e.g., by tertiary
10 structure data. Testing of potential interacting analogs is now possible upon the development of highly automated assay methods using a purified DC-STAMP or DSP-1. In particular, new agonists and antagonists will be discovered by using screening techniques described herein. Of particular
15 importance are compounds found to have a combined binding affinity for a spectrum of DC-STAMP molecules, e.g., compounds which can serve as antagonists for species variants of DC-STAMP.

One method of drug screening utilizes eukaryotic or
20 prokaryotic host cells which are stably transformed with recombinant DNA molecules expressing a DC-STAMP or DSP-1. Cells may be isolated which express an antigen in isolation from other molecules. Such cells, either in viable or fixed form, can be used for standard binding partner binding
25 assays. See also, Parce, et al. (1989) Science 246:243-247; and Owicki, et al. (1990) Proc. Nat'l Acad. Sci. USA 87:4007-4011, which describe sensitive methods to detect cellular responses.

Another technique for drug screening involves an
30 approach which provides high throughput screening for compounds having suitable binding affinity to an antigen and is described in detail in Geysen, European Patent Application 84/03564, published on September 13, 1984. First, large numbers of different small peptide test
35 compounds are synthesized on a solid substrate, e.g., plastic pins or some other appropriate surface, see Fodor, et al. (1991). Then all the pins are reacted with

solubilized, unpurified or solubilized, purified DC-STAMP, and washed. The next step involves detecting bound DC-STAMP.

Rational drug design may also be based upon structural studies of the molecular shapes of the DC-STAMP or DSP-1 and other effectors or analogs. Effectors may be other proteins which mediate other functions in response to binding, or other proteins which normally interact with the membrane proteins, e.g., a receptor. One means for determining which sites interact with specific other proteins is a physical structure determination, e.g., x-ray crystallography or 2 dimensional NMR techniques. These will provide guidance as to which amino acid residues form molecular contact regions, as modeled, e.g., against other cytokine-receptor models. For a detailed description of protein structural determination, see, e.g., Blundell and Johnson (1976) Protein Crystallography, Academic Press, New York.

IX. Kits

This invention also contemplates use of DC-STAMP or DSP-1 proteins, fragments thereof, peptides, and their fusion products in a variety of diagnostic kits and methods for detecting the presence of another DC-STAMP or DSP-1 or binding partner. Typically the kit will have a compartment containing either a defined DC-STAMP or DSP-1 peptide or gene segment or a reagent which recognizes one or the other, e.g., DC-STAMP or DSP-1 fragments or antibodies.

A kit for determining the binding affinity of a test compound to a DC-STAMP would typically comprise a test compound; a labeled compound, for example a binding partner or antibody having known binding affinity for DC-STAMP; a source of DC-STAMP (naturally occurring or recombinant); and a means for separating bound from free labeled compound, such as a solid phase for immobilizing the molecule. Compartments containing reagents, and instructions, will normally be provided. Once test compounds are screened, those having suitable binding affinity to the antigen can be

evaluated in suitable biological assays, as are well known in the art, to determine whether they act as agonists or antagonists to DC-STAMP signaling pathway. The availability of recombinant DC-STAMP polypeptides also provides well defined standards for calibrating such assays.

Antibodies, including antigen binding fragments, specific for the DC-STAMP or DSP-1 or fragments are useful in diagnostic applications to detect the presence of elevated levels of antigen and/or its fragments. Such diagnostic assays can employ lysates, live cells, fixed cells, immunofluorescence, cell cultures, body fluids, and further can involve the detection of antigens related to the antigen in serum, or the like. Diagnostic assays may be homogeneous (without a separation step between free reagent and antigen-binding partner complex) or heterogeneous (with a separation step). Various commercial assays exist, such as radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), enzyme immunoassay (EIA), enzyme-multiplied immunoassay technique (EMIT), substrate-labeled fluorescent immunoassay (SLFIA), and the like. See, e.g., Van Vunakis, et al. (1980) Meth Enzymol. 70:1-525; Harlow and Lane (1980) Antibodies: A Laboratory Manual, CSH Press, NY; and Coligan, et al. (eds. 1993) Current Protocols in Immunology, Greene and Wiley, NY.

Anti-idiotypic antibodies may have similar use to diagnose presence of antibodies against a DC-STAMP or DSP-1, as such may be diagnostic of various abnormal states. For example, overproduction of DSP-1 may result in production of various immunological reactions which may be diagnostic of abnormal physiological states, particularly in allergic conditions.

Frequently, the reagents for diagnostic assays are supplied in kits, so as to optimize the sensitivity of the assay. For the subject invention, depending upon the nature of the assay, the protocol, and the label, either labeled or unlabeled antibody or binding partner, or labeled antigen is provided. This is usually in conjunction with other

additives, such as buffers, stabilizers, materials necessary for signal production such as substrates for enzymes, and the like. Preferably, the kit will also contain instructions for proper use and disposal of the contents after use. Typically the kit has compartments for each useful reagent. Desirably, the reagents are provided as a dry lyophilized powder, where the reagents may be reconstituted in an aqueous medium providing appropriate concentrations of reagents for performing the assay.

10 Many of the aforementioned constituents of the drug screening and the diagnostic assays may be used without modification or may be modified in a variety of ways. For example, labeling may be achieved by covalently or non-covalently joining a moiety which directly or indirectly provides a detectable signal. In any of these assays, the binding partner, test compound, antigen, or antibodies thereto can be labeled either directly or indirectly. Possibilities for direct labeling include label groups: radiolabels such as ^{125}I , enzymes (U.S. Pat. No. 3,645,090) such as peroxidase and alkaline phosphatase, and fluorescent labels (U.S. Pat. No. 3,940,475) capable of monitoring the change in fluorescence intensity, wavelength shift, or fluorescence polarization. Possibilities for indirect labeling include biotinylation of one constituent followed by binding to avidin coupled to one of the above label groups.

There are also numerous methods of separating the bound from the free antigen, or alternatively the bound from the free test compound. The antigen can be immobilized on various matrixes followed by washing. Suitable matrixes include plastic such as an ELISA plate, filters, and beads. See, e.g., Coligan, et al. (eds. 1993) Current Protocols in Immunology, Vol. 1, Chapter 2, Greene and Wiley, NY. Other suitable separation techniques include, without limitation, the fluorescein antibody magnetizable particle method described in Rattle, et al. (1984) Clin. Chem. 30:1457-1461,

and the double antibody magnetic particle separation as described in U.S. Pat. No. 4,659,678.

Methods for linking proteins or their fragments to the various labels are well known. Many of the techniques
5 involve the use of activated carboxyl groups either through the use of carbodiimide or active esters to form peptide bonds, the formation of thioethers by reaction of a mercapto group with an activated halogen such as chloroacetyl, or an activated olefin such as maleimide, for linkage, or the
10 like. Fusion proteins will also find use in these applications.

Another diagnostic aspect of this invention involves use of oligonucleotide or polynucleotide sequences taken from the sequence of a DC-STAMP or DSP-1. These sequences
15 can be used as probes for detecting levels of the antigen message in samples from patients suspected of having an abnormal condition, e.g., inflammatory or autoimmune. The preparation of both RNA and DNA nucleotide sequences, the labeling of the sequences, and the preferred size of the
20 sequences has received ample description and discussion in the literature. See, e.g., Langer-Safer, et al. (1982) Proc. Nat'l. Acad. Sci. 79:4381-4385; Caskey (1987) Science 236:962-967; and Wilchek et al. (1988) Anal. Biochem. 171:1-32.

25 Diagnostic kits which also test for the qualitative or quantitative expression of other molecules are also contemplated. Diagnosis or prognosis may depend on the combination of multiple indications used as markers. Thus, kits may test for combinations of markers. See, e.g.,
30 Viallet, et al. (1989) Progress in Growth Factor Res. 1:89-97. Kits may contain additional reagents to evaluate other cell subsets.

X. Isolating a DC-STAMP or DSP-1 Ligand or Receptor

35 Both DC-STAMP and DSP-1 are cell surface antigens, which may be receptor for a ligand or another surface antigen. Having isolated one component of such an

interaction, methods exist for isolating a ligand or binding
receptor partner. See, Gearing, et al. (1989) EMBO J.
8:3667-3676. For example, means to label the antigen
without interfering with the binding to its partner can be
5 determined. For example, an affinity label can be fused to
either the amino- or carboxyl-terminus of the ligand. Such
label may be a FLAG epitope tag, or, e.g., an Ig or Fc
domain. An expression library can be screened for specific
binding of the antigen, e.g., by cell sorting, or other
10 screening to detect subpopulations which express such a
binding component. See, e.g., Ho, et al. (1993) Proc. Nat'l
Acad. Sci. USA 90:11267-11271; and Liu, et al. (1994) J.
Immunol. 152:1821-29. Alternatively, a panning method may
be used. See, e.g., Seed and Aruffo (1987) Proc. Nat'l
15 Acad. Sci. USA 84:3365-3369.

Protein cross-linking techniques with label can be
applied to isolate binding partners of the DC-STAMP or DSP-
1. This would allow identification of proteins which
specifically interact with the antigen, e.g., in a ligand-
20 receptor or receptor-receptor manner.

Many modifications and variations of this invention
can be made without departing from its spirit and scope, as
will be apparent to those skilled in the art. The specific
embodiments described herein are offered by way of example
25 only, and the invention is to be limited only by the terms
of the appended claims, along with the full scope of
equivalents to which such claims are entitled.

EXAMPLES

I. General Methods

Many of the standard methods below are described or referenced, e.g., in Maniatis, et al. (1982) Molecular Cloning, A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor Press, NY; Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual (2d ed.) Vols. 1-3, CSH Press, NY; Ausubel, et al., Biology Greene Publishing Associates, Brooklyn, NY; or Ausubel, et al. (1987 and Supplements) Current Protocols in Molecular Biology Wiley/Greene, NY; Innis, et al. (eds. 1990) PCR Protocols: A Guide to Methods and Applications Academic Press, NY.

Methods for protein purification include such methods as ammonium sulfate precipitation, column chromatography, electrophoresis, centrifugation, crystallization, and others. See, e.g., Ausubel, et al. (1987 and periodic supplements); Deutscher (1990) "Guide to Protein Purification," Methods in Enzymology vol. 182, and other volumes in this series; Coligan, et al. (1995 and supplements) Current Protocols in Protein Science John Wiley and Sons, New York, NY; P. Matsudaira (ed. 1993) A Practical Guide to Protein and Peptide Purification for Microsequencing, Academic Press, San Diego, CA; and manufacturer's literature on use of protein purification products, e.g., Pharmacia, Piscataway, NJ, or Bio-Rad, Richmond, CA. Combination with recombinant techniques allow fusion to appropriate segments (epitope tags), e.g., to a FLAG sequence or an equivalent which can be fused, e.g., via a protease-removable sequence. See, e.g., Hochuli (1989) Chemische Industrie 12:69-70; Hochuli (1990) "Purification of Recombinant Proteins with Metal Chelate Absorbent" in Setlow (ed.) Genetic Engineering, Principle and Methods 12:87-98, Plenum Press, NY; and Crowe, et al. (1992) OIAexpress: The High Level Expression & Protein Purification System QUIAGEN, Inc., Chatsworth, CA.

Standard immunological techniques are described, e.g., in Hertenberg, et al. (eds. 1996) Weir's Handbook of

Experimental Immunology vols. 1-4, Blackwell Science;
Coligan (1991) Current Protocols in Immunology Wiley/Greene,
NY; and Methods in Enzymology vols. 70, 73, 74, 84, 92, 93,
108, 116, 121, 132, 150, 162, and 163. Cytokine assays are
5 described, e.g., in Thomson (ed. 1998) The Cytokine Handbook
(3d ed.) Academic Press, San Diego; Mire-Sluis and Thorpe
(1998) Cytokines Academic Press, San Diego; Metcalf and
Nicola (1995) The Hematopoietic Colony Stimulating Factors
Cambridge University Press; and Aggarwal and Gutterman
10 (1991) Human Cytokines Blackwell Pub.

Assays for vascular biological activities are well
known in the art. They will cover angiogenic and
angiostatic activities in tumor, or other tissues, e.g.,
arterial smooth muscle proliferation (see, e.g., Koyoma, et
15 al. (1996) Cell 87:1069-1078), monocyte adhesion to vascular
epithelium (see McEvoy, et al. (1997) J. Exp. Med.
185:2069-2077), etc. See also Ross (1993) Nature 362:801-
809; Rekhater and Gordon (1995) Am. J. Pathol. 147:668-677;
Thyberg, et al. (1990) Atherosclerosis 10:966-990; and
20 Gumbiner (1996) Cell 84:345-357.

Assays for neural cell biological activities are
described, e.g., in Wouterlood (ed. 1995) Neuroscience
Protocols modules 10, Elsevier; Methods in Neurosciences
Academic Press; and Neuromethods Humana Press, Totowa, NJ.
25 Methodology of developmental systems is described, e.g., in
Meisami (ed.) Handbook of Human Growth and Developmental
Biology CRC Press; and Chrispeels (ed.) Molecular Techniques
and Approaches in Developmental Biology Interscience.

FACS analyses are described in Melamed, et al. (1990)
30 Flow Cytometry and Sorting Wiley-Liss, Inc., New York, NY;
Shapiro (1988) Practical Flow Cytometry Liss, New York, NY;
and Robinson, et al. (1993) Handbook of Flow Cytometry
Methods Wiley-Liss, New York, NY.

II. Cloning of Human DC-STAMP and DSP-1

The sequence of the primate, e.g., human, DC-STAMP gene is provided in Table 1. The sequence is derived from sequence of a cDNA clone isolated from dendritic cells.

5 This sequence allows preparation of PCR primers, or probes, to determine cellular distribution of the gene. The sequence allows isolation of genomic DNA which encode the message.

10 The ORF of DC-STAMP predicts a protein of 470 amino acids, with a predicted molecular weight of around 53 kD and an isoelectric point of 9.41. The amino terminus of the protein starts with a short stretch of hydrophobic amino acids, which predicts an uncleavable signal sequence (pSORT, Osaka University, Japan). Hydrophobicity analysis of the
15 sequence revealed 5 strong and 2 weak hydrophobic stretches of 18-20 amino acids, suggesting that the DC-STAMP molecule is spanning the membrane multiple times. The TM Predict program from BCM Search Launcher (K. Hofman and W. Hofman) suggests a topology model in which the DC-STAMP protein
20 contains 7 transmembrane spanning regions, with the N-terminus located outside and the C-terminus on the luminal side of the membrane.

Interestingly, the DC-STAMP protein contains two pairs of cysteine residues, one at the start of the first
25 transmembrane domain (TM1), the other at the end of the second transmembrane domain (TM2). These cysteines might form a disulphide bridge near the outer side of the membrane, and stabilize the protein structure. Prosite analysis of the protein revealed 3 potential glycosylation
30 sites, two on the second and one on the third putative extracellular loop. In addition, there is a consensus sequence for phosphorylation by protein kinase C between the fifth and sixth transmembrane region, which is the second intracellular loop according to the proposed topology. The
35 72 amino acid cytoplasmic tail of DC-STAMP contains several serine residues, two of which might serve as a target for phosphorylation. Interestingly, the C-terminus of the DC-

STAMP protein is surprisingly rich in positively charged residues, comprising 25% of the tail and conferring an overall positive charge (+14).

5 The DSP-1 gene was isolated from a cDNA library made from human HEL cells.

Using the probe or PCR primers, various tissues or cell types are probed to determine cellular distribution. PCR products are cloned using, e.g., a TA cloning kit (Invitrogen). The resulting cDNA plasmids are sequenced
10 from both termini on an automated sequencer (Applied Biosystems).

Leukocyte preparations

PBMC were obtained by leukophoresis of blood from
15 healthy donors, and adherence for 2 hours resulted in a non-adherent PBL fraction. Monocytes were elutriated from PBMC by counterflow centrifugation, resulting in a population of cells that were greater than 85% CD14⁺. Fractions were cultured in Iscove's medium supplemented with 5% FCS and 1%
20 antibiotics/antimycotics (Life Technologies Inc., Grand Island, NY). Both the non-adherent PBL and total PBMC were stimulated with phytohemagglutinin (PHA; 1 µg/ml; Murex Diagnostics Ltd, Dartford, England) and rIL-2 (200 U/ml; Cetus Corp., Emeryville, CA) for 16 h. Elutriated monocytes
25 were stimulated with 2 µg/ml LPS for 16 h.

DC were generated in vitro from monocytes using a modification of described methods. See Ridge, et al. (1998) Nature 393:474-478; and Bennett, et al. (1998) Nature 393:478-480. Monocytes were cultured in AIM-V medium (Life
30 Technologies Ltd, Paisley, Scotland) supplemented with 5% fetal calf serum and in the presence of 800 U/ml GM-CSF and 500 U/ml IL-4 (both from Schering-Plough, The Netherlands) for 5-7 days. Resulting DC were collected directly or after activation with either LPS for 16 h (2 µg/ml), or after the
35 sequential addition of TNFα (10 ng/ml, 24 h) and the activating anti-CD40 antibody MAB89, generously provided by DNAX, Palo Alto, CA (1.5 µg/ml, 24 h). Purified tonsil B

lymphocytes were isolated according to the method described by Falkoff, et al. (1982). J. Immunol. Methods 50:39-49.

cDNA library preparation

Complementary DNA libraries were prepared. See
5 Marland, et al. (1997) in Ricciardi-Castagnoli (ed.)
Dendritic Cells in Fundamental and Clinical Immunology, Vol
3, Plenum Publ. Corporation; and Adema, et al. (1997) Nature
387:713-717. Nucleotide sequences were analyzed against the
non-redundant GenBank and EMBL databases using the BLAST
10 program. See Altschul, et al. (1990) J. Mol. Biol.
215:403-410.

Northern blot analysis for DC-STAMP

Total RNA was isolated from DC cultures, e.g.,
15 monocyte-derived DC cultured for 7 days in IL-4 and GM-CSF,
freshly isolated leukocytes and cell lines using the
guanidine thiocyanate/cesium chloride procedure. Poly(A)⁺
RNA was isolated from the DC fraction by affinity
chromatography (Oligotex, Qiagen). Per sample 20 µg total
20 RNA or 2 µg poly(A)⁺ RNA was resolved overnight on a
formaldehyde gel and transferred to a nylon membrane by
capillary blotting. Hybridization was performed overnight
at 65° C in Church solution (0.5 M NaHPO₄, pH 7.2; 7 % SDS;
0,5 M EDTA). Multiple tissue Northern blot #7780-1
25 (Clontech, Palo Alto, CA) was probed and washed under
stringent conditions according to the manufacturer's
recommendations. Both Northern blots were probed with the
444 bp SalI-RcaI fragment, comprising part of the 3' UTR of
DC-STAMP, randomly labeled with ³²P (T7 QuickPrime Kit,
30 Pharmacia).
RT-PCR

Total RNA was isolated using Trizol Reagent (Gibco
BRL) and treated with RNase free DNase (Boehringer
Mannheim). 1 µg RNA was transcribed into cDNA using an
35 oligodT primer and Superscript II reverse transcriptase (RT,
Gibco BRL). Half of the cDNA was used to amplify the DC-

STAMP message, according to a standard PCR protocol (24 cycles). The primers were located in the most 3' part of the DC-STAMP ORF, yielding a specific product of 334 bp. As a control for RNA quality, the other half of the cDNA was used to amplify a β actin product of 328 bp (18 cycles). Southern blot analysis of the PCR products was performed using an 32 P-end labeled internal oligonucleotide (Klenow polymerase, Boehringer Mannheim) from either DC-STAMP or β actin. Samples without RT were always completely negative.

10

Library screening and 5' RACE PCR

100,000 colonies from a cDNA library derived from non-stimulated DC were screened using the randomly labeled 444 bp RcaI/SalI fragment from the original 936 bp cDNA clone as a probe. The most 5' end of the DC-STAMP cDNA was isolated by 5' RACE PCR. Briefly, 1 μ g of total DC RNA was transcribed into cDNA (Superscript II Reverse Transcriptase, Gibco BRL), using a DC-STAMP specific 5' RACE-1 primer. The cDNA was purified with a QIAQuick PCR purification kit (Qiagen) and subsequently tailed using 50 U of Terminal Transferase (Boehringer Mannheim) in the presence of dCTP (5 μ M) and 0.75 mM CoCl₂ (15 minutes 37° C). The tailed cDNA was extracted once with phenol/chloroform and precipitated using glycogen (50 μ g). 5% of the tailed cDNA was used in a hemi-nested PCR reaction, using nested DC-STAMP specific primer 5'RACE-2 and a 5' primer annealing to the C-tail of the cDNA. 30 PCR cycles were performed using a standard program (1 min 94° C, 1 min 58° C, 1 min 72° C, 10 min extension at 72° C). The resulting PCR product was gel-purified and cloned into the TA-cloning vector pGEM-T (Promega). The overlapping cDNA fragments were sequenced by the dideoxy chain reaction (AutoRead Sequencing kit, Pharmacia Biotech) on the ALF Express automated sequencer (Pharmacia Biotech). The complete ORF of DC-STAMP was amplified from oligo dT transcribed cDNA (Superscript II, Gibco BRL) using the Expand Long Template PCR System (30 cycles, Boehringer Mannheim) and cloned into pGEM-T Easy.

Sequence analysis of several clones confirmed the sequence obtained by 5'RACE PCR.

DC-STAMP cDNA encodes a 470 amino acid multimembrane spanning molecule

5 Since expression of DC-STAMP was specifically detected in DC, a DC cDNA library was screened with a specific probe for DC-STAMP in order to obtain the full-length transcript. Several DC-STAMP cDNA clones were isolated, of which the
10 longest clone contained an insert of 1.4 kb, identical to the original clone at its 3' end. 5' RACE PCR resulted in the cloning of the most 5' region of the DC-STAMP messenger. Northern blot analysis using this 5' DC-STAMP fragment as a probe resulted in the same 2.3 kb message as described,
15 indicating that both fragments belong to a single cDNA. The cDNA encoding DC-STAMP has a total length of 1954 bp, which nicely fits with the 2.3 kb messenger on Northern blot, suggesting a poly A tail of around 350 bp. It contains a single long ORF of 1410 nucleotides starting with the first
20 ATG codon at nucleotide 52, which is in the appropriate sequence context for translation initiation (Kozak (1987) Nucleic Acid. Res. 15:8125-8148), and is followed by a 490-nucleotide 3' UTR. The poly A-tail is preceded by the polyadenylation signal sequence ATTAAA. See Table 1.

25 Comparison of the DC-STAMP amino acid and nucleotide sequence with known sequences in the GenBank/EMBL databases revealed no homology, except two nucleotide matches with unpublished EST fragments in the dbEST, derived from human skin tumor and human neuroendocrine lung carcinoid
30 (accession numbers AA380009 and AI268407, respectively).

The sequence of the primate, e.g., human, DSP-1 gene is provided in Table 2. The sequence is derived from sequence of a cDNA clone isolated human HEL cells.

III. Cellular Expression of Antigen

An appropriate probe or primers specific for cDNA encoding primate antigen are prepared. Typically, the probe is labeled, e.g., by random priming.

5 Southern Analysis: DNA (5 µg) from a primary amplified cDNA library was digested with appropriate restriction enzymes to release the inserts, run on a 1% agarose gel and transferred to a nylon membrane (Schleicher and Schuell, Keene, NH).

10 Samples for human mRNA isolation may include:
peripheral blood mononuclear cells (monocytes, T cells, NK cells, granulocytes, B cells), resting (T100); peripheral blood mononuclear cells, activated with anti-CD3 for 2, 6, 12 h pooled (T101); T cell, TH0 clone Mot 72, resting
15 (T102); T cell, TH0 clone Mot 72, activated with anti-CD28 and anti-CD3 for 3, 6, 12 h pooled (T103); T cell, TH0 clone Mot 72, anergic treated with specific peptide for 2, 7, 12 h pooled (T104); T cell, TH1 clone HY06, resting (T107); T cell, TH1 clone HY06, activated with anti-CD28 and anti-CD3
20 for 3, 6, 12 h pooled (T108); T cell, TH1 clone HY06, anergic treated with specific peptide for 2, 6, 12 h pooled (T109); T cell, TH2 clone HY935, resting (T110); T cell, TH2 clone HY935, activated with anti-CD28 and anti-CD3 for 2, 7, 12 h pooled (T111); T cell tumor lines Jurkat and Hut78,
25 resting (T117); T cell clones, pooled AD130.2, Tc783.12, Tc783.13, Tc783.58, Tc782.69, resting (T118); T cell random γδ T cell clones, resting (T119); CD28- T cell clone; Splenocytes, resting (B100); Splenocytes, activated with anti-CD40 and IL-4 (B101); B cell EBV lines pooled WT49,
30 RSB, JY, CVIR, 721.221, RM3, HSY, resting (B102); B cell line JY, activated with PMA and ionomycin for 1, 6 h pooled (B103); NK 20 clones pooled, resting (K100); NK 20 clones pooled, activated with PMA and ionomycin for 6 h (K101); NKL clone, derived from peripheral blood of LGL leukemia
35 patient, IL-2 treated (K106); hematopoietic precursor line TF1, activated with PMA and ionomycin for 1, 6 h pooled (C100); U937 premonocytic line, resting (M100); U937

premonocytic line, activated with PMA and ionomycin for 1, 6 h pooled (M101); elutriated monocytes, activated with LPS, IFN γ , anti-IL-10 for 1, 2, 6, 12, 24 h pooled (M102); elutriated monocytes, activated with LPS, IFN γ , IL-10 for 1, 2, 6, 12, 24 h pooled (M103); elutriated monocytes, activated with LPS, IFN γ , anti-IL-10 for 4, 16 h pooled (M106); elutriated monocytes, activated with LPS, IFN γ , IL-10 for 4, 16 h pooled (M107); elutriated monocytes, activated LPS for 1 h (M108); elutriated monocytes, activated LPS for 6 h (M109); DC 70% CD1a+, from CD34+ GM-CSF, TNF α 12 days, resting (D101); DC 70% CD1a+, from CD34+ GM-CSF, TNF α 12 days, activated with PMA and ionomycin for 1 hr (D102); DC 70% CD1a+, from CD34+ GM-CSF, TNF α 12 days, activated with PMA and ionomycin for 6 hr (D103); DC 95% CD1a+, from CD34+ GM-CSF, TNF α 12 days FACS sorted, activated with PMA and ionomycin for 1, 6 h pooled (D104); DC 95% CD14+, ex CD34+ GM-CSF, TNF α 12 days FACS sorted, activated with PMA and ionomycin 1, 6 hr pooled (D105); DC CD1a+ CD86+, from CD34+ GM-CSF, TNF α 12 days FACS sorted, activated with PMA and ionomycin for 1, 6 h pooled (D106); DC from monocytes GM-CSF, IL-4 5 days, resting (D107); DC from monocytes GM-CSF, IL-4 5 days, resting (D108); DC from monocytes GM-CSF, IL-4 5 days, activated LPS 4, 16 h pooled (D109); DC from monocytes GM-CSF, IL-4 5 days, activated TNF α , monocyte supe for 4, 16 h pooled (D110); epithelial cells, unstimulated; epithelial cells, IL-1 β activated; lung fibroblast sarcoma line MRC5, activated with PMA and ionomycin for 1, 6 h pooled (C101); kidney epithelial carcinoma cell line CHA, activated with PMA and ionomycin for 1, 6 h pooled (C102).

Rodent counterparts, e.g., mouse, should be identified, and their distributions will be similarly evaluated. Samples for mouse mRNA isolation can include: resting mouse fibroblastic L cell line (C200); Braf:ER (Braf fusion to estrogen receptor) transfected cells, control (C201); Mel14+ naive T cells from spleen, resting (T209); Mel14+ naive T cells from spleen, stimulated with IFN γ , IL-

12, and anti IL-4 to polarize to TH1 cells, exposed to IFN γ and IL-4 for 6, 12, 24 h, pooled (T210); Mel14+ naive T cells from spleen, stimulated with IL-4 and anti IFN γ to polarize to Th2 cells, exposed to IL-4 and anti IFN γ for 6,
5 13, 24 h, pooled (T211); T cells, TH1 polarized (Mel14 bright, CD4+ cells from spleen, polarized for 7 days with IFN- γ and anti IL-4; T200); T cells, TH2 polarized (Mel14 bright, CD4+ cells from spleen, polarized for 7 days with IL-4 and anti-IFN- γ ; T201); T cells, highly TH1 polarized 3x
10 from transgenic Balb/C (see Openshaw, et al. (1995) J. Exp. Med. 182:1357-1367; activated with anti-CD3 for 2, 6, 24 h pooled; T202); T cells, highly TH2 polarized 3x from transgenic Balb/C (activated with anti-CD3 for 2, 6, 24 h pooled (T203); T cells, highly TH1 polarized 3x from
15 transgenic C57 bl/6 (activated with anti-CD3 for 2, 6, 24 h pooled; T212); T cells, highly TH2 polarized 3x from transgenic C57 bl/6 (activated with anti-CD3 for 2, 6, 24 h pooled; T213); T cells, highly TH1 polarized (naive CD4+ T cells from transgenic Balb/C, polarized 3x with IFN γ , IL-12,
20 and anti-IL-4; stimulated with IGIF, IL-12, and anti IL-4 for 6, 12, 24 h, pooled); CD44- CD25+ pre T cells, sorted from thymus (T204); TH1 T cell clone D1.1, resting for 3 weeks after last stimulation with antigen (T205); TH1 T cell clone D1.1, 10 μ g/ml ConA stimulated 15 h (T206); TH2 T cell
25 clone CDC35, resting for 3 weeks after last stimulation with antigen (T207); TH2 T cell clone CDC35, 10 μ g/ml ConA stimulated 15 h (T208); unstimulated B cell line CH12 (B201); unstimulated mature B cell leukemia cell line A20 (B200); unstimulated large B cells from spleen (B202); B
30 cells from total spleen, LPS activated (B203); metrizamide enriched dendritic cells from spleen, resting (D200); dendritic cells from bone marrow, resting (D201); unstimulated bone marrow derived dendritic cells depleted with anti B220, anti CD3, and anti Class II, cultured in GM-
35 CSF and IL-4 (D202); bone marrow derived dendritic cells depleted with anti B220, anti CD3, and anti Class II, cultured in GM-CSF and IL-4, stimulated with anti CD40 for

1, 5 d, pooled (D203); monocyte cell line RAW 264.7
activated with LPS 4 h (M200); bone-marrow macrophages
derived with GM and M-CSF (M201); bone-marrow macrophages
derived with GM-CSF, stimulated with LPS, IFN γ , and IL-10
5 for 24 h (M205); bone-marrow macrophages derived with GM-
CSF, stimulated with LPS, IFN γ , and anti IL-10 for 24 h
(M206); peritoneal macrophages (M207); macrophage cell line
J774, resting (M202); macrophage cell line J774 + LPS +
anti-IL-10 at 0.5, 1, 3, 6, 12 h pooled (M203); macrophage
10 cell line J774 + LPS + IL-10 at 0.5, 1, 3, 5, 12 h pooled
(M204); unstimulated mast cell lines MC-9 and MCP-12 (M208);
immortalized endothelial cell line derived from brain
microvascular endothelial cells, unstimulated (E200);
immortalized endothelial cell line derived from brain
15 microvascular endothelial cells, stimulated overnight with
TNF α (E201); immortalized endothelial cell line derived
from brain microvascular endothelial cells, stimulated
overnight with TNF α (E202); immortalized endothelial cell
line derived from brain microvascular endothelial cells,
20 stimulated overnight with TNF α and IL-10 (E203); total
aorta from wt C57 bl/6 mouse; total aorta from 5 month ApoE
KO mouse (X207); total aorta from 12 month ApoE KO mouse
(X207); wt thymus (O214); total thymus, rag-1 (O208); total
kidney, rag-1 (O209); total kidney, NZ B/W mouse; and total
25 heart, rag-1 (O202).

To further analyze the expression pattern of DC-STAMP,
RT-PCR was performed on RNA from a panel of freshly isolated
resting or activated leukocyte populations and several cell
lines of haematopoietic as well as non-haematopoietic
30 origin. The PCR products were Southern blotted and
hybridized with a specific DC-STAMP oligonucleotide. A
distinct band of the expected size was detected in immature
as well as in mature DC, stimulated with either LPS or a
combination of TNF α and an activating anti-CD40 antibody.
35 In contrast, freshly isolated monocytes did not express the
DC-STAMP RNA, even after overnight stimulation with LPS. A
low expression was detected in total PBMC, which could be

explained by the presence of contaminating DC, and in the pre-monocytic cell line U937. The β -actin mRNA control was similar in all samples, indicating that equal amounts of RNA were used for the RT-PCR.

5 Hybridization of a Northern blot containing mRNA from 12 human tissues (Clontech MTN # 7780-1) with a DC-STAMP specific probe did not result in any detectable signal, not even after exposure of the blot for several days. The absence of detectable expression of DC-STAMP in the 12
10 different human tissues tested is consistent with a relatively low expression in DC.

Initial distribution studies of the DSP-1 suggest that the antigen is primarily expressed on monocytes, mast cells, T cells, and NK cells. Thus, it is likely that the receptor
15 has a negative regulatory role for those cell types.

IV. Fusion Protein Constructs

The DC-STAMP ORF was amplified with Pwo DNA polymerase (Boehringer Mannheim) using appropriate primers, containing
20 a EcoRI or BglIII site, respectively, deleting the DC-STAMP STOP codon. This PCR product was cloned as an EcoRI/BglIII fragment into the pN3-EGFP expression vector (Clontech, Palo Alto, CA), digested with EcoRI and BamHI, inserting the DC-STAMP cDNA N-terminal of the transcript encoding the
25 enhanced green fluorescent protein (EGFP). The CCR1 molecule was amplified by RT-PCR using total RNA from monocytes and primers based on the published sequence (see Adema, et al. (1997) Nature 387:713-717; and Falkoff, et al. (1982). J. Immunol. Methods 50:39-49) and cloned as a GFP
30 fusion protein using a similar approach. Primers contained a NotI or BamHI restriction site. The digested PCR product was cloned into the NotI-BamHI digested pBluescript SK⁻ vector (Stratagene, La Jolla, CA) and subsequently cloned as a SacI-BamHI fragment into the expression vector pN3-EGFP.

35 Similar constructs can be made using the DSP-1 sequences.

V. Cellular Localization of DC-STAMP

To determine the cellular localization of DC-STAMP, the DC-STAMP-EGFP (Enhanced Green Fluorescent Protein) fusion protein was subjected to analysis. This construct possessed the EGFP sequence fused to the C-terminal of the DC-STAMP ORF. 293 cells were transfected with this construct, and analyzed by Confocal Laser Scan Microscopy (CLSM). Since multimembrane spanning proteins are very hydrophobic and complex proteins, the CCR1 molecule, a 7TM chemokine receptor expressed at the cell membrane, was compared as a control. Transfection of CCR1-EGFP into 293 cells resulted in a bright membrane fluorescence, often accompanied by an additional highly fluorescent spot in the cytoplasm, possibly representing the Golgi. Analysis of transient as well as stable transfectants of the DC-STAMP-EGFP construct showed a similar fluorescence staining pattern as seen for CCR1-EGFP, indicating that DC-STAMP can also be expressed at the cell surface. Transfectants expressing the EGFP protein alone showed a bright cytoplasmic fluorescence, not localized to a particular cell structure.

The localization of the C-terminus of the DC-STAMP-EGFP protein was determined by staining the DC-STAMP-EGFP transient transfectants with polyclonal anti-GFP serum either before or after permeabilization. Cytospin stainings showed that EGFP could only be detected after permeabilization, indicating that DC-STAMP has an intracellular C-terminus. The amount of positive cells was consistent with the percentage of GFP positive cells in the transient transfected bulk population as observed by FACS analysis (30%). The few cells that stained positive after pre-incubation with the anti-GFP serum were due to leakage of the antibody into dead cells.

35 VI. Chromosome mapping of DC-STAMP and DSP-1

An isolated cDNA encoding the antigen is used. Chromosome mapping is a standard technique. See, e.g., BIOS

Laboratories (New Haven, CT) and methods for using a mouse somatic cell hybrid panel with PCR.

VII. Purification of DC-STAMP or DSP-1 Protein

5 Multiple transfected cell lines are screened for one which expresses the desired antigen at a high level compared with other cells. Various cell lines are screened and selected for their favorable properties in handling. Natural antigen can be isolated from natural sources, or by
10 expression from a transformed cell using an appropriate expression vector. Purification of the expressed protein is achieved by standard procedures, or may be combined with engineered means for effective purification at high efficiency from cell lysates or supernatants. FLAG or His6
15 segments can be used for such purification features. Alternatively, affinity chromatography may be used with specific antibodies, see below. Protein is produced in coli, insect cell, or mammalian expression systems, as desired.

20 Human embryonic kidney (HEK) 293 cells were transfected with 3 µg DC-STAMP DNA using LipofectAMINE (Gibco BRL). See Lanier, et al. (1994) J. Immunol. 153:2417-2428. 2 days after transfection, cells were harvested and used for Confocal Laser Scanning Microscopy
25 (CLSM). Expression was checked by FACScan analysis in the FITC channel (Becton Dickinson & Co., Oxnard, CA) and usually 30-60% of the cells were positive for expression. In order to obtain a stable bulk population, G418 (1 mg/ml; Life Technologies Ltd, Paisley, Scotland) was added to the
30 culture medium at day 2 after transfection. After 1 to 2 weeks, cells were sorted for GFP expression on the Coulter Epics Elite (Coulter, Hialeah, FL) and the resulting bulk population was used for CLSM. Cells were stained with rabbit polyclonal anti-GFP serum (kindly provided by E.
35 Cuppen, Dept. of Cell Biology and Histology, University of Nijmegen, The Netherlands), either before or after cytopspin preparations. Cytopspins were fixed with acetone for 10

minutes, incubated with a horse anti-mouse biotinylated antibody and positive cells visualized by immunoperoxidase staining (Vectastain Elite ABC kit, Vector Laboratories, Burlingame, USA; AEC Substrate Kit, Zymed Laboratories, CA).

5

Confocal laser scanning microscopy

Cells were attached to poly-l-lysine coated glass slides, after which GFP-fusion protein distribution was determined by Confocal Laser Scanning Microscopy (CLSM) at
10 488 nm with a krypton/argon Laser (Biorad 1000, Hercules, CA). The CSLM settings were: lens, 60x; gain, 1100-1350; pinhole, 1.5 μm ; and magnification, 60x.

VIII. Isolation of Homologous Genes

15 The DC-STAMP or DSP-1 cDNA, or other species counterpart sequence, can be used as a hybridization probe to screen a library from a desired source, e.g., a primate cell cDNA library. Many different species can be screened both for stringency necessary for easy hybridization, and
20 for presence using a probe. Appropriate hybridization conditions will be used to select for clones exhibiting specificity of cross hybridization.

Screening by hybridization using degenerate probes based upon the peptide sequences will also allow isolation
25 of appropriate clones. Alternatively, use of appropriate primers for PCR screening will yield enrichment of appropriate nucleic acid clones.

Similar methods are applicable to isolate either species, polymorphic, or allelic variants. Species
30 variants are isolated using cross-species hybridization techniques based upon isolation of a full length isolate or fragment from one species as a probe.

Alternatively, antibodies raised against human antigen will be used to screen for cells which express cross-
35 reactive proteins from an appropriate, e.g., cDNA library. The purified protein or defined peptides are useful for generating antibodies by standard methods, as described

above. Synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press. The resulting antibodies are used for screening, purification, or diagnosis, as described.

IX. Preparation of Antibodies Specific for Antigen

Synthetic peptides or purified protein are presented to an immune system to generate monoclonal or polyclonal antibodies. See, e.g., Coligan (1991) Current Protocols in Immunology Wiley/Greene; and Harlow and Lane (1989) Antibodies: A Laboratory Manual Cold Spring Harbor Press. Polyclonal serum, or hybridomas may be prepared. In appropriate situations, the binding reagent is either labeled as described above, e.g., fluorescence or otherwise, or immobilized to a substrate for panning methods. Immunoselection, absorptions, and related techniques are available to prepare selective reagents, e.g., exhibiting the desired spectrum of selectivity for binding.

X. Evaluation of Breadth of Biological Functions

DC-STAMP could possibly serve as a receptor for growth factors or hormones, which upon activation drive the differentiation into DC, or modulate DC function by directing T cell responses. Another possibility is a putative role for DC-STAMP as a receptor connecting the neuro-endocrine system to the immune system. Analysis of the effects of differentiation, maturation by various stimuli, and co-culture with T cells on the expression levels of DC-STAMP, will provide more insight into the specific function of this novel multimembrane surface receptor on DC.

Recently, DC pulsed with tumor antigens have been successfully used in vivo for the induction of anti-tumor T

cell reactivity in melanoma patients. Nestle, et al. (1998) Nat. Med. 4:328-332. Thus, DC treated with these reagents may be useful in cell based therapies, e.g., cell transfer or in vitro cell treatments.

5 Biological activities of antibody to antigen are tested, based, in part, on the sequence and structural homology between the DC-STAMP and other membrane proteins. Initially, assays that show biological activities of 7TM receptors are examined. For the DSP-1, biological
10 activities related to the function of monocyte, T, NK, and/or mast cells will be tested. Thus, assay for effects of polyclonal antibodies likely to contain antagonist antibodies affecting cells possessing the antigens will be tested. Primary assays include chemotaxis assays for the
15 various cell types, e.g., monocytes, T, NK, and/or mast cells. Mast cell specific assays include, e.g., IgE mediated degranulation assays, mast cell chemotaxis assays, and effects on SCF/.IL-6 induced mast cell proliferation assays. Similarly, assays for effects on T cell, NK cells,
20 or monocytes will be tested.

A. Effects on proliferation/differentiation of progenitor cells

 The effect on proliferation or differentiation of
25 various cell types are evaluated with various concentrations of antibody. A dose response analysis is performed.

 In particular, antibodies will be tested on cord blood cells to see if they have effects on proliferation or differentiation of early progenitor cells derived therefrom.
30 Preferably, the cells are early precursor cells, e.g., stem cells, originating from, e.g., cord blood, bone marrow, thymus, spleen, or CD34+ progenitor cells. The antibodies will be tested for effects on myeloid and/or erythroid precursors, including B cell precursors.

B. Effects of antibodies on proliferation

Total PBMC are isolated from buffy coats of normal healthy donors by centrifugation through ficoll-hypaque as described (Boyum, et al.). PBMC are cultured in 200 μ l
5 Yssel's medium (Gemini Bioproducts, Calabasas, CA) containing 1% human AB serum in 96 well plates (Falcon, Becton-Dickinson, NJ) in the absence or presence of antibodies. Cells are cultured in medium alone or in combination with 100 U/ml IL-2 (R&D Systems) for 120 hours.
10 3H-Thymidine (0.1 mCi) is added during the last six hours of culture and 3H-Thymidine incorporation determined by liquid scintillation counting.

The antibodies would be tested for blocking signaling activity in many other biological assay systems, e.g., on T-
15 cells, B-cells, NK, macrophages, dendritic cells, mast cells, hematopoietic progenitors, etc.

Antibodies are evaluated for effects in macrophage/dendritic cell activation and antigen presentation assays, T cell cytokine production or
20 proliferation in response to antigen or allogeneic stimulus. See, e.g., de Waal Malefyt et al. (1991) J. Exp. Med. 174:1209-1220; de Waal Malefyt et al. (1991) J. Exp. Med. 174:915-924; Fiorentino, et al. (1991) J. Immunol. 147, 3815-3822; Fiorentino, et al. (1991) J. Immunol. 146:3444-
25 3451; and Groux, et al. (1996) J. Exp. Med. 184:19-29. Antibodies will be tested for ability to affect mast cell degranulation, chemotaxis, etc.

Antibodies will also be evaluated for effects on NK cell stimulation. Assays may be based, e.g., on Hsu, et al.
30 (1992) Internat. Immunol. 4:563-569; and Schwarz, et al. (1994) J. Immunother. 16:95-104. Other assays are applied to evaluate effects on cytotoxic T cells and LAK cells. See, e.g., Namien and Mire-Sluis (1998).

B cell growth and differentiation effects will be
35 analyzed, e.g., by the methodology described, e.g., in Defrance, et al. (1992). J. Exp. Med. 175:671-682; Rousset, et al. (1992) Proc. Nat'l Acad. Sci. USA 89:1890-1893;

including IgG2 and IgA2 switch factor assays. Note that, unlike COS7 supernatants, NIH3T3 and COP supernatants apparently do not interfere with human B cell assays.

5 C. Effects on the expression of cell surface molecules on human monocytes

Monocytes are purified by negative selection from peripheral blood mononuclear cells of normal healthy donors. Briefly, 3×10^8 ficoll banded mononuclear cells are
10 incubated on ice with a cocktail of monoclonal antibodies (Becton-Dickinson; Mountain View, CA) consisting, e.g., of 200 μ l of α CD2 (Leu-5A), 200 μ l of α CD3 (Leu-4), 100 μ l of α CD8 (Leu 2a), 100 μ l of α CD19 (Leu-12), 100 μ l of α CD20 (Leu-16), 100 μ l of α CD56 (Leu-19), 100 μ l of α CD67 (IOM
15 67; Immunotech, Westbrook, ME), and anti-glycophorin antibody (10F7MN, ATCC, Rockville, MD). Antibody bound cells are washed and then incubated with sheep anti-mouse IgG coupled magnetic beads (Dynal, Oslo, Norway) at a bead to cell ratio of 20:1. Antibody bound cells are separated
20 from monocytes by application of a magnetic field. Subsequently, human monocytes are cultured in Yssel's medium (Gemini Bioproducts, Calabasas, CA) containing 1% human AB serum in the absence or presence of antibodies.

Analyses of the expression of cell surface molecules
25 can be performed by direct immunofluorescence. For example, 2×10^5 purified human monocytes are incubated in phosphate buffered saline (PBS) containing 1% human serum on ice for 20 minutes. Cells are pelleted at $200 \times g$. Cells are resuspended in 20 ml PE or FITC labeled mAb. Following an
30 additional 20 minute incubation on ice, cells are washed in PBS containing 1% human serum followed by two washes in PBS alone. Cells are fixed in PBS containing 1% paraformaldehyde and analyzed on FACScan flow cytometer (Becton Dickinson; Mountain View, CA). Exemplary mAbs are
35 used, e.g.: CD11b (anti-mac1), CD11c (a gp150/95), CD14 (Leu-M3), CD54 (Leu 54), CD80 (anti-BB1/B7), HLA-DR (L243)

from Becton-Dickinson and CD86 (FUN 1; Pharmingen), CD64 (32.2; Medarex), CD40 (mAb89; Schering-Plough France).

5 D. Effects of antibodies on cytokine production by human monocytes

Human monocytes are isolated as described and cultured in Yssel's medium (Gemini Bioproducts, Calabasas, CA) containing 1% human AB serum in the absence or presence of antibodies. In addition, monocytes are stimulated with LPS 10 (E. coli 0127:B8 Difco) in the absence or presence of antibodies and the concentration of cytokines (IL-1 β , IL-6, TNF α , GM-CSF, and IL-10) in the cell culture supernatant determined by ELISA.

Additional assays will be tested in the areas of bone 15 remodeling, chondriocytes, neurons, adipocytes, gastrointestinal epithelium, or bronchial epithelium.

XI. Generation and Analysis of Genetically Altered Animals

Transgenic mice can be generated by standard methods. 20 Such animals are useful to determine the effects of deletion of the gene, in specific tissues, or completely throughout the organism. Such may provide interesting insight into development of the animal or particular tissues in various stages. Moreover, the effect on various responses to 25 biological stress can be evaluated. See, e.g., Hogan, et al. (1995) Manipulating the Mouse Embryo: A Laboratory Manual (2d ed.) Cold Spring Harbor Laboratory Press.

All references cited herein are incorporated herein by 30 reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.

Many modifications and variations of this invention 35 can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example

only, and the invention is to be limited only by the terms of the appended claims, along with the full scope of equivalents to which such claims are entitled.

WHAT IS CLAIMED IS:

1. An isolated or recombinant polynucleotide encoding an antigenic polypeptide comprising at least 17
5 contiguous amino acids from the mature polypeptide from:
 - a) SEQ ID NO: 2; or
 - b) SEQ ID NO: 5 or 7.
- 10 2. The polynucleotide of Claim 1, encoding a mature polypeptide from SEQ ID NO: 2, 5, or 7.
3. The polynucleotide of Claim 1, which hybridizes at 55° C, less than 500 mM salt, and 50% formamide to the coding portions of SEQ ID NO: 1 or 4 or 6.
15
4. The polynucleotide of Claim 3, comprising at least 35 contiguous nucleotides of the coding portion of SEQ ID NO: 1 or 4 or 6.
- 20 5. An expression vector comprising the polynucleotide of Claim 1.
6. A host cell containing the expression vector of Claim 5, including a eukaryotic cell.
25
7. A method of making an antigenic polypeptide comprising expressing a recombinant polynucleotide of Claim 1.
- 30 8. A method for forming a duplex with a polynucleotide of Claim 1, comprising contacting said polynucleotide with a probe that hybridizes, under stringent conditions, to at least 25 contiguous nucleotides of the coding portion of SEQ ID NO: 1 or 4 or 6; thereby forming
35 said duplex.

9. A kit for the detection of a polynucleotide of Claim 1, comprising a polynucleotide that hybridizes, under stringent hybridization conditions, to at least 17 contiguous nucleotides of a polynucleotide of Claim 1.

5

10. The kit of claim 9, wherein said probe is detectably labeled.

11. A binding compound comprising an antibody binding site which specifically binds to at least 17 contiguous amino acids from SEQ ID NO: 2 or 5 or 7.

12. The binding compound of Claim 11, wherein:

a) said antibody binding site is:

15

- 1) specifically immunoreactive with a polypeptide of SEQ ID NO: 2 or 5 or 7;
- 2) raised against a purified or recombinantly produced human DC-STAMP or DSP-1 protein; or
- 3) in a monoclonal antibody, Fab, or F(ab)2; or

20

b) said binding compound is:

- 1) an antibody molecule;
- 2) a polyclonal antiserum;
- 3) detectably labeled;
- 4) sterile; or
- 5) in a buffered composition.

25

13. A method using the binding compound of Claim 11, comprising contacting said binding compound with a biological sample comprising an antigen, wherein said contacting results in formation of a binding compound:antigen complex.

30

14. The method of Claim 13, wherein said biological sample is from a human, and wherein said binding compound is an antibody.

35

15. A detection kit comprising said binding compound of Claim 12, and:

- a) instructional material for the use of said binding compound for said detection; or
- 5 b) a compartment providing segregation of said binding compound.

16. A substantially pure or isolated antigenic polypeptide, which binds to said binding composition of Claim 11, and further comprises at least 17 contiguous amino acids from SEQ ID NO: 2 or 5 or 7.

17. The polypeptide of Claim 16, which:

- 15 a) comprises at least a fragment of at least 25 contiguous amino acid residues from a primate DC-STAMP or DSP-1 protein;
- b) is a soluble polypeptide;
- c) is detectably labeled;
- d) is in a sterile composition;
- 20 e) is in a buffered composition;
- f) binds to a cell surface receptor;
- g) is recombinantly produced; or
- h) has a naturally occurring polypeptide sequence.

25 18. The polypeptide of Claim 17, which comprises at least 17 contiguous amino acids of SEQ ID NO: 2 or 5 or 7.

19. A method of modulating physiology or development of a cell or tissue culture cells comprising contacting said cell with an agonist or antagonist of a primate DC-STAMP or DSP-1.

20. The method of Claim 19, wherein:

a) said contacting is in combination with an agonist or antagonist of Flt3 ligand; or

b) said contacting is with an antagonist, including binding composition comprising an antibody binding site which specifically binds a DC-STAMP or DSP-1.

5

SEQUENCE SUBMISSION

5 SEQ ID NO: 1 is primate, e.g., human, DC-STAMP nucleic acid sequence.
 SEQ ID NO: 2 is primate DC-STAMP polypeptide sequence.
 SEQ ID NO: 3 is reverse translation of primate DC-STAMP.
 SEQ ID NO: 4 is primate, e.g., human, DSP-1L nucleic acid sequence.
 SEQ ID NO: 5 is primate DSP-1L polypeptide sequence.
 10 SEQ ID NO: 6 is primate, e.g., human, DSP-1S nucleic acid sequence.
 SEQ ID NO: 7 is primate DSP-1S polypeptide sequence.
 SEQ ID NO: 8 is reverse translation of primate DSP-1L.
 SEQ ID NO: 9 is reverse translation of primate DSP-1S.

15 <110> Zlot, Constance F.
 Adema, Gosse J.
 Figdor, Carl
 Phillips, Joseph H.

20 <120> Mammalian Genes; Related Reagents and Methods
 <130> DX1051Q
 <140>
 <141>
 25 <160> 9
 <170> PatentIn Ver. 2.0

30 <210> 1
 <211> 1960
 <212> DNA
 <213> primate

35 <220>
 <221> CDS
 <222> (58)..(1467)

40 <400> 1
 ggggggtggc atttctgcat tcgaagaaga atctgagaga aacctgacgc aggggagc 57
 atg ggt atc tgg acc tca ggc act gat atc ttc cta agt ctt tgg gag 105
 Met Gly Ile Trp Thr Ser Gly Thr Asp Ile Phe Leu Ser Leu Trp Glu
 1 5 10 15
 45 att tac gtg tct cca aga agc ccc gga tgg atg gac ttt atc cag cat 153
 Ile Tyr Val Ser Pro Arg Ser Pro Gly Trp Met Asp Phe Ile Gln His
 20 25 30
 50 ttg gga gtt tgc tgt ttg gtt gct ctt att tca gtg ggc ctc ctg tct 201
 Leu Gly Val Cys Cys Leu Val Ala Leu Ile Ser Val Gly Leu Leu Ser
 35 40 45
 55 gtg gcc gcc tgc tgg ttt ctg cca tca atc ata gcg gcc gct gcc tcc 249
 Val Ala Ala Cys Trp Phe Leu Pro Ser Ile Ile Ala Ala Ala Ala Ser
 50 55 60
 60 tgg att atc acg tgt gtt ctg ctg tgt tgc tcc aag cat gca cga tgt 297
 Trp Ile Ile Thr Cys Val Leu Leu Cys Cys Ser Lys His Ala Arg Cys
 65 70 75 80

	ttt att ctt ctt gtc ttt ctc tct tgt ggc ctg cgt gaa ggc agg aat	345
	Phe Ile Leu Leu Val Phe Leu Ser Cys Gly Leu Arg Glu Gly Arg Asn	
	85 90 95	
5	gct ttg att gca gct ggc aca ggg atc gtc atc ttg gga cac gta gaa	393
	Ala Leu Ile Ala Ala Gly Thr Gly Ile Val Ile Leu Gly His Val Glu	
	100 105 110	
10	aat att ttt cac aac ttt aaa ggt ctc cta gat ggt atg act tgc aac	441
	Asn Ile Phe His Asn Phe Lys Gly Leu Leu Asp Gly Met Thr Cys Asn	
	115 120 125	
15	cta agg gca aag agc ttt tcc ata cat ttt cca ctt ttg aaa aaa tat	489
	Leu Arg Ala Lys Ser Phe Ser Ile His Phe Pro Leu Leu Lys Lys Tyr	
	130 135 140	
20	att gag gca att cag tgg att tat ggc ctt gcc act cca cta agt gta	537
	Ile Glu Ala Ile Gln Trp Ile Tyr Gly Leu Ala Thr Pro Leu Ser Val	
	145 150 155 160	
25	ttt gat gac ctt gtt tct tgg aac cag acc ctg gca gtc tct ctt ttc	585
	Phe Asp Asp Leu Val Ser Trp Asn Gln Thr Leu Ala Val Ser Leu Phe	
	165 170 175	
30	agt ccc agc cat gtc ctg gag gca cag cta aat gac agc aaa ggg gaa	633
	Ser Pro Ser His Val Leu Glu Ala Gln Leu Asn Asp Ser Lys Gly Glu	
	180 185 190	
35	gtc ctg agc gtc ttg tac cag atg gca aca acc aca gag gtg ttg tcc	681
	Val Leu Ser Val Leu Tyr Gln Met Ala Thr Thr Thr Glu Val Leu Ser	
	195 200 205	
40	tcc ctg ggt cag aag cta ctt gcc ttt gca ggg ctt tcg ctc gtc ctg	729
	Ser Leu Gly Gln Lys Leu Leu Ala Phe Ala Gly Leu Ser Leu Val Leu	
	210 215 220	
45	ctt ggc act ggc ctc ttc atg aag cga ttt ttg ggc cct tgt ggt tgg	777
	Leu Gly Thr Gly Leu Phe Met Lys Arg Phe Leu Gly Pro Cys Gly Trp	
	225 230 235 240	
50	aag tat gaa aac atc tac atc acc aga caa ttt gtt cag ttt gat gaa	825
	Lys Tyr Glu Asn Ile Tyr Ile Thr Arg Gln Phe Val Gln Phe Asp Glu	
	245 250 255	
55	agg gag aga cat caa cag agg ccc tgt gtg ctc ccg ctg aat aag gag	873
	Arg Glu Arg His Gln Gln Arg Pro Cys Val Leu Pro Leu Asn Lys Glu	
	260 265 270	
60	gaa agg agg aag tat gtc atc atc ccg act ttc tgg ccg act cct aaa	921
	Glu Arg Arg Lys Tyr Val Ile Ile Pro Thr Phe Trp Pro Thr Pro Lys	
	275 280 285	
65	gaa agg aaa aac ctg ggg ctg ttt ttc ctc ccc ata ctt atc cat ctc	969
	Glu Arg Lys Asn Leu Gly Leu Phe Phe Leu Pro Ile Leu Ile His Leu	
	290 295 300	
70	tgc atc tgg gtg ctg ttt gca gct gta gat tat ctg ctg tat cgg ctc	1017
	Cys Ile Trp Val Leu Phe Ala Ala Val Asp Tyr Leu Leu Tyr Arg Leu	
	305 310 315 320	

	att ttc tca gtg agc aag cag ttt caa agc ttg cca ggg ttt gag gtt	1065
	Ile Phe Ser Val Ser Lys Gln Phe Gln Ser Leu Pro Gly Phe Glu Val	
	325 330 335	
5	cac ttg aaa ctg cac gga gag aaa caa gga act caa gat att atc cat	1113
	His Leu Lys Leu His Gly Glu Lys Gln Gly Thr Gln Asp Ile Ile His	
	340 345 350	
10	gat tct tcc ttt aat ata tct gtg ttt gaa ccc aac tgt atc cca aaa	1161
	Asp Ser Ser Phe Asn Ile Ser Val Phe Glu Pro Asn Cys Ile Pro Lys	
	355 360 365	
15	cca aaa ttc ctt cta tct gag acc tgg gtt cct ctc agt gtt att ctt	1209
	Pro Lys Phe Leu Leu Ser Glu Thr Trp Val Pro Leu Ser Val Ile Leu	
	370 375 380	
20	ttg ata tta gtg atg ctg gga ctg ttg tcc tct atc ctt atg caa ctt	1257
	Leu Ile Leu Val Met Leu Gly Leu Leu Ser Ser Ile Leu Met Gln Leu	
	385 390 395 400	
25	aaa atc ctg gtg tca gca tct ttc tac ccc agc gtg gag agg aag cgc	1305
	Lys Ile Leu Val Ser Ala Ser Phe Tyr Pro Ser Val Glu Arg Lys Arg	
	405 410 415	
30	atc caa tat ctg cat gca aag ctg ctt aaa aaa aga tca aag cag ccg	1353
	Ile Gln Tyr Leu His Ala Lys Leu Leu Lys Lys Arg Ser Lys Gln Pro	
	420 425 430	
35	ctg gga gaa gtc aaa aga cgg ctg agt ctc tat ctt aca aag att cat	1401
	Leu Gly Glu Val Lys Arg Arg Leu Ser Leu Tyr Leu Thr Lys Ile His	
	435 440 445	
40	ttc tgg ctt cca gtc ctg aaa atg att agg aag aag caa atg gac atg	1449
	Phe Trp Leu Pro Val Leu Lys Met Ile Arg Lys Lys Gln Met Asp Met	
	450 455 460	
45	gca agt gca gac aag tca tgagagaccc cgactactcc tcagccacat	1497
	Ala Ser Ala Asp Lys Ser	
	465 470	
50	cgcaccaaca attctcttca ggtctaggat ggcagtcact attcatgccg gataatagag	1557
	aactatgtga cgcagtcctc tcaggagtct gagtttacag agccaacttg cagcacctgg	1617
	ttatgcctcc ttctatctca aagccaaaga gctgccaggt aaatgggttat gtggtctatg	1677
	ttccaaacaa accacatgat cttgcctgtg tcacaatgta acaagactct agctgggtcc	1737
55	cctggtgatg agtttcagca tagaataatg ttcaaggaaa agaaaacgaa aacagtttaa	1797
	atctctacca cagcctcaca agcaaagtct aaggggaaca tacatgtaaa aagccagcaa	1857
	actatcttca aactcttccg tccttaaatgt cttccatggc tattgcccc acaatgggtct	1917
	cttttctccc tgctccotta ttaaagaact ctttctgaaa ccc	1960
60	<210> 2	
	<211> 470	

<212> PRT

<213> primate

<400> 2

5 Met Gly Ile Trp Thr Ser Gly Thr Asp Ile Phe Leu Ser Leu Trp Glu
 1 5 10 15

 Ile Tyr Val Ser Pro Arg Ser Pro Gly Trp Met Asp Phe Ile Gln His
 20 25 30
 10 Leu Gly Val Cys Cys Leu Val Ala Leu Ile Ser Val Gly Leu Leu Ser
 35 40 45

 Val Ala Ala Cys Trp Phe Leu Pro Ser Ile Ile Ala Ala Ala Ala Ser
 50 55 60
 15 Trp Ile Ile Thr Cys Val Leu Leu Cys Cys Ser Lys His Ala Arg Cys
 65 70 75 80

 Phe Ile Leu Leu Val Phe Leu Ser Cys Gly Leu Arg Glu Gly Arg Asn
 85 90 95
 20 Ala Leu Ile Ala Ala Gly Thr Gly Ile Val Ile Leu Gly His Val Glu
 100 105 110

 Asn Ile Phe His Asn Phe Lys Gly Leu Leu Asp Gly Met Thr Cys Asn
 115 120 125
 25 Leu Arg Ala Lys Ser Phe Ser Ile His Phe Pro Leu Leu Lys Lys Tyr
 130 135 140

 Ile Glu Ala Ile Gln Trp Ile Tyr Gly Leu Ala Thr Pro Leu Ser Val
 145 150 155 160
 35 Phe Asp Asp Leu Val Ser Trp Asn Gln Thr Leu Ala Val Ser Leu Phe
 165 170 175

 Ser Pro Ser His Val Leu Glu Ala Gln Leu Asn Asp Ser Lys Gly Glu
 180 185 190
 40 Val Leu Ser Val Leu Tyr Gln Met Ala Thr Thr Thr Glu Val Leu Ser
 195 200 205

 Ser Leu Gly Gln Lys Leu Leu Ala Phe Ala Gly Leu Ser Leu Val Leu
 210 215 220
 45 Leu Gly Thr Gly Leu Phe Met Lys Arg Phe Leu Gly Pro Cys Gly Trp
 225 230 235 240

 Lys Tyr Glu Asn Ile Tyr Ile Thr Arg Gln Phe Val Gln Phe Asp Glu
 245 250 255
 50 Arg Glu Arg His Gln Gln Arg Pro Cys Val Leu Pro Leu Asn Lys Glu
 260 265 270

 Glu Arg Arg Lys Tyr Val Ile Ile Pro Thr Phe Trp Pro Thr Pro Lys
 275 280 285
 55 Glu Arg Lys Asn Leu Gly Leu Phe Phe Leu Pro Ile Leu Ile His Leu
 290 295 300
 60

Cys Ile Trp Val Leu Phe Ala Ala Val Asp Tyr Leu Leu Tyr Arg Leu
305 310 315 320

5 Ile Phe Ser Val Ser Lys Gln Phe Gln Ser Leu Pro Gly Phe Glu Val
325 330 335

His Leu Lys Leu His Gly Glu Lys Gln Gly Thr Gln Asp Ile Ile His
340 345 350

10 Asp Ser Ser Phe Asn Ile Ser Val Phe Glu Pro Asn Cys Ile Pro Lys
355 360 365

15 Pro Lys Phe Leu Leu Ser Glu Thr Trp Val Pro Leu Ser Val Ile Leu
370 375 380

Leu Ile Leu Val Met Leu Gly Leu Leu Ser Ser Ile Leu Met Gln Leu
385 390 395 400

20 Lys Ile Leu Val Ser Ala Ser Phe Tyr Pro Ser Val Glu Arg Lys Arg
405 410 415

Ile Gln Tyr Leu His Ala Lys Leu Leu Lys Lys Arg Ser Lys Gln Pro
420 425 430

25 Leu Gly Glu Val Lys Arg Arg Leu Ser Leu Tyr Leu Thr Lys Ile His
435 440 445

Phe Trp Leu Pro Val Leu Lys Met Ile Arg Lys Lys Gln Met Asp Met
450 455 460

30 Ala Ser Ala Asp Lys Ser
465 470

35 <210> 3
<211> 1410
<212> DNA
<213> Artificial Sequence

40 <220>
<223> Description of Artificial Sequence:reverse
translation

45 <220>
<221> misc_feature
<222> (1)..(1410)
<223> n may be a, c, g, or t

50 <400> 3
atgggnatht ggacnwsngg nacngayath ttyytnwsny tntgggarat htaygtnwsn 60
ccnmgnwsnc cnggntggat ggayttyath carcayytnng gngtntgytg yytnngtngcn 120

55 ytnathwsng tnggnytnyt nwsngtngcn gcntgytggt tyytnccnws nathathgcn 180
gcngcngcnw sntggathat hacntgygtn ytnytnngyt gywsnaarca ygcnmngtgy 240
ttyathytny tngtnttyyt nwsntgyggn ytnmgngarg gnmgnaaygc nytnathgcn 300

60

```

gcnggnacng gnathgtnat hytnggncay gtngaraaya thttycayaa yttyaarggn 360
ytntyngayg gnatgacntg yaayytnmgn gcnaarwsnt tywsnathca ytttyccnytn 420
5 ytnaaraart ayathgargc nathcartgg athtayggny tngcnacncc nytnwsngtn 480
ttygaygayy tngtnwsntg gaaycaracn ytngcngtnw snytnntyws necnwsncay 540
gtntyngarg cncarytnaa ygaywsnaar ggngargtny tnwsngtnyt ntaycaratg 600
10 gcnacnacna cngargtnyt nwsnwsnytn ggncaraary tnytnngcntt ygcnngnytn 660
wsnytngtny tnytnngnac nggnytnnty atgaarmgnt tyytnngncc ntgyggntgg 720
15 aartaygara ayathtayat hacnmgnar ttygtncart tygaygarmg ngarmgncay 780
carcarmgnc cntgygtnyt nccnytnaay aargargarm gnmgnaarta ygtnathath 840
ccnacnttyt ggccnacncc naargarmgn aaraayytn gnytnntytt yytnccnath 900
20 ytnathcayy tntgyathtg ggtnytnnty gcngcngtn gytayytnyt ntaymgnytn 960
athttywsng tnwsnaarca rttycarwsn ytnccnggnt tygargtnca yytnaarytn 1020
25 cayggngara arcarggnac ncargayath athcaygayw snwsnttyaa yathwsngtn 1080
ttygarccna aytgyathcc naarcnaar tyytynytnw sngaracntg ggtncnytn 1140
wsngtnathy tnytnathyt ngtnatgytn ggnytnytnw snwsnathyt natgcarytn 1200
30 aarathytn gtnwsngcnws nttytayccn wsngtnngarm gnaarmgnat hcartayytn 1260
caygcnaary tnytnaaraa rmgnwsnaar carccnytn gngargtnaa rmgnmgnytn 1320
35 wsnytnntayy tnacnaarat hcayttytg ytnccngtny tnaaratgat hmgnaaraar 1380
caratggaya tggcnwsngc ngayaarwsn 1410

40 <210> 4
    <211> 942
    <212> DNA
    <213> primate

45 <220>
    <221> CDS
    <222> (1)..(939)

    <220>
50 <221> mat_peptide
    <222> (64)..(939)

    <400> 4
55 atg gcc tta cca gtg acc gcc ttg ctc ctg ccg cta gcc ttg ctg ctc 48
    Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
        -20              -15              -10

    cac gcc gcc agg ccg gat tac aag gac gat gac gac aag atc gat ctg 96
60 His Ala Ala Arg Pro Asp Tyr Lys Asp Asp Asp Asp Lys Ile Asp Leu
    -5              -1 1              5              10

```

	agc	aaa	tgc	agg	acc	gtg	gcg	ggc	ccc	gtg	ggg	gga	tcc	ctg	agt	gtg	144
	Ser	Lys	Cys	Arg	Thr	Val	Ala	Gly	Pro	Val	Gly	Gly	Ser	Leu	Ser	Val	
				15					20					25			
5	cag	tgt	ccc	tat	gag	aag	gaa	cac	agg	acc	ctc	aac	aaa	tac	tgg	tgc	192
	Gln	Cys	Pro	Tyr	Glu	Lys	Glu	His	Arg	Thr	Leu	Asn	Lys	Tyr	Trp	Cys	
			30					35					40				
10	aga	cca	cca	cag	att	ttc	cta	tgt	gac	aag	att	gtg	gag	acc	aaa	ggg	240
	Arg	Pro	Pro	Gln	Ile	Phe	Leu	Cys	Asp	Lys	Ile	Val	Glu	Thr	Lys	Gly	
		45					50					55					
15	tca	gca	gga	aaa	agg	aac	ggc	cga	gtg	tcc	atc	agg	gac	agt	cct	gca	288
	Ser	Ala	Gly	Lys	Arg	Asn	Gly	Arg	Val	Ser	Ile	Arg	Asp	Ser	Pro	Ala	
	60					65					70					75	
20	aac	ctc	agc	ttc	aca	gtg	acc	ctg	gag	aat	ctc	aca	gag	gag	gat	gca	336
	Asn	Leu	Ser	Phe	Thr	Val	Thr	Leu	Glu	Asn	Leu	Thr	Glu	Glu	Asp	Ala	
					80					85					90		
25	ggc	acc	tac	tgg	tgt	ggg	gtg	gat	aca	ccg	tgg	ctc	cga	gac	ttt	cat	384
	Gly	Thr	Tyr	Trp	Cys	Gly	Val	Asp	Thr	Pro	Trp	Leu	Arg	Asp	Phe	His	
				95				100						105			
30	gat	ccc	ggt	gtc	gag	ggt	gag	gtg	tcc	gtg	ttc	ccg	gca	tca	acg	tca	432
	Asp	Pro	Val	Val	Glu	Val	Glu	Val	Ser	Val	Phe	Pro	Ala	Ser	Thr	Ser	
			110					115					120				
35	atg	aca	cct	gca	agt	atc	act	gcg	gcc	aag	acc	tca	aca	atc	aca	act	480
	Met	Thr	Pro	Ala	Ser	Ile	Thr	Ala	Ala	Lys	Thr	Ser	Thr	Ile	Thr	Thr	
		125					130					135					
40	gca	ttt	cca	cct	gta	tca	tcc	act	acc	ctg	ttt	gca	gtg	ggg	gcc	acc	528
	Ala	Phe	Pro	Pro	Val	Ser	Ser	Thr	Thr	Leu	Phe	Ala	Val	Gly	Ala	Thr	
	140					145					150					155	
45	cac	agt	gcc	agc	atc	cag	gag	gaa	act	gag	gag	gtg	gtg	aac	tca	cag	576
	His	Ser	Ala	Ser	Ile	Gln	Glu	Glu	Thr	Glu	Glu	Val	Val	Asn	Ser	Gln	
				160						165					170		
50	ctc	ccg	ctg	ctc	ctc	tcc	ctg	ctg	gca	ttg	ttg	ctg	ctt	ctg	ttg	gtg	624
	Leu	Pro	Leu	Leu	Leu	Ser	Leu	Leu	Ala	Leu	Leu	Leu	Leu	Leu	Leu	Val	
				175					180					185			
55	ggg	gcc	tcc	ctg	cta	gcc	tgg	agg	atg	ttt	cag	aaa	tgg	atc	aaa	gct	672
	Gly	Ala	Ser	Leu	Leu	Ala	Trp	Arg	Met	Phe	Gln	Lys	Trp	Ile	Lys	Ala	
			190					195					200				
60	ggt	gac	cat	tca	gag	ctg	tcc	cag	aac	ccc	aag	cag	gct	gcc	acg	cag	720
	Gly	Asp	His	Ser	Glu	Leu	Ser	Gln	Asn	Pro	Lys	Gln	Ala	Ala	Thr	Gln	
		205					210					215					
65	agt	gag	ctg	cac	tac	gca	aat	ctg	gag	ctg	ctg	atg	tgg	cct	ctg	cag	768
	Ser	Glu	Leu	His	Tyr	Ala	Asn	Leu	Glu	Leu	Leu	Met	Trp	Pro	Leu	Gln	
	220					225					230					235	
70	gaa	aag	cca	gca	cca	cca	agg	gag	gtg	gag	gtg	gaa	tac	agc	act	gtg	816
	Glu	Lys	Pro	Ala	Pro	Pro	Arg	Glu	Val	Glu	Val	Glu	Tyr	Ser	Thr	Val	
				240						245						250	

```

gcc tcc ccc agg gaa gaa ctt cac tat gcc tcg gtg gtg ttt gat tct 864
Ala Ser Pro Arg Glu Glu Leu His Tyr Ala Ser Val Val Phe Asp Ser
255 260 265

5 aac acc aac agg ata gct gct cag agg cct cgg gag gag gaa cca gat 912
Asn Thr Asn Arg Ile Ala Ala Gln Arg Pro Arg Glu Glu Glu Pro Asp
270 275 280

10 tca gat tac agt gtg ata agg aag aca tag 942
Ser Asp Tyr Ser Val Ile Arg Lys Thr
285 290

15 <210> 5
    <211> 313
    <212> PRT
    <213> primate

20 <400> 5
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
-20 -15 -10

25 His Ala Ala Arg Pro Asp Tyr Lys Asp Asp Asp Asp Lys Ile Asp Leu
-5 -1 1 5 10

Ser Lys Cys Arg Thr Val Ala Gly Pro Val Gly Gly Ser Leu Ser Val
15 20 25

30 Gln Cys Pro Tyr Glu Lys Glu His Arg Thr Leu Asn Lys Tyr Trp Cys
30 35 40

Arg Pro Pro Gln Ile Phe Leu Cys Asp Lys Ile Val Glu Thr Lys Gly
45 50 55

35 Ser Ala Gly Lys Arg Asn Gly Arg Val Ser Ile Arg Asp Ser Pro Ala
60 65 70 75

40 Asn Leu Ser Phe Thr Val Thr Leu Glu Asn Leu Thr Glu Glu Asp Ala
80 85 90

Gly Thr Tyr Trp Cys Gly Val Asp Thr Pro Trp Leu Arg Asp Phe His
95 100 105

45 Asp Pro Val Val Glu Val Glu Val Ser Val Phe Pro Ala Ser Thr Ser
110 115 120

Met Thr Pro Ala Ser Ile Thr Ala Ala Lys Thr Ser Thr Ile Thr Thr
125 130 135

50 Ala Phe Pro Pro Val Ser Ser Thr Thr Leu Phe Ala Val Gly Ala Thr
140 145 150 155

His Ser Ala Ser Ile Gln Glu Glu Thr Glu Glu Val Val Asn Ser Gln
160 165 170

55 Leu Pro Leu Leu Leu Ser Leu Leu Ala Leu Leu Leu Leu Leu Val
175 180 185

```

Gly Ala Ser Leu Leu Ala Trp Arg Met Phe Gln Lys Trp Ile Lys Ala
 190 195 200
 5 Gly Asp His Ser Glu Leu Ser Gln Asn Pro Lys Gln Ala Ala Thr Gln
 205 210 215
 Ser Glu Leu His Tyr Ala Asn Leu Glu Leu Leu Met Trp Pro Leu Gln
 220 225 230 235
 10 Glu Lys Pro Ala Pro Pro Arg Glu Val Glu Val Glu Tyr Ser Thr Val
 240 245 250
 Ala Ser Pro Arg Glu Glu Leu His Tyr Ala Ser Val Val Phe Asp Ser
 255 260 265
 15 Asn Thr Asn Arg Ile Ala Ala Gln Arg Pro Arg Glu Glu Glu Pro Asp
 270 275 280
 20 Ser Asp Tyr Ser Val Ile Arg Lys Thr
 285 290
 <210> 6
 <211> 603
 25 <212> DNA
 <213> primate
 <220>
 <221> CDS
 30 <222> (1)..(600)
 <220>
 <221> mat_peptide
 <222> (64)..(600)
 35 <400> 6
 atg gcc tta cca gtg acc gcc ttg ctc ctg ccg cta gcc ttg ctg ctc 48
 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 -20 -15 -10
 40 cac gcc gcc agg ccg gat tac aag gac gat gac gac aag atc gat atg 96
 His Ala Ala Arg Pro Asp Tyr Lys Asp Asp Asp Asp Lys Ile Asp Met
 -5 -1 1 5 10
 45 aca cct gca agt atc act gcg gcc aag acc tca aca atc aca act gca 144
 Thr Pro Ala Ser Ile Thr Ala Ala Lys Thr Ser Thr Ile Thr Thr Ala
 15 20 25
 50 ttt cca cct gta tca tcc act acc ctg ttt gca gtg ggt gcc acc cac 192
 Phe Pro Pro Val Ser Ser Thr Thr Leu Phe Ala Val Gly Ala Thr His
 30 35 40
 agt gcc agc atc cag gag gaa act gag gag gtg gtg aac tca cag ctc 240
 Ser Ala Ser Ile Gln Glu Glu Thr Glu Glu Val Val Asn Ser Gln Leu
 45 50 55
 ccg ctg ctc ctc tcc ctg ctg gca ttg ttg ctg ctt ctg ttg gtg ggg 288
 Pro Leu Leu Leu Ser Leu Leu Ala Leu Leu Leu Leu Leu Leu Val Gly
 60 65 70 75
 60

	gcc tcc ctg cta gcc tgg agg atg ttt cag aaa tgg atc aaa gct ggt	336
	Ala Ser Leu Leu Ala Trp Arg Met Phe Gln Lys Trp Ile Lys Ala Gly	
	80 85 90	
5	gac cat tca gag ctg tcc cag aac ccc aag cag gct gcc acg cag agt	384
	Asp His Ser Glu Leu Ser Gln Asn Pro Lys Gln Ala Ala Thr Gln Ser	
	95 100 105	
10	gag ctg cac tac gca aat ctg gag ctg ctg atg tgg cct ctg cag gaa	432
	Glu Leu His Tyr Ala Asn Leu Glu Leu Leu Met Trp Pro Leu Gln Glu	
	110 115 120	
15	aag cca gca cca cca agg gag gtg gag gtg gaa tac agc act gtg gcc	480
	Lys Pro Ala Pro Pro Arg Glu Val Glu Val Glu Tyr Ser Thr Val Ala	
	125 130 135	
20	tcc ccc agg gaa gaa ctt cac tat gcc tcg gtg gtg ttt gat tct aac	528
	Ser Pro Arg Glu Glu Leu His Tyr Ala Ser Val Val Phe Asp Ser Asn	
	140 145 150 155	
25	acc aac agg ata gct gct cag agg cct cgg gag gag gaa cca gat tca	576
	Thr Asn Arg Ile Ala Ala Gln Arg Pro Arg Glu Glu Glu Pro Asp Ser	
	160 165 170	
30	gat tac agt gtg ata agg aag aca tag	603
	Asp Tyr Ser Val Ile Arg Lys Thr	
	175	
35	<210> 7	
	<211> 200	
	<212> PRT	
	<213> primate	
40	<400> 7	
	Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu	
	-20 -15 -10	
45	His Ala Ala Arg Pro Asp Tyr Lys Asp Asp Asp Asp Lys Ile Asp Met	
	-5 -1 1 5 10	
50	Thr Pro Ala Ser Ile Thr Ala Ala Lys Thr Ser Thr Ile Thr Thr Ala	
	15 20 25	
55	Phe Pro Pro Val Ser Ser Thr Thr Leu Phe Ala Val Gly Ala Thr His	
	30 35 40	
60	Ser Ala Ser Ile Gln Glu Glu Thr Glu Glu Val Val Asn Ser Gln Leu	
	45 50 55	
65	Pro Leu Leu Leu Ser Leu Leu Ala Leu Leu Leu Leu Leu Leu Val Gly	
	60 65 70 75	
70	Ala Ser Leu Leu Ala Trp Arg Met Phe Gln Lys Trp Ile Lys Ala Gly	
	80 85 90	
75	Asp His Ser Glu Leu Ser Gln Asn Pro Lys Gln Ala Ala Thr Gln Ser	
	95 100 105	

Glu Leu His Tyr Ala Asn Leu Glu Leu Leu Met Trp Pro Leu Gln Glu
110 115 120

5 Lys Pro Ala Pro Pro Arg Glu Val Glu Val Glu Tyr Ser Thr Val Ala
125 130 135

Ser Pro Arg Glu Glu Leu His Tyr Ala Ser Val Val Phe Asp Ser Asn
140 145 150 155

10 Thr Asn Arg Ile Ala Ala Gln Arg Pro Arg Glu Glu Glu Pro Asp Ser
160 165 170

Asp Tyr Ser Val Ile Arg Lys Thr
175

15

<210> 8
<211> 939
<212> DNA
20 <213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:reverse
translation

25

<220>
<221> misc_feature
<222> (1)..(939)
<223> n may be a, c, g, or t

30

<400> 8
atggcnytn cngtnacngc nytnytnytn ccnytnngcny tnytnytnca ygcngcnmgn 60

35 ccngaytaya argaygayga ygayaarath gayytnwsna artgymgnac ngtnngcnggn 120

ccngtnggng gnwsnytnws ngtncartgy ccntaygara argarcaymg nacnytnaay 180

aartaytggt gymgnccncc ncarathtty ytntgygaya arathgtnga racnaarggn 240

40 wsngcnggna armgnaaygg nmngntnwsn athmgngayw snccngcnaa yytnwsntty 300

acngtnacny tngaraayyt nacngargar gaygcnggna cntaytggtg yggngtngay 360

45 acncntggy tnmngaytt ycaygayccn gtngtngarg tngargtnws ngtnnttyccn 420

gcnwsnacnw snatgacncc ngcnwsnath acngcngcna aracnwsnac nathacnacn 480

gcnttyccnc cngtnwsnws nacnacnytn ttygcngtng gngcnacnca ywsngcnwsn 540

50 athcargarg aracngarga rgtngtnaay wsncarytn cnytnytnyt nwsnytnytn 600

gcnytnytny tnytnytnyt ngtnngngcn wsnytnytny cntggmgngat gttycaraar 660

55 tggathaarg cnggngayca ywsngarytn wsncaraayc cnaarcargc ngcnacncar 720

wsngarytn aytagcnaa yytngarytn ytnatgtggc cnytnarga raarccngcn 780

ccnccnmngng argtngargt ngartaywsn acngtngcnw snccnmngna rgarytnay 840

60 taygcnwsng tngtnnttyga ywsnaayacn aaymgngathg cngcncarmg nccnmngnar 900

gargarccng aywsngayta ywsngtnath mgnaaracn

939

5 <210> 9
<211> 600
<212> DNA
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence:reverse
translation

15 <220>
<221> misc_feature
<222> (1)..(600)
<223> n may be a, c, g, or t

20 <400> 9
atggcnytn cngtnacngc nytnytnytn ccnytngcny tnytnytnca ygcngcnmgn 60
ccngaytaya argaygayga ygayaarath gayatgacnc cngcnwsnat hacngcngcn 120
aaracnwsna cnathacnac ngcnttyccn ccngtnwsnw snacnacnyt nttygcngtn 180
25 ggngcnacnc aywsngcnws nathcargar garacngarg argtngtnaa ywsncarytn 240
ccnytnytny tnwsnytnyt ngcnytnytn ytnytnytny tngtnggngc nwsnytnytn 300
30 gcntggmgna tgttycaraa rtggathaar gcngnggayc aywsngaryt nwsncaraay 360
ccnaarcarg cngcnacnca rwsngarytn caytaygcna ayytngaryt nytnatgtgg 420
ccnytnrcarg araarcngc nccnccnmgn gargtngarg tngartayws nacngtngcn 480
35 wsnccnmngn argarytnca ytaygcwnsn gtngtnttyg aywsnaayac naaymgnath 540
gcngcncarm gncnmgnga rgargarccn gaywsngayt aywsngtnat hmgnaaracn 600
40

MAMMALIAN GENES; RELATED REAGENTS AND METHODS

5

ABSTRACT

Purified genes encoding proteins from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided.

SEQUENCE LISTING

<110> Zlot, Constance H.
Adema, Gosse J.
Figdor, Carl
Phillips, Joseph H.

<120> Mammalian Genes; Related Reagents and Methods

<130> DX1051Q

<140>

<141>

<160> 9

<170> PatentIn Ver. 2.0

<210> 1

<211> 1960

<212> DNA

<213> primate

<220>

<221> CDS

<222> (58)..(1467)

<400> 1

```

gggggggtggc atttctgcat tcgaagaaga atctgagaga aacctgacgc agggagc      57

atg ggt atc tgg acc tca ggc act gat atc ttc cta agt ctt tgg gag      105
Met Gly Ile Trp Thr Ser Gly Thr Asp Ile Phe Leu Ser Leu Trp Glu
  1             5             10             15

att tac gtg tct cca aga agc ccc gga tgg atg gac ttt atc cag cat      153
Ile Tyr Val Ser Pro Arg Ser Pro Gly Trp Met Asp Phe Ile Gln His
          20             25             30

ttg gga gtt tgc tgt ttg gtt gct ctt att tca gtg ggc ctc ctg tct      201
Leu Gly Val Cys Cys Leu Val Ala Leu Ile Ser Val Gly Leu Leu Ser
          35             40             45

gtg gcc gcc tgc tgg ttt ctg cca tca atc ata gcg gcc gct gcc tcc      249
Val Ala Ala Cys Trp Phe Leu Pro Ser Ile Ile Ala Ala Ala Ala Ser
          50             55             60

tgg att atc acg tgt gtt ctg ctg tgt tgc tcc aag cat gca cga tgt      297
Trp Ile Ile Thr Cys Val Leu Leu Cys Cys Ser Lys His Ala Arg Cys
          65             70             75             80

ttt att ctt ctt gtc ttt ctc tct tgt ggc ctg cgt gaa ggc agg aat      345
Phe Ile Leu Leu Val Phe Leu Ser Cys Gly Leu Arg Glu Gly Arg Asn
          85             90             95

gct ttg att gca gct ggc aca ggg atc gtc atc ttg gga cac gta gaa      393
Ala Leu Ile Ala Ala Gly Thr Gly Ile Val Ile Leu Gly His Val Glu
          100             105             110

```

aat att ttt cac aac ttt aaa ggt ctc cta gat ggt atg act tgc aac	441
Asn Ile Phe His Asn Phe Lys Gly Leu Leu Asp Gly Met Thr Cys Asn	
115 120 125	
cta agg gca aag agc ttt tcc ata cat ttt cca ctt ttg aaa aaa tat	489
Leu Arg Ala Lys Ser Phe Ser Ile His Phe Pro Leu Leu Lys Lys Tyr	
130 135 140	
att gag gca att cag tgg att tat ggc ctt gcc act cca cta agt gta	537
Ile Glu Ala Ile Gln Trp Ile Tyr Gly Leu Ala Thr Pro Leu Ser Val	
145 150 155 160	
ttt gat gac ctt gtt tct tgg aac cag acc ctg gca gtc tct ctt ttc	585
Phe Asp Asp Leu Val Ser Trp Asn Gln Thr Leu Ala Val Ser Leu Phe	
165 170 175	
agt ccc agc cat gtc ctg gag gca cag cta aat gac agc aaa ggg gaa	633
Ser Pro Ser His Val Leu Glu Ala Gln Leu Asn Asp Ser Lys Gly Glu	
180 185 190	
gtc ctg agc gtc ttg tac cag atg gca aca acc aca gag gtg ttg tcc	681
Val Leu Ser Val Leu Tyr Gln Met Ala Thr Thr Thr Glu Val Leu Ser	
195 200 205	
tcc ctg ggt cag aag cta ctt gcc ttt gca ggg ctt tgc ctc gtc ctg	729
Ser Leu Gly Gln Lys Leu Leu Ala Phe Ala Gly Leu Ser Leu Val Leu	
210 215 220	
ctt ggc act ggc ctc ttc atg aag cga ttt ttg ggc cct tgt ggt tgg	777
Leu Gly Thr Gly Leu Phe Met Lys Arg Phe Leu Gly Pro Cys Gly Trp	
225 230 235 240	
aag tat gaa aac atc tac atc acc aga caa ttt gtt cag ttt gat gaa	825
Lys Tyr Glu Asn Ile Tyr Ile Thr Arg Gln Phe Val Gln Phe Asp Glu	
245 250 255	
agg gag aga cat caa cag agg ccc tgt gtg ctc ccg ctg aat aag gag	873
Arg Glu Arg His Gln Gln Arg Pro Cys Val Leu Pro Leu Asn Lys Glu	
260 265 270	
gaa agg agg aag tat gtc atc atc ccg act ttc tgg ccg act cct aaa	921
Glu Arg Arg Lys Tyr Val Ile Ile Pro Thr Phe Trp Pro Thr Pro Lys	
275 280 285	
gaa agg aaa aac ctg ggg ctg ttt ttc ctc ccc ata ctt atc cat ctc	969
Glu Arg Lys Asn Leu Gly Leu Phe Phe Leu Pro Ile Leu Ile His Leu	
290 295 300	
tgc atc tgg gtg ctg ttt gca gct gta gat tat ctg ctg tat cgg ctc	1017
Cys Ile Trp Val Leu Phe Ala Ala Val Asp Tyr Leu Leu Tyr Arg Leu	
305 310 315 320	
att ttc tca gtg agc aag cag ttt caa agc ttg cca ggg ttt gag gtt	1065
Ile Phe Ser Val Ser Lys Gln Phe Gln Ser Leu Pro Gly Phe Glu Val	
325 330 335	

cac ttg aaa ctg cac gga gag aaa caa gga act caa gat att atc cat 1113
 His Leu Lys Leu His Gly Glu Lys Gln Gly Thr Gln Asp Ile Ile His
 340 345 350

gat tct tcc ttt aat ata tct gtg ttt gaa ccc aac tgt atc cca aaa 1161
 Asp Ser Ser Phe Asn Ile Ser Val Phe Glu Pro Asn Cys Ile Pro Lys
 355 360 365

cca aaa ttc ctt cta tct gag acc tgg gtt cct ctc agt gtt att ctt 1209
 Pro Lys Phe Leu Leu Ser Glu Thr Trp Val Pro Leu Ser Val Ile Leu
 370 375 380

ttg ata tta gtg atg ctg gga ctg ttg tcc tct atc ctt atg caa ctt 1257
 Leu Ile Leu Val Met Leu Gly Leu Leu Ser Ser Ile Leu Met Gln Leu
 385 390 395 400

aaa atc ctg gtg tca gca tct ttc tac ccc agc gtg gag agg aag cgc 1305
 Lys Ile Leu Val Ser Ala Ser Phe Tyr Pro Ser Val Glu Arg Lys Arg
 405 410 415

atc caa tat ctg cat gca aag ctg ctt aaa aaa aga tca aag cag ccg 1353
 Ile Gln Tyr Leu His Ala Lys Leu Lys Lys Arg Ser Lys Gln Pro
 420 425 430

ctg gga gaa gtc aaa aga cgg ctg agt ctc tat ctt aca aag att cat 1401
 Leu Gly Glu Val Lys Arg Arg Leu Ser Leu Tyr Leu Thr Lys Ile His
 435 440 445

ttc tgg ctt cca gtc ctg aaa atg att agg aag aag caa atg gac atg 1449
 Phe Trp Leu Pro Val Leu Lys Met Ile Arg Lys Lys Gln Met Asp Met
 450 455 460

gca agt gca gac aag tca tgagagaccc cgactactcc tcagccacat 1497
 Ala Ser Ala Asp Lys Ser
 465 470

cgcaccaaca attctcttca ggtctaggat ggcagtcact attcatgccg gataatagag 1557
 aactatgtga cgcagtcctc tcaggagtct gagtttacag agccaacttg cagcacctgg 1617
 ttatgcctcc tttcatctca aagccaaaga gctgccaggt aaatgggttat gtgggtctatg 1677
 ttccaaacaa accacatgat cttgcctgtg tcacaatgta acaagactct agctgggtcc 1737
 cctggatgat agtttcagca tagaataatg ttcaaggaaa agaaaacgaa aacagtttaa 1797
 atctctacca cagcctcaca agcaaatgct aaggggaaca tacatgtaaa aagccagcaa 1857
 actatcttca aactcttccg tccttaatgt cttccatggc tattgcccc acaatgggtct 1917
 cttttctccc tgctccctta ttaaagaact ctttctgaaa ccc 1960

<210> 2
 <211> 470
 <212> PRT
 <213> primate

<400> 2

Met Gly Ile Trp Thr Ser Gly Thr Asp Ile Phe Leu Ser Leu Trp Glu
1 5 10 15

Ile Tyr Val Ser Pro Arg Ser Pro Gly Trp Met Asp Phe Ile Gln His
20 25 30

Leu Gly Val Cys Cys Leu Val Ala Leu Ile Ser Val Gly Leu Leu Ser
35 40 45

Val Ala Ala Cys Trp Phe Leu Pro Ser Ile Ile Ala Ala Ala Ser
50 55 60

Trp Ile Ile Thr Cys Val Leu Leu Cys Cys Ser Lys His Ala Arg Cys
65 70 75 80

Phe Ile Leu Leu Val Phe Leu Ser Cys Gly Leu Arg Glu Gly Arg Asn
85 90 95

Ala Leu Ile Ala Ala Gly Thr Gly Ile Val Ile Leu Gly His Val Glu
100 105 110

Asn Ile Phe His Asn Phe Lys Gly Leu Leu Asp Gly Met Thr Cys Asn
115 120 125

Leu Arg Ala Lys Ser Phe Ser Ile His Phe Pro Leu Leu Lys Lys Tyr
130 135 140

Ile Glu Ala Ile Gln Trp Ile Tyr Gly Leu Ala Thr Pro Leu Ser Val
145 150 155 160

Phe Asp Asp Leu Val Ser Trp Asn Gln Thr Leu Ala Val Ser Leu Phe
165 170 175

Ser Pro Ser His Val Leu Glu Ala Gln Leu Asn Asp Ser Lys Gly Glu
180 185 190

Val Leu Ser Val Leu Tyr Gln Met Ala Thr Thr Thr Glu Val Leu Ser
195 200 205

Ser Leu Gly Gln Lys Leu Leu Ala Phe Ala Gly Leu Ser Leu Val Leu
210 215 220

Leu Gly Thr Gly Leu Phe Met Lys Arg Phe Leu Gly Pro Cys Gly Trp
225 230 235 240

Lys Tyr Glu Asn Ile Tyr Ile Thr Arg Gln Phe Val Gln Phe Asp Glu
245 250 255

Arg Glu Arg His Gln Gln Arg Pro Cys Val Leu Pro Leu Asn Lys Glu
260 265 270

Glu Arg Arg Lys Tyr Val Ile Ile Pro Thr Phe Trp Pro Thr Pro Lys
275 280 285

Glu Arg Lys Asn Leu Gly Leu Phe Phe Leu Pro Ile Leu Ile His Leu

290	295	300
Cys Ile Trp Val Leu Phe Ala Ala Val Asp Tyr Leu Leu Tyr Arg Leu 305 310 315 320		
Ile Phe Ser Val Ser Lys Gln Phe Gln Ser Leu Pro Gly Phe Glu Val 325 330 335		
His Leu Lys Leu His Gly Glu Lys Gln Gly Thr Gln Asp Ile Ile His 340 345 350		
Asp Ser Ser Phe Asn Ile Ser Val Phe Glu Pro Asn Cys Ile Pro Lys 355 360 365		
Pro Lys Phe Leu Leu Ser Glu Thr Trp Val Pro Leu Ser Val Ile Leu 370 375 380		
Leu Ile Leu Val Met Leu Gly Leu Leu Ser Ser Ile Leu Met Gln Leu 385 390 395 400		
Lys Ile Leu Val Ser Ala Ser Phe Tyr Pro Ser Val Glu Arg Lys Arg 405 410 415		
Ile Gln Tyr Leu His Ala Lys Leu Leu Lys Lys Arg Ser Lys Gln Pro 420 425 430		
Leu Gly Glu Val Lys Arg Arg Leu Ser Leu Tyr Leu Thr Lys Ile His 435 440 445		
Phe Trp Leu Pro Val Leu Lys Met Ile Arg Lys Lys Gln Met Asp Met 450 455 460		
Ala Ser Ala Asp Lys Ser 465 470		

<210> 3

<211> 1410

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:reverse
translation

<220>

<221> misc_feature

<222> (1)..(1410)

<223> n may be a, c, g, or t

<400> 3

atgggnatht ggacnwsngg nacngayath ttyytnwsny tntgggarat htaygtnwsn 60

ccnmgnwsnc cnggntggat ggayttyath carcayytng gngtntgytg yytngtngcn 120

ytnathwsng tnggnytnyt nwsngtngcn gcntgytggt tyytnccnws nathathgcn 180

gcngcngcnw sntggathat hacntgygtn ytnytnngyt gywsnaarca ygcnmngntgy 240
 ttyathytny tngtnttyt nwsntgyggn ytnmgngarg gnmgnaaygc nytnathgcn 300
 gcnggnacong gnathgtnat hytnggncay gtngaraaya thttycayaa yttyaarggn 360
 ytnytngayg gnatgacntg yaayytnmgn gcnaarwsnt tywsnathca yttyccnytn 420
 ytnaaraart ayathgargc nathcartgg athtayggny tngcnacncc nytnwsngtn 480
 ttygaygayy tngtnwsntg gaaycaracn ytngcngtnw snytnntyws nccnwsncay 540
 gtnytnngarg cncarytnaa ygaywsnaar ggngargtny tnwsngtnyt ntaycaratg 600
 gcnacnacna cngargtnyt nwsnwsnytn ggncaraary tnytnngcntt ygcnggnytn 660
 wsnytnngtny tnytnngnac nggnytnnty atgaarmgnt tyytnngncc ntgyggntgg 720
 aartaygara ayathtayat hacnmgnar ttygtncart tygaygarmg ngarmgncay 780
 carcarmgnc cntgygtnyt nccnytnaay aargargarm gnmgnaarta ygtnathath 840
 ccnacnttyt ggccnacncc naargarmgn aaraayytn gnytnntytt yytnccnath 900
 ytnathcayy tntgyathtg ggtnytnnty gcngcngtn gytayytnyt ntaymgnytn 960
 athttysng tnwsnaarca rttycarwsn ytncnggnt tygargtnca yytnaarytn 1020
 cayggngara arcarggnac ncargayath athcaygayw snwsnttyaa yathwsngtn 1080
 ttygarccna aytgyathcc naarccnaar ttyytnytnw sngaracntg ggtncnytn 1140
 wsngtnathy tnytnathyt ngtnatgytn ggnytnytnw snwsnathyt natgcarytn 1200
 aarathytn gtnwsngcnws nttytayccn wsngtnngarm gnaarmgnat hcartayytn 1260
 caygcnaary tnytnaaraa rmgnwsnaar carccnytn gngargtnaa rmgnmgnytn 1320
 wsnytntayy tnacnaarat hcayttytg ytnccngtny tnaaratgat hmgnaaraar 1380
 caratggaya tggcnwsngc ngayaarwsn 1410

<210> 4
 <211> 942
 <212> DNA
 <213> primate

<220>
 <221> CDS
 <222> (1)..(939)

<220>
 <221> mat_peptide
 <222> (64)..(939)

<400> 4

atg gcc tta cca gtg acc gcc ttg ctc ctg ccg cta gcc ttg ctg ctc	48
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu	
-20 -15 -10	
cac gcc gcc agg ccg gat tac aag gac gat gac gac aag atc gat ctg	96
His Ala Ala Arg Pro Asp Tyr Lys Asp Asp Asp Asp Lys Ile Asp Leu	
-5 -1 1 5 10	
agc aaa tgc agg acc gtg gcg ggc ccc gtg ggg gga tcc ctg agt gtg	144
Ser Lys Cys Arg Thr Val Ala Gly Pro Val Gly Gly Ser Leu Ser Val	
15 20 25	
cag tgt ccc tat gag aag gaa cac agg acc ctc aac aaa tac tgg tgc	192
Gln Cys Pro Tyr Glu Lys Glu His Arg Thr Leu Asn Lys Tyr Trp Cys	
30 35 40	
aga cca cca cag att ttc cta tgt gac aag att gtg gag acc aaa ggg	240
Arg Pro Pro Gln Ile Phe Leu Cys Asp Lys Ile Val Glu Thr Lys Gly	
45 50 55	
tca gca gga aaa agg aac ggc cga gtg tcc atc agg gac agt cct gca	288
Ser Ala Gly Lys Arg Asn Gly Arg Val Ser Ile Arg Asp Ser Pro Ala	
60 65 70 75	
aac ctc agc ttc aca gtg acc ctg gag aat ctc aca gag gag gat gca	336
Asn Leu Ser Phe Thr Val Thr Leu Glu Asn Leu Thr Glu Glu Asp Ala	
80 85 90	
ggc acc tac tgg tgt ggg gtg gat aca ccg tgg ctc cga gac ttt cat	384
Gly Thr Tyr Trp Cys Gly Val Asp Thr Pro Trp Leu Arg Asp Phe His	
95 100 105	
gat ccc gtt gtc gag gtt gag gtg tcc gtg ttc ccg gca tca acg tca	432
Asp Pro Val Val Glu Val Glu Val Ser Val Phe Pro Ala Ser Thr Ser	
110 115 120	
atg aca cct gca agt atc act gcg gcc aag acc tca aca atc aca act	480
Met Thr Pro Ala Ser Ile Thr Ala Ala Lys Thr Ser Thr Ile Thr Thr	
125 130 135	
gca ttt cca cct gta tca tcc act acc ctg ttt gca gtg ggt gcc acc	528
Ala Phe Pro Pro Val Ser Thr Thr Leu Phe Ala Val Gly Ala Thr	
140 145 150 155	
cac agt gcc agc atc cag gag gaa act gag gag gtg gtg aac tca cag	576
His Ser Ala Ser Ile Gln Glu Glu Thr Glu Glu Val Val Asn Ser Gln	
160 165 170	
ctc ccg ctg ctc ctc tcc ctg ctg gca ttg ttg ctg ctt ctg ttg gtg	624
Leu Pro Leu Leu Leu Ser Leu Leu Ala Leu Leu Leu Leu Leu Val	
175 180 185	
ggg gcc tcc ctg cta gcc tgg agg atg ttt cag aaa tgg atc aaa gct	672
Gly Ala Ser Leu Leu Ala Trp Arg Met Phe Gln Lys Trp Ile Lys Ala	
190 195 200	
ggt gac cat tca gag ctg tcc cag aac ccc aag cag gct gcc acg cag	720

Gly	Asp	His	Ser	Glu	Leu	Ser	Gln	Asn	Pro	Lys	Gln	Ala	Ala	Thr	Gln		
205							210				215						
agt	gag	ctg	cac	tac	gca	aat	ctg	gag	ctg	ctg	atg	tgg	cct	ctg	cag	768	
Ser	Glu	Leu	His	Tyr	Ala	Asn	Leu	Glu	Leu	Leu	Met	Trp	Pro	Leu	Gln		
220					225					230					235		
gaa	aag	cca	gca	cca	cca	agg	gag	gtg	gag	gtg	gaa	tac	agc	act	gtg	816	
Glu	Lys	Pro	Ala	Pro	Pro	Arg	Glu	Val	Glu	Val	Glu	Tyr	Ser	Thr	Val		
				240					245					250			
gcc	tcc	ccc	agg	gaa	gaa	ctt	cac	tat	gcc	tcg	gtg	gtg	ttt	gat	tct	864	
Ala	Ser	Pro	Arg	Glu	Glu	Leu	His	Tyr	Ala	Ser	Val	Val	Phe	Asp	Ser		
			255					260					265				
aac	acc	aac	agg	ata	gct	gct	cag	agg	cct	cgg	gag	gag	gaa	cca	gat	912	
Asn	Thr	Asn	Arg	Ile	Ala	Ala	Gln	Arg	Pro	Arg	Glu	Glu	Glu	Pro	Asp		
		270					275					280					
tca	gat	tac	agt	gtg	ata	agg	aag	aca	tag							942	
Ser	Asp	Tyr	Ser	Val	Ile	Arg	Lys	Thr									
	285					290											

<210> 5
 <211> 313
 <212> PRT
 <213> primate

<400> 5
 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 -20 -15 -10

His Ala Ala Arg Pro Asp Tyr Lys Asp Asp Asp Asp Lys Ile Asp Leu
 -5 -1 1 5 10

Ser Lys Cys Arg Thr Val Ala Gly Pro Val Gly Gly Ser Leu Ser Val
 15 20 25

Gln Cys Pro Tyr Glu Lys Glu His Arg Thr Leu Asn Lys Tyr Trp Cys
 30 35 40

Arg Pro Pro Gln Ile Phe Leu Cys Asp Lys Ile Val Glu Thr Lys Gly
 45 50 55

Ser Ala Gly Lys Arg Asn Gly Arg Val Ser Ile Arg Asp Ser Pro Ala
 60 65 70 75

Asn Leu Ser Phe Thr Val Thr Leu Glu Asn Leu Thr Glu Glu Asp Ala
 80 85 90

Gly Thr Tyr Trp Cys Gly Val Asp Thr Pro Trp Leu Arg Asp Phe His
 95 100 105

Asp Pro Val Val Glu Val Glu Val Ser Val Phe Pro Ala Ser Thr Ser
 110 115 120

Met Thr Pro Ala Ser Ile Thr Ala Ala Lys Thr Ser Thr Ile Thr Thr
125 130 135

Ala Phe Pro Pro Val Ser Ser Thr Thr Leu Phe Ala Val Gly Ala Thr
140 145 150 155

His Ser Ala Ser Ile Gln Glu Glu Thr Glu Glu Val Val Asn Ser Gln
160 165 170

Leu Pro Leu Leu Leu Ser Leu Leu Ala Leu Leu Leu Leu Leu Val
175 180 185

Gly Ala Ser Leu Leu Ala Trp Arg Met Phe Gln Lys Trp Ile Lys Ala
190 195 200

Gly Asp His Ser Glu Leu Ser Gln Asn Pro Lys Gln Ala Ala Thr Gln
205 210 215

Ser Glu Leu His Tyr Ala Asn Leu Glu Leu Leu Met Trp Pro Leu Gln
220 225 230 235

Glu Lys Pro Ala Pro Pro Arg Glu Val Glu Val Glu Tyr Ser Thr Val
240 245 250

Ala Ser Pro Arg Glu Glu Leu His Tyr Ala Ser Val Val Phe Asp Ser
255 260 265

Asn Thr Asn Arg Ile Ala Ala Gln Arg Pro Arg Glu Glu Glu Pro Asp
270 275 280

Ser Asp Tyr Ser Val Ile Arg Lys Thr
285 290

<210> 6
<211> 603
<212> DNA
<213> primate

<220>
<221> CDS
<222> (1)..(600)

<220>
<221> mat_peptide
<222> (64)..(600)

<400> 6
atg gcc tta cca gtg acc gcc ttg ctc ctg ccg cta gcc ttg ctg ctc 48
Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
-20 -15 -10

cac gcc gcc agg ccg gat tac aag gac gat gac gac aag atc gat atg 96
His Ala Ala Arg Pro Asp Tyr Lys Asp Asp Asp Asp Lys Ile Asp Met
-5 -1 1 5 10

aca cct gca agt atc act gcg gcc aag acc tca aca atc aca act gca 144

Thr Pro Ala Ser Ile Thr Ala Ala Lys Thr Ser Thr Ile Thr Thr Ala
 15 20 25

ttt cca cct gta tca tcc act acc ctg ttt gca gtg ggt gcc acc cac 192
 Phe Pro Pro Val Ser Ser Thr Thr Leu Phe Ala Val Gly Ala Thr His
 30 35 40

agt gcc agc atc cag gag gaa act gag gag gtg gtg aac tca cag ctc 240
 Ser Ala Ser Ile Gln Glu Glu Thr Glu Glu Val Val Asn Ser Gln Leu
 45 50 55

ccg ctg ctc ctc tcc ctg ctg gca ttg ttg ctg ctt ctg ttg gtg ggg 288
 Pro Leu Leu Leu Ser Leu Leu Ala Leu Leu Leu Leu Leu Val Gly
 60 65 70 75

gcc tcc ctg cta gcc tgg agg atg ttt cag aaa tgg atc aaa gct ggt 336
 Ala Ser Leu Leu Ala Trp Arg Met Phe Gln Lys Trp Ile Lys Ala Gly
 80 85 90

gac cat tca gag ctg tcc cag aac ccc aag cag gct gcc acg cag agt 384
 Asp His Ser Glu Leu Ser Gln Asn Pro Lys Gln Ala Ala Thr Gln Ser
 95 100 105

gag ctg cac tac gca aat ctg gag ctg ctg atg tgg cct ctg cag gaa 432
 Glu Leu His Tyr Ala Asn Leu Glu Leu Leu Met Trp Pro Leu Gln Glu
 110 115 120

aag cca gca cca cca agg gag gtg gag gtg gaa tac agc act gtg gcc 480
 Lys Pro Ala Pro Pro Arg Glu Val Glu Val Glu Tyr Ser Thr Val Ala
 125 130 135

tcc ccc agg gaa gaa ctt cac tat gcc tcg gtg gtg ttt gat tct aac 528
 Ser Pro Arg Glu Glu Leu His Tyr Ala Ser Val Val Phe Asp Ser Asn
 140 145 150 155

acc aac agg ata gct gct cag agg cct cgg gag gag gaa cca gat tca 576
 Thr Asn Arg Ile Ala Ala Gln Arg Pro Arg Glu Glu Glu Pro Asp Ser
 160 165 170

gat tac agt gtg ata agg aag aca tag 603
 Asp Tyr Ser Val Ile Arg Lys Thr
 175

<210> 7
 <211> 200
 <212> PRT
 <213> primate

<400> 7
 Met Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu
 -20 -15 -10

His Ala Ala Arg Pro Asp Tyr Lys Asp Asp Asp Asp Lys Ile Asp Met
 -5 -1 1 5 10

Thr Pro Ala Ser Ile Thr Ala Ala Lys Thr Ser Thr Ile Thr Thr Ala

acngtnacny tngaraayyt nacngargar gaygcnggna cntaytggtg yggngtngay 360
 acnccntggy tnmnggaytt ycaygayccn gtngtngarg tngargtnws ngtnnttyccn 420
 gcnwsnacnw snatgacncc ngcnwsnath acngcngcna aracnwsnac nathacnacn 480
 gcnttyccnc cngtnwsnws nacnacnytn ttygcngtng gngcnacnca ywsngcnwsn 540
 athcargarg aracngarga rgtngtnaay wsncarytnc cnytnytnyt nwsnytnytn 600
 gcnytnytny tnytnytnyt ngtnngngcn wsnytnytny cntggmgnt gttycaraar 660
 tggathaarg cnggngayca ywsngarytn wsncaraayc cnaarcargc ngcnacncar 720
 wsngarytnc aytaygcnaa yytngarytn ytnatgtggc cnytncarga raarcngcn 780
 ccnccnmngn argtngargt ngartaywsn acngtngcnw snccnmngna rgarytnca 840
 taygcnwsng tngtnnttyga ywsnaayacn aaymgntathg cngcncarmg nccnmngnar 900
 gargarcng aywsngayta ywsngtnath mgnaaracn 939

<210> 9

<211> 600

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:reverse
 translation

<220>

<221> misc_feature

<222> (1)..(600)

<223> n may be a, c, g, or t

<400> 9

atggcnytn cngtnacngc nytnytnytn ccnytngcny tnytnytnca ygcngcnmgn 60
 ccngaytaya argaygayga ygayaarath gayatgacnc cngcnwsnat hacngcngcn 120
 aaracnwsna cnathacnac ngcnttyccn ccngtnwsnw snacnacnyt nttygcngtn 180
 ggngcnacnc aywsngcnws nathcargar garacngarg argtngtnaa ywsncarytn 240
 ccnytnytny tnwsnytnyt gcnytnytn ytnytnytny tngtnngngc nwsnytnytn 300
 gcntggmgna tgttycaraa rtggathaar gcnggngayc aywsngaryt nwsncaraay 360
 ccnaarcarg cngcnacnca rwsngarytn caytaygcna ayytngaryt nytnatgtgg 420
 ccnytncarg araarcngc nccnccnmgn gargtngarg tngartayws nacngtngcn 480
 wsncnccnmngn argarytnca ytaygcnwsn gtngtnnttyg aywsnaayac naaymgntath 540

gcngeacarm gncenmgnga rgargarccn gaywsngayt aywsngtnat hmgnaaracn 600

gcngeacarm gncenmgnga rgargarccn gaywsngayt aywsngtnat hmgnaaracn 600

Variable	Mean		SD		t		p	
	Control	Case	Control	Case	Control	Case	Control	Case
Age	30.5	30.5	1.2	1.2	0.0	0.0	0.999	0.999
Gender	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Education	12.0	12.0	1.0	1.0	0.0	0.0	0.999	0.999
Marital status	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Occupation	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Income	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Religion	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Health status	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Family size	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Urban/rural	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Marriage duration	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Number of children	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental education	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental occupation	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental income	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental health status	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental family size	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental urban/rural	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental marriage duration	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental number of children	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental education	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental occupation	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental income	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental health status	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental family size	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental urban/rural	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental marriage duration	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental number of children	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental education	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental occupation	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental income	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental health status	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental family size	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental urban/rural	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental marriage duration	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental number of children	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental parental education	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental parental occupation	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental parental income	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental parental health status	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental parental family size	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental parental urban/rural	1.0	1.0	0.0	0.0	0.0	0.0	0.999	0.999
Parental parental parental parental marriage duration	1.0	1.0	0					

Attorney's Docket No. **DX01051Q**

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"MAMMALIAN GENES; RELATED REAGENTS AND METHODS"

the specification of which

☒ is attached hereto.

☐ was filed on November 14, 2000 as Application Serial No. _____

and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a).

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s): Priority Claimed

(Number)	(Country)	(Day/Month/Year Filed)	Yes or No
----------	-----------	------------------------	-----------

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

<u>60/165,438</u> (Application Number)	<u>November 15, 1999</u> (Filing Date)
---	---

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Application Serial No.)	(Filing Date)	(Status – patented, pending, abandoned)
--------------------------	---------------	---

Power of Attorney: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in Patent and Trademark Office connected therewith. (List name and registration number.)

Edwin P. Ching	Reg. No. 34,090	Anita W. Magatti	Reg. No. 29,825
Eric S. Dicker	Reg. No. 31,699	Arthur Mann	Reg. No. 35,598
Robert A. Franks	Reg. No. 28,605	Christine F. Martins	Reg. No. 39,762
James M. Gould	Reg. No. 33,702	Edward H. Mazer	Reg. No. 27,573
Richard J. Grochala	Reg. No. 31,518	Richard B. Murphy	Reg. No. 35,298
Henry S. Hadad	Reg. No. 35,888	James R. Nelson	Reg. No. 27,929
Thomas D. Hoffman	Reg. No. 28,221	David B. Schram	Reg. No. 43,096
Henry C. Jeanette	Reg. No. 30,856	Immac J. Thampoe	Reg. No. 36,322
Palaiyur S. Kalyanaraman	Reg. No. 34,634	Paul A. Thompson	Reg. No. 35,385
Allan N. Kutzeno	Reg. No. 38,945	Donald W. Wyatt	Reg. No. 40,879

Send Correspondence to: Edwin P. Ching DNAX Research Institute 901 California Avenue Palo Alto, CA 94304-1104	Direct Telephone Calls to: Name: Edwin P. Ching Telephone No.: (650) 496-1204 Facsimile No.: (650) 496-1200
--	---

FULL NAME OF 1ST OR SOLE INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	Zlot	Constance	H.
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	San Francisco	California	United States of America
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
	949 Filbert Street, # 6	San Francisco	CA 94133 / USA

FULL NAME OF 2ND JOINT INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	Adema	Gosse	Jan
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	Groesbeek	The Netherlands	The Netherlands
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
	Haydnstraat 53	6561 ED Groesbeek	The Netherlands

FULL NAME OF 3RD JOINT INVENTOR	FAMILY NAME	FIRST GIVEN NAME	SECOND GIVEN NAME
	Figdor	Carl	
RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
	Den Bosch	The Netherlands	The Netherlands
POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE & ZIP CODE/COUNTRY
	Westwal 54	5211 DD Den Bosch	The Netherlands

FULL NAME OF 4TH JOINT INVENTOR	FAMILY NAME Phillips	FIRST GIVEN NAME Joseph	SECOND GIVEN NAME H.
RESIDENCE & CITIZENSHIP	CITY Palo Alto	STATE OR FOREIGN COUNTRY California	COUNTRY OF CITIZENSHIP United States of America
POST OFFICE ADDRESS	POST OFFICE ADDRESS 1511 Walnut Drive	CITY Palo Alto	STATE & ZIP CODE/COUNTRY CA 94133 / USA

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Signature of First Inventor	Signature of Second Inventor	Signature of Third Inventor
Constance H. Zlot	Gosse Jan Adema	Carl Figdor
Date	Date	Date

Signature of Fourth Inventor
Joseph H. Phillips
Date